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CD98 constitutively and specifically associates with (31 integrins and is highly
expressed on the surface of tumour cells irrespective of tissue of origin. This
investigation has demonstrated that over expression of the CD98 heavy chain promotes
both anchorage-independent and serum-independent growth. This oncogenic activity is
dependent on phosphoinositol-3-OH kinase stimulation and the level of surface
expression of CD98. Using chimeras of the CD98 heavy chain and the Type II
membrane protein CD69,1 have shown that the transmembrane domain is necessary and
sufficient for integrin association. Amino acids 82-87 in the putative
cytoplasmic/transmembrane region appear to be critical for the oncogenic potential of
CD98 and provide a novel mechanism for tumour promotion by integrins. This
demonstrates how high expression of CD98 in human cancers causes transformation.
The transmembrane association of CD98 and (31 integrins may provide a unique target to
intervene in cancer.
The diverse effects of CD98 prompted an investigation in to whether there were
any other molecules like CD98 which had similar effects on integrins. The Neural cell
adhesion molecule (NCAM), a membrane associated glycoprotein of the Ig superfamily
appeared to be a potential candidate. This study has shown that CD98 and NCAM and
NCAM and, (31 colocalise together and indicate that NCAM, CD98 and (31 may form a
complex inducing a signalling cascade.
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CHAPTER 1
INTRODUCTION
Normal cells and tissues exist in defined and regulated relationships to
components of the extracellular matrix (ECM) in their immediate micro-environment
(Keely et al., 1998). The life and death situation at the cellular level is therefore
profoundly influenced by components of the ECM (Stupack and Cheresh, 2002), which
mediate events such as tissue re-modelling, differentiation and development. Many of
these processes are governed by members of a family of cell-surface adhesion receptors
known as integrins. Integrins play critical roles in many aspects of cell physiology and
when aberrations occur within these interactions pathological disorders can develop.
Many cancers show abnormalities of integrin function and this may be as a consequence
of transformed cells losing their appropriate contacts with the ECM. These transformed
cells then acquire anchorage independence and a motile-invasive phenotype (Keely et
al., 1998). Although much is known about the extracellular interactions between
integrins and their ligands, significantly less is known about the biochemical pathways
that integrins regulate and the cellular functions which are thereby controlled (Clark and
Brugge, 1995).
1.1 INTEGRINS
Integrins are a large family of heterodimeric cell surface receptors that mediate
attachment to the extracellular matrix and cell surface ligands (Fernandez et al., 1998).
They are expressed on a wide variety of cells and most cells express several integrins.
Integrins are receptors for ECM proteins such as fibronectin, laminin, vitronectin and
collagen,(Table 1).
The phenomenon "anchorage dependence" was first described by Stoker et al.,
(1968). They found that normal cells were blocked in the G1 phase of the cell cycle
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when cultured in suspension. This indicated a requirement of cell adhesion for growth in
normal cells. The ability of integrins to bind to various ECM proteins mediates
important cell-cell and cell-matrix adhesive interactions involved in many cellular
functions. These include, embryogenesis, wound healing, platelet aggregation,
programmed cell death, and leucocyte homing and activation. As a result of their
involvement in cell adhesion, integrins are also implicated in tumour cell growth and
metastasis. However in addition to their roles as adhesion receptors, integrin's also play
a role in signalling. They have been found to have a role in regulating reorganization of
the cytoskeleton, intracellular ion transport, lipid metabolism, kinase activation and gene
expression. This variety of functional roles is a consequence of integrins ability to
regulate ligand binding. This regulation of ligand binding can occur in two different
ways, either by a conformational change or by clustering many integrins together. This
will be discussed in more detail in section 1.1.3 and 1.1.4.
2
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Table 1. Integrin extracellular ligands
This table summarises the major extracellular ligands of integrins. This table also
demonstrates the ability of individual integrin family members to recognize multiple
ligands. Table adapted from Plow et al, 2000.
1.1.1 INTEGRIN STRUCTURE
Integrins are heterodimeric transmembrane receptors composed of non-
covalently linked alpha and beta subunits. Each subunit has a type I transmembrane
protein and a large N-terminus extracellular domain, a single membrane spanning
region, and a short C-terminal cytoplasmic tail (Shattil et al., 1998). The integrin
receptor family consists of at least 18 distinct alpha subunits and 8 beta subunits, leading
to a large number of possible combinations (Juliano et al., 2002). Some of these integrin
subunits are promiscuous, ie. (31 interacts with lots of alpha subunits, (as shown in figure
1.1.1a), whereas some subunits only interact with one specific subunit. The diversity of
integrins is expanded further by alternative splicing, post-translational modifications,
and interactions with other cell-surface and intracellular molecules (Plow et al., 2000).
The alpha subunits are approximately 1000 residues in length and the beta subunits are
approximately 750 residues in length.
The specificity of an integrin binding to a particular ligand appears to depend
primarily on the extracellular portion of the alpha subunit. However both subunits are
required for an integrin complex to function properly. The binding of integrins to ligands
depends on the extracellular divalent cations present, (Ca2+, Mn2+ or Mg2+ , depending
on the integrin). This reflects the presence of the 3-4 divalent cation-binding domains in
the extracellular domain of the alpha subunit. The alpha subunits all contain seven
tandem repeats of about 60 amino acids at their N-terminus. The last three or four of
these repeats contain sequences (Asp-x-Asp-x-Asp-Gly-x-x-Asp) or related sequences
that are thought to contribute to the divalent cation-binding properties of these subunits,
(Hynes, 1992). Gailit and Ruoslahti., (1988) and Kirchhofer et al., (1990,1991)
speculated that the nature of these cations could affect both affinity and specificity for
ligands and that they were essential for alpha (a) beta ((3) subunit associations of some
integrins. The role of divalent cations in integrin function was demonstrated by lack of
ligand binding upon removal of cations by chelating agents. Mn2+, Mg2+ and Ca2+ were
found to have distinct effects on integrin function in vitro. With (31 integrins, Mn2+
4
21confers high affinity binding properties, whereas Ca inhibits binding of ligand and
Mg2+ stimulates ligand binding.
p subunits have a characteristic four fold repeat of a cysteine rich segment,
which is believed to be internally disulphide bonded, (Calvete et al., 1991). This
segment appears to contribute to the ligand binding domain. A diagram of the current
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Figure 1.1.1a The pi subfamily
The largest subfamily of integrins is the group of heterodimers which share the pi







Figure 1.1.1b The subunit structure of an integrin
The figure above shows the structure of an integrin. An integrin is a heterodimeric cell
surface receptor, composed of non-covalently linked a and (3 subunits. Ligand binding is
dependent on the presence of divalent cations either Ca2+ or Mg2+. Adapted from Alberts
et al., Molecular Biology Of The Cell.
1.1.2 INTEGRIN SIGNALLING
During the ligand binding process integrins undergo dynamic changes, involving
conformational changes and/or receptor clustering. Integrins are components of both
"inside-out" and "outside-in" signalling mechanisms. Inside-out signalling is intiated by
specific intracellular proteins interacting with the cytoplasmic tail of the integrin,
stimulating a conformational change to the extracellular-ligand binding sites. Outside-in
signalling occurs when integrin receptors engage and cluster together leading to the
formation of focal adhesions, generating a cytoplasmic signalling cascade. However in
some cases both inside-out and outside-in signalling play a role in transmitting signals in
biological systems. One integrin which has been studied in great depth is the am,^,
which is the predominant complex in platelets and is involved in haemostasis. Inside-out
signalling leads to the conversion of anbp3 from a low affinity/avidity state to a high
affinity/avidity state. This determines whether 0CnbP3 can engage soluble ligands such as
fibrinogen and consequently whether platelet aggregation occurs. Outside-in signalling
is then involved in the post-ligand binding events. In terms of 0tnbp3, these events
include platelet spreading, granule secretion and clot retraction (Shattil et al.,
1998). 0Cnbp3 has therefore been a powerful model to study integrin activation as
discussed below, (figure 1.1.2).
Integrin affinity modulation
Integrin adhesive functions can itself be regulated by cellular signals. Integrin
activation is often caused by intracellular signals which change the affinity of some
integrins for their ligands, a process known as affinity modulation (Hughes and Pfaff.,
1998). A classical example of integrin affinity modulation at work is platelet
aggregation. On resting circulating platelets, the integrin anbp3 does not bind to any
soluble ligands. However when fibrinogen, a soluble plasma protein which binds to
0Cnbp3 is crosslinked with platelets, platelet aggregation occurs. Platelet activation is
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induced by various agonists such as thrombin, ADP and epinephrine which causes a
conformational change to the anbp3 integrin, increases its binding affinity for fibrinogen
resulting in platelet activation (Shattil et al., 1998). A further conformational change
occurs on ligand binding (Freilinger et al., 1988; 1990; 1991). A role for tyrosine kinases
in integrin activation/inside-out signalling and platelet activation was suggested by
Savage et al., (1996). They observed that tyrosine kinase inhibitors partially blocked
fibrinogen binding and platelet aggregation. Another signalling molecule which has been
implicated in integrin function is Phosphatidylinositol 3-OH Kinase (PBKinase) and its
products, phosphatidylinositol phosphates (PIP's), PIP2 and PIP3. In platelets, the
agonist thrombin stimulates an increase in PIP3 leading to an increase in PIP2. Inhibitors
of PBKinase partially block agonist-induced activation of 0Cnt>p3 and platelet
aggregation. It has been suggested that the 3-phosphorylated phosphoinositides function
to stabilise binding to fibrinogen.
Another example of inside out signalling is an essential feature of leucocyte
adhesion. Integrins such as OC4P1 and two (32 integrins, aLp2 (LFA-1) and ocm(32 (Mac-1),
found on leucocytes, mediate cell-cell adhesion and sometimes cell-substrate adhesion.
The process of adhesion is a critical aspect of leucocyte function and is therefore tightly
regulated. When leucocytes and platelets circulate in the blood stream, they need to
remain non-adhesive. However at sites of inflammation they must be able to recognise
and adhere to the endothelium and then migrate through the vessel wall. This regulation
is very complex and therefore requires inside-out signalling for activation and
deactivation of integrins (Brown and Hogg., 1996). In the genetic disease, leucocyte
adhesion deficiency (LAD), (32 integrins are absent and the leucocyte cannot adhere
stably to the endothelium. This leads to recurrent pyogenic infections, problems with
wound healing and the development of gingivitis (severe inflammation of the gums) in
patients suffering from LAD.
Conformational changes may be modified by the divalent cations present in the
alpha subunit. This role for divalent cations was suggested after studies using
monoclonal antibodies (mAbs), which recognised conformation dependent epitopes in
(31 integrins. Stimulatory mAbs such as TS2/16, 8A2, A1A5 and 12G10, and inhibitory
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antibodies such as mAbl3, 4B4 and P4C10, all recognized a twelve amino acid
sequence present in the (3A domain.
The conformational changes required for ligand binding to 0Cnbp3 could be
regulated by intracellular molecules which bind to the cytoplasmic tails of the integrin or
integrin associated membrane proteins. These will be described in more detail in section
1.1.6.
Integrin avidity modulation
Outside-in signalling or integrin avidity is the process in which integrins mediate
information transfer into cells by integrin clustering and ligation. Outside-in signalling
collaborates with signals originating from growth factor receptors and other plasma
membrane receptors to regulate a host of anchorage-dependent cellular functions (Shattil
etal., 1998).
As mentioned earlier, platelet functions are regulated by outside-in signalling,
such as granule secretion and secondary aggregation. These outside-in signals determine
the ultimate size of a hemostatic plug or a pathological thrombus and are initiated at
localized regions of cell-matrix and cell-cell contact. Signals are triggered by
oligomerization and clustering of aiibp3 in platelets, and then propagated by interactions
between integrin cytoplasmic tails and signalling molecules and cytoskeletal proteins
(Shatill etal., 1998).
An example of avidity modulation is the specific kinase FAK (focal adhesion kinase).
FAK is a 125kDa non-receptor tyrosine kinase which localises to the plasma membrane
at sites of integrin-mediated adhesion. A distinct domain of FAK directly associates with
integrin cytoplasmic tails. A signalling cascade is initiated when integrins cluster as a
consequence of an interaction with ECM proteins. This clustering creates a binding site
for c-Src via integrin-associated FAK autophosphorylation of tyrosine 397. After c-Src
has bound, additional tyrosines on FAK can become phosphorylated and in turn become
docking sites for paxillin and grb2 and other signalling proteins, eventually leading to
10





Figure 1.1.2 Integrin Affinity and Avidity modulation.
Panel A shows affinity modulation of integrin complexes which is initiated by
interaction with specific intracellular proteins with the cytoplasmic tail of the integrin
promoting a conformational change in the extracellullar domain, resulting in increased
affinity for ligands such as fibrinogen. Panel B represents avidity modulation which
occurs when integrins cluster together at focal contacts promoting a cytoplasmic signal
cascade.
1.1.3. INTEGRIN SIGNALLING PATHWAYS
In addition to mediation of cellular adhesion to ECM proteins, integrins also
transduce intracellular signals that promote cell migration as well as cell survival and
proliferation (Meredith et al., 1993; Stromblad and Cheresh, 1996). Unlike growth factor
receptors, integrins, have no intrinsic enzymatic activity. They activate signalling
pathways via the clustering of kinases and adaptor proteins in focal adhesion complexes
(Jin and Varner, 2004). Signal transduction by integrins influence many growth
regulatory pathways. Examples of this are the activation of tyrosine kinases such as
FAK , pp60src and c-Abl; serine threonine kinases such as MAP kinases, jun kinase
(JNK) and protein kinase C (PKC); intracellular ions such as protons (pH) and calcium;
the small GTPase Rho and lipid mediators such as phosphoinositides, diacylglycerol and
arachidonic acid metabolites (Shwartz et al., 1997).
Upon integrin stimulation, PKC and MAP kinase are activated, leading to cell
attachment and spreading. An increase in intracellular calcium concentration can also be
induced by integrin engagement and this calcium release is a key regulator of
intracellular signalling via multiple integrins (Clark and Brugge, 1995). Phospholipid
metabolites also have a role in integrin-mediated signal transduction, by activating PKC
(Divecha and Irvine, 1995). Integrins also appear to regulate changes in gene expression,
crucial for developmental and proliferative responses and integrins also affect cell
survival, as mentioned earlier by regulating programmed cell death (Damsky and Werb,
1992; Yurochko et al., 1992; Schwartz and Ingber, 1994).
Focal Adhesion Kinase (FAK)
The tyrosine kinase FAK plays an important role in integrin-mediated signalling.
A number of proteins tyrosines are phosphorylated upon integrin engagement, such as
paxillin, tensin and FAK.. The clustering of chimeric integrin receptors expressing
several different (3 cytoplasmic domains is sufficient to induce FAK phosphorylation
(Clark and Brugge, 1995). FAK is phosphorylated on at least 7 different tyrosines and
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has the ability to interact with cellular proteins that contain SH2 domains such as Src,
Grb2 and PI3-Kinase (Schlaepfer et al., 1994; Pawson, 1995; Brakenbusch et ah, 2000).
Through these interactions FAK has the capacity to integrate integrin-mediated
signalling as shown in figure 1.1,3a.
After autophosphorylation of FAK on Tyr 397 a binding site is formed for Src.
Once Src has bound, additional tyrosines on FAK can become phosphorylated and
become a docking site for Grb2 (Brown and Hogg, 19996). Grb2 (growth factor receptor
bound protein-2), links activated tyrosine kinase to an activator of mSOSl, a guanine
nucleotide exchange factor that functions by converting inactive Ras-GDP to active Ras-
GTP. This suggests that integrins may regulate the Ras/Raf/Mek/Erk pathway (Clark
and Brugge, 1995).
FAK also binds to PI3-Kinase, which is thought to promote cell activation.
Autophosphorylation of FAK on Tyr 397 also allows FAK to bind to and activate PI3-
Kinase. PI3K influences integrin affinity and avidity but also contributes to activation of
Rac-1 (Brakenbusch et al., 2002). Rac-1 is involved in membrane ruffling but also when
activated stimulates p21 activated kianse (PAK) which then stimulates migration by
increasing the turnover of focal adhesions (Kiosses et al., 1999). Increased levels of
FAK expression have also been correlated with the invasiveness and metastatic
phenotype in solid tumours (Weiner et al., 1993; Akasaka et al., 1995; Owens et al.,
1995).
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Figure 1.1.3a FAK signalling pathways
After integrin engagement, FAK is autophosphorylated on Tyr 397, forming a binding
site for c-Src. Once c-Src is bound additional tyrosines on FAK are phosphorylated and
form a docking site for Grb2. Grb2 once bound links FAK to mSOSl. mSOSl converts
inactive Ras-GDP to active Ras -GTP and this stimulates the Ras/Mek pathway.
Autophosphorylation of FAK also allows FAK to bind and activate PI3-Kinase.
RAS-MAP Kinase pathway
Many groups have indicated a link between outside-in signalling through
integrins and the activation of the Ras/MAPK pathways. Miyamoto et al, (1995), found
that 20 signal transduction molecules, including Rho A, Rac-1, Ras, Raf, MAPK, MEK
and JNK were colocalised with clustered integrins, suggesting they might be localised in
focal adhesions. Ras is a member of the Ras-superfamily of small GTPases. As
previously mentioned, the association of Grb2 and mSOSl with FAK suggests that
integrins may regulate Ras. Another mechanism of activation of the Ras/MAPK
pathway does not involve FAK, but does involve caveolin-1, Fyn and the adaptor protein
She. Integrin a subunits activate Fyn, causing tyrosine phosphorylation of She leading to
recruitment of the Grb2/SOS complex. This triggers Ras and the downstream kinase
cascade leading to Erk activation (Juliano, 2002) as shown in figure 1.1.3b.
Ras is activated by guanine nucleotide exchange factors, (GEF's) that release
GDP and allow GTP binding. Ras-GTP then interacts with several effector proteins such
as Raf and PI3-Kinase. When Raf is activated it then activates MAPK, Erk and Mek 1
+ 2 (Hancock, 2003). MAP kinases have the requirement for both a tyrosine and a
threonine to be phosphorylated for full activation. Erk phosphorlates tyrosine 185 and
threonine 183 and this translocates Erk to the nucleus where it phosphorylates ELK-1.
ELK-1 is a gene regulatory protein which is in a complex with the serum response
factor, which upon phosphorylation binds to a specific DNA sequence (the serum
response element) (Marais et al., 1993; Price et al., 1996). This then activates ELK-1
turning on the transcription of fos and then the transcription of cyclin D and p21cip, the
former of which is involved in the induction of cell proliferation and the latter in
degradation of the cyclin which facilitates passage through G1 and allows entry into the
S-phase (Woods et al., 1997). Erk also phosphorylates MLCK (Myosin light chain
kinase) which in turn phosphorylates Myosin light chain. This leads to a fully
activational actin-myosin motor unit, serving the process of motility (Klemke et al.,
1997).
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There has also been a lot of focus on other members of the Ras superfamily,
Rho, Rac and cdc42, (Parise et ah, 2000). By activating Rho and Rac, cell migration is
stimulated and actin filaments are anchored to the cell membrane (Ren et al., 1999). This
in turn promotes cell cycle entry by stimulating cyclin expression (Assoian and
Schwartz, 2001; Jin and Varner, 2004). The Rho family of small GTPases, therefore
seems essential for the regulation of the actin cytoskeleton. Rho A has been implicated
in the formation of stress fibres, while Rac and cdc42 regulate the cortical actin
structures such as lamellipodia and filipodia (Parise et al., 2000). These findings indicate
that there is a detailed pattern of communication between integrins, small GTPases and
the actin cytoskeleton. This communication therefore plays an important role in
functions which are characteristic of metastatic tumour cells, such as invasion and
mobility.
Integrin engagement has been a suggested mechanism of activating members of
Rho GTPases. A direct demonstration of this is a study where ligation of 0C6p4 integrin in
clone A colon carcinoma cells, activated Rho A (O'Connor et al., 2000). It is also
thought that activated Rac and cdc42 couple to a variety of downstream effectors and
this may be achieved by integrin engagement. However the evidence for this remains
unclear (Parise et al., 2000).
In addition to a role in outside-in integrin signalling, small GTPases also play a
role in inside-out signalling by converting integrins to a high affinity state. A
constitutively active form of R-Ras (G38V) has been shown to increase adherence to
fibronectin and an increase in binding of soluble fibronectin. Zhang et al., (1996),
showed using CHO cells co-expressing both the platelet integrin aubP.^ and R-Ras
(G38V), that anbPi was converted to a high affinity state as detected by a monoclonal
antibody specific for the active conformation of the integrin. Hughes et al., (1997)
showed that H-Ras and its downstream effector kinase Raf 1 suppresses integrin
activation whereas Sethi et al., (1999) showed that R-Ras can reverse the suppressive
effect of both activated H-ras and its effector Raf-, therefore regulating integrin affinity.
Another small GTPase which has been implicated as an integrin activator is Rap-
1. Katagiri et al, (2000), found that Rap-1 is a potent activator of the leucocyte integrin
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LFA-1 and Reedquist et al., (2000), found that Rap-1 is an important component of a
pathway leading from CD31 or PECAM engagement to integrin activation.
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Figure 1.1.3b Ras/Mek pathway
Ras is activated by GEF's which release GDP and allow GTP binding. Ras-GTP then
interacts with Raf and PI3-Kinase. Raf activates MAPK which activates MEK which in
turn activates ERK 1+2. ERK phosphorylates tyrosine 185 and threonine 183 and this
translocates ERK to the nucleus. In the nucleus ERK phosphorylates ELK-1 which turns
on the transcription factor Fos which in turn transcribes cyclin D and many other genes
and induces cell proliferation. Erk also phosphorylates MLCK (Myosin light chain
kinase) which in turn phosphorylates Myosin light chain leading to a fully activational
actin-myosin motor unit, serving the process of motility.
PI3 Kinase (Phosphoinositol 3 Kinase) -pathway
Promotion of cell survival can occur via MAPK (ERK) ,NFkB, Bcl-2, PI3K and
AKT, whereas proteins such as c-Jun kinase (JNK), p38-kinase and Bad and the caspase
family of proteases can stimulate apoptosis. PI3-Kinase and its downstream effector
PKB/AKT (a serine threonine kinase), often plays a role in the regulation of cell
survival. After integrin engagement, receptor tyrosine kinases are activated and PI3-
Kinase is recruited to phosphotyrosine residues. PI3-Kinase catalyses the
phosphorylation of inositol lipids at the D-3 position of the inositol ring, resulting in the
formation of 3-phosphorylated phosphoinositides (King et al., 1997). These products
PtdIns(3,4,5)P3 (PIP3) and Ptdlns (3,4)Pt (PIP2) then stimulate 3-phosphoinositide
dependent protein kinase 1 and 2 (PDK1+2). These kinases phosphorylate Thr308 and
Ser473 on AKT respectively. AKT then phosphorylates many different downstream
substrates such as Bad (death effector) or phosphorylates Caspase-9, inhibiting its
protease activity, leading to cell survival (Parise et al., 2000). This pathway can be seen
more clearly in figure 1.1.3c.
As discussed earlier PI3-Kinase can be activated through autophosphorylation of
FAK, which consequently activates Rac-1. In addition to its role in membrane ruffling,
Rac-1 also activates PAK (p21 activated kinase) which phosphorylates Raf and Mek,
therefore having effects on transcription factors and cell migration. PI3-Kinase also
downregulates p21 cip, contributing to the induction of cyclin Dl, thereby affecting cell
cycle progression (Brakenbusch et al., 2002).
As mentioned earlier when normal cells are deprived of integrin-mediated
anchorage to the ECM they undergo a form of apoptosis, "anoikis". The importance of
FAK/ PI3K/ AKT pathway in anoikis has been reported by Frisch et al., (1996) and
Khwaja et al., (1997), however it also appears that this pathway is important in cell
survival and therefore an important mechanism to study in terms of malignancy.
Reduced apoptosis can contribute to tumourgenesis, since it helps tumour cells to escape
natural elimination (Brakenbusch et al., 2000). Many human tumours carry mutations in
20
the proteins of the PI3-kinase signalling pathway. This indicates the importance of

















Figure 1.1.3c PI3-Kinase pathway
Through autophosphorylation of FAK, PI3-Kinase is activated. PI3-Kinase can then
activate Rac-1, activating PAK which then phosphorylates Raf and MEK. PI3-Kinase
can also downregulate p21cip inducing cyclin D which affects the cell cycle. PI3-Kinase
can also promote cell survival through the production of AKT. The products PIP3 and
PIP2, these then stimulate production of PDK 1+2 which in turn phosphorylates AKT.
AKT then phosphorylates Bad or Caspase-9, promoting cell survival.
1.1.4. ROLE IN CANCER
The ability to proliferate in the absence of adhesion to the extracellular matrix
(ECM) is a property of cancer cells and is termed "anchorage independence" (Schwartz
et al., 1997). This property reflects the tendency of tumour cells to proliferate, survive
and their ability to migrate beyond their original location into other tissues to form
metastases (Brakenbusch et al., 2002). Therefore the relationship between tumour cells
and the ECM strongly influences tumour development. An essential requirement for the
survival of normal cells is cell attachment (Meredith et al, 1993). Complete loss of cell
contact with substratum or adhesion to non-specific substratum such as poly-L-lysine
induces apoptosis (Meredith et al., 1993; Frisch and Francis, 1994; Boudreau et al.,
1996; Stupack et al., 2001; Bakre et al., 2002; Kim et al., 2002). As mentioned earlier,
loss of contact does not however necessarily kill tumours, there are many examples of
oncogenes or mutational changes in survival factors, such as upregulation of Bcl-2 or
loss of p53 activity, which render the cells independent of survival signals (Jin and
Varner, 2004).
A gene or gene locus in which mutation, loss of function or reduction in
expression induces neoplasia is known as an oncogene. Oncogenes have the ability to
overcome the mechanisms involved in normal cell processes. It is now well known that
there is a connection between oncogenesis and integrins. As integrins are adhesion
receptors which are involved in mediating the interactions between normal cells and
tissues and the ECM they are essential for cell attachment and the control of cell
migration, cell cycle progression and programmed cell death (Brakenbusch et al 2002).




Anchorage independent tumour cells survive loss of contact with the substrate as
a consequence of oncogenic activity such as mutations in survival factors. However,
recent studies have shown that integrins can regulate survival. Stupack et al., (2001) and
Kim et al., (2002) have shown that cell death can occur when a subset of integrins in a
cell fail to bind their ECM ligands. Stupack et al., (2001), found that expression of OC5P3
or CC5P1 inhibited survival in cells attached to the matrix through other integrins. They
also found that expression of dominant negative integrins such as Tac(33, inhibited
survival by impairing normal integrin-mediated survival signalling. Suppression of
Caspase 8 activity was found to be a consequence of integrin engagement whereas
unligated integrins facilitated Caspase 8 activation and apoptosis (Kim et al., 2002).
Therefore integrins can control cell survival; ligation of integrins in normal cells allows
the cells to survive and apoptosis is initiated if the integrins do not engage (Jin and
Varner, 2004).
The main cause of mortality from cancer is not due to primary tumours but to
secondary tumours (Schwartz et al., 1997). A requirement for the formation of
metastases is the process of cell migration. Inititation of migration occurs when the cell
polarizes and the membrane protrusions form. These protrusions are fixed to the ECM
via integrins and this process promotes interactions with the actin cytoskeleton
triggering many different signalling molecules at the focal contacts. Cell contraction is
then stimulated through integrin signalling allowing the movement of the cell on the
adhesive contacts (Brakenbusch et al., 2002). This process is highly dependent on the
integrins affinity or avidity for various ligands.
Increased expression levels of certain integrins have been recently reported to be
associated with increased cell invasion and metastasis. OC5P3 has been found to be
expressed on invasive melanoma but not benign or normal melanocytes (Gehlsen et al.,
1992). Integrin ot6 has also been found to be significantly upregulated in numerous
carcinomas, including head and neck and breast cancers (Garzino-Demo et al., 1998;
Mercurio et al., 2001; Ramos et al., 20002).
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Angiogenesis
The ongoing formation of new tumour vasculature is a key part of tumour
progression. This process highlights another important way in which integrins modulate
tumour growth and behaviour (Keely et ah, 1998). Angiogenesis is the process by which
new blood vessels develop from pre-existing vessels. Regulation of angiogenesis is
carried out by growth factors and their receptors but also by the adhesive nature of the
ECM. Several integrins therefore play important roles in regulating angiogenesis. One
example of this is OC5P3, (X5P3 regulates the survival of newly sprouting blood vessels.
Friedlander et al., (1995), showed that antibodies to OC5P3 caused the regression of some
types of tumour in experimental animals by destroying the newly forming tumour
vasculature. Both OC5P3 and (X5P1 are significantly upregulated on the endothelium during
angiogenesis, and their expression partially controls angiogenesis (Brooks et al., 1999;
Kim et al., 2000). The transcription factor Hox D3 controls these integrins' expression
(Boudreau et al., 1997; Boudreau and Varner, 2003; Zhong et al., 2003), and is thought
to be the switch to activate angiogenesis. Therefore integrins play important roles in
regulating tumour angiogenesis.
Integrin inhibitors are thought to be possible theurapeutic agents for the
treatment of cancer. Antibody inhibitors for (X5P3, OC5P5 and OC5P1 are currently in clinical
trials for the inhibition of tumour angiogenesis. Vitaxin (LM609) is a humanised
monoclonal antibody against (X5P3 and reduces tumour-associated angiogenesis without
affecting normal blood vessels. Vitaxin inhibits growth of human xenografts in mice and
is being tested against a variety of cancers in patients (King, 2000).
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1.1.5 INTEGRIN CROSS-TALK
Cross-talk is defined in the Merriam Webster Collegiate Dictionary as
"unwanted signals in a communication channel (as in television, phone, radio or
computer), caused by transfer of energy from another circuit (as by leakage or
couplings)". An "unanticipated event", could also be added to this definition in terms of
a biological signalling network. An example of authentic cross-talk is trans-activation of
growth factor recptors by integrins. Trans-activation is the process where cell adhesion
through integrins causes the phosphorylation of several growth factors, such as PDGF,
FGF, VEGF, HGF and EGF. This process is therefore associated with the formation of
complexes containing both integrins and growth factor receptors, (Schwartz and
Ginsberg, 2002). c-Src, phosphoinositides and PKC are involved in cytokine and growth
factor-dependent signalling. FAK, pl30LJS and paxillin which localize to focal
adhesions, mediate integrin signalling, connecting downstream to growth factor
regulated pathways such as PI3-Kinase and MAP-kinase, (Schwartz et al., 1997). Moro
et ah, (1998), showed that an EGF receptor (EGFR) kinase inhibitor could block
adhesion dependent activation of the ERK/MAP-kinase pathway in cells which
expressed high levels of the EGFR. Pathways such as the PI3-Kinase or the MAPKinase
pathway provide multiple points of intersection between integrins and growth factors,
(Figure 1.1.5), (Zhou et ah, 2003)
The purpose of integrin trans-activation has been postulated as a method of
modulating rather than controlling growth factor signalling, (Schwartz and Ginsberg,
2002). However a possible downside to trans-activation could be the formation of
tumours. Mistaking signals from integrins as signals from growth factors could lead to
inappropriate cell growth leading to tumourigenesis, (Schwartz and Ginsberg, 2002).
This process of crosstalk and transactivation between integrins and growth factors
therefore needs to be examined in more detail and more understanding in this event, may
lead to new discoveries into malignant transformation.
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Figure 1.1.5 Crosstalk between integrin and growth factor receptors.
There are three steps in the process of convergence between integrin-mediated adhesion
and signalling by growth factor receptor. These steps are: 1) autophosphorylation and
activation of the receptors themselves; 2) hydrolysis of phosphatidylinositol 4,5-
bisphosphate (PIP2) to produce diacylglycerol and inositol triphosphate, leading to
activation of protein kinase C (PKC); 3) activation of Raf and/or MEK in the MAP-
• • p RSKkinase pathway and activation of PI3-Kinase, leading to activation of p70 and AKT
protein kinases. Figure adapted from Schwartz, 1997.
1.1.6 INTEGRIN-ASSOCIATED PROTEINS
Integrin Cytoplasmic domains
The cytoplasmic domain or tail of each subunit is actually the only portion of
each integrin that is directly "seen" by the cytoplasm (Yamada, 1997). Inside-out
signalling regulates the adhesive functions of integrins via the interaction of specific
intracellular proteins with the integrin cytoplasmic tail. (3 cytoplasmic domains have
been suggested to have an important role in targeting integrins to focal adhesions in a
ligand -independent manner. From analyses of chimeric integrin receptors or mutant a
and (3 subunits, (3 subunits have been shown to be necessary and sufficient for this
function (LaFlamme et al., 1997). The a cytoplasmic domains regulate the specificity of
the ligand-dependent interactions (Sastry et al., 1993; LaFlamme et al., 1994).
B cytoplasmic domains
As mentioned above (3 cytoplasmic domains are required for most aspects of
integrin function, including cell adhesion and signal transduction events (Sastry and
Horwitz, 1993). Chimeric receptors containing (3 cytoplasmic domains, connected to
extracellular reporters such as IL-2 receptor extracellular domain (the Tac Ag) or the
CD4 extracellular domain were sufficient to activate specific signalling events (Akiyama
et al., 1994; Lukashev et al., 1994). (3 cytoplasmic domains have also been shown to
function as dominant negative mutants, and inhibit endogenous integrin functions such
as fibronectin matrix assembly, cell spreading and cell migration (LaFlamme et al.,
1994). Several cytoskeletal and signalling proteins have been found to bind to integrin (3









A guanine nucleotide exchange protein.
Overexpression increases 0ClP2
adhesion.
pp59ILK Pi, P2 and P3





Interacts with o^Pi and overexpression
increases cell spreading and decreases
motility.
CIB allb Calcium binding protein.
ICAP-1 (31
Ligation of pi integrins induce ICAP-1
phosphorylation.
ppl25FAK P subunits
A tyrosine kinase which localizes to
focal adhesions and overexpression
induces increased migration.
Filamin P1A,P2, P3 Structural cytoskeletal protein
Talin p, allb Structural cytoskeletal protein
Paxillin p subunits Structural cytoskeletal protein
Table 2. Cytoplasmic proteins which interact directly with integrin cytoplasmic
domains.
Table adapted from Fernandez et al., 1998; Hughes and Pfaff, 1998; Brown, 2002.
Interactions of proteins with integrin cytoplasmic domains.
Cytohesin-1, is a cytoplasmic protein which has been shown to be a guanine
nucleotide exchange protein for ADP-ribosylation factor (ARF) responsible for the
formation of active ARF-GTP (Meacci et al., 1997). However it has also been shown to
regulate (32 integrins (Table 2); when overexpressed, (XL^-dependent binding to ICAM-
1 was induced (Kolanus et al., 1996). Cytohesin contains a PH domain which binds to 3-
phosphorylated phosphoinositides and a sec 7 domain which binds to the (3a tail (Shattil
et al., 1990).
The serine threonine kinase p59 ILK has also been shown to bind to integrin (31,
(32 and (33 cytoplasmic tails. When overexpressed, p59 ILK disrupts cell-substratum
adhesion (Hannigan et al., 1996).
(33-endonexin, which is specific for (33 tails (Shattil et al., 1995), has been shown
to regulate the affinity state of GCnbP.i when co-transfected into CHO cells and analysed
by FAC's (Kashiwagi et al., 1997).
FAIC
Focal adhesion kinase (ppl25 ) and paxillin have been shown to interact
directly with integrin cytoplasmic domains (Shaller et al., 1995). The N-terminal domain
of FAK has been shown to bind directly to the cytoplasmic tail of the (31 subunit.
Paxillin and other cytoplasmic proteins such as F-actin, talin, tensin and vinculin have
all been shown to associate directly or indirectly with integrin cytoplasmic domains,
connecting the actin cytoskeleton with the integrin cytoplasmic domain (Fernandez et
al., 1998).
The cytoskeletal protein talin, binds to most integrin (3-tails (Calderwood et al.,
2000). It has been shown to have a modulating effect on integrin activation. Talin
binding to integrin (3 tails activates integrins (Calderwood et al., 1999, 2002; Kim et al.,
2003), and if this interaction is disrupted integrin activation is prevented (Tadokoro et
al., 2003). Calderwood et al., (2004) have now shown that competition for talin results in
trans-dominant inhibition of integrin activation. This trans-dominant inhibition of
integrin activation is one form of integrin cross-talk and occurs when ligand binding to
30
one integrin inhibits the activation of a second integrin. This process may have a role in
normal physiology, such as leucocyte transmigration, platelet adhesion and control of
angiogenesis. This finding could have implications for the mechanisms of drugs that
target integrins (Reiderer et ah, 2002; Schwartz and Ginsberg, 2002; Hynes, 2002).
A number of calcium binding proteins or calcium dependent proteins have been
reported to associate with integrin cytoplasmic domains. An example of these proteins is
Calpain, which is a calcium dependent protease, and thought to cleave the cytoplasmic
domains of integrins. It has now been reported that it regulates migration. Huttenlocher
et al., (1997) demonstrated that a.^pi and 0Ciib|33 mediated migration in CHO cells could
be blocked when Calpain inhibitors were used in the system. Another protein thought to
interact with integrin cytoplasmic domains is Calreticulin. Calreticulin is an intracellular
calcium binding protein and has been shown to interact with a highly conserved GFFKR
motif present in the a subunit cytoplasmic domains. It has been suggested to associate
with active but not inactive OC2P1 and acts by maintaining the integrin in a high affinity
state, primed for ligand binding (Coppolino et al., 1995).
ICAP-1 (Integrin cytoplasmic domain associated protein-1) is another protein
thought to have a role in the regulation of affinity or avidity modulation. Chang et al.,









IAP (33 Thrombospondin-1 receptor.
uPAR (31,(32 and (33 Association required for cell migration,
tumour invasion and host defense.
TM4SF (CD9,
CD81, CD151 etc.)
(31, a4(37,aL(32 Precise function unknown at present but
may play a role in ahesion, motility and
aggregation via integrins
MMP-1 oc2(31 ECM degradation, possible members of
a supramolecular complex.
MMP-2 a5(33 ECM degradation, possible members of
a supramolecular complex.
CD98 PI Amino acid transporter, regulator of
integrin function.
Table 3 . Membrane anchored and GPI-linked proteins which interact directly with
integrin cytoplasmic domains.
Table adapted from Fernandez et al., 1998; Porter and Hogg, 1998; Brown, 2002.
Membrane-Anchored proteins
Many transmembrane or GPI-linked membrane proteins have also been shown to
bind to integrins, via immunoprecipiatation experiments or colocalization analysis using
fluorescence microscopy, (Table 3). It has been clear over the past several years that
integrins do not only work as individual receptors but also as components of
supramolecular complexes at the plasma membrane (Brown, 2002).
Possible components of these supramolecular complexes are matrix
metalloproteinases (MMP's). MMP's are secreted proteins but have been found to bind
to cell-surface integrins. MMP-2 has been shown to interact with OC5P3 (Brooks et al.,
1998), and when this association is blocked, angiogenesis is inhibited. Silletti et al.,
(2001) reported that this inhibition indicated a physical association between integrin and
protease is required for angiogenesis and enhancement of endothelial proliferation or
migration.
GPI-linked proteins (glycan phosphatidylinositol-linked) also associate with
integrins. An example of this association is with Urokinase-type plasminogen activator
receptor (uPAR). uPAR is a heavily glycosylated cell surface receptor which binds to
urokinase and vitronectin (Chapman, 1997). uPAR and pi integrins interact directly as a
consequence of a conformational change in the integrin and lead to an inhibition of
adhesion to fibronectin (Wei et al., 1996). uPAR has also been shown to interact with P2
integrins activated by mAbs (Fernandez et al., 1998).
CD47, also known as IAP (integrin associated protein), is a receptor for
thrombospondin. It spans the membrane five times and co-immunoprecipitates with p3
integrins. It has been shown that CD47 binding to thrombospondin induces the
activation of the platelet integrin oqibp3 (Lindberg et al., 1994; Chung et al., 1997).
CD47 has also been shown to associate with OC5P3. This association is dependent on
cholesterol. It is thought that this cholesterol is required for a conformational change to
the molecule CD47 in order for CD47 to associate with OC5P3 (Green et al., 1999).
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Tetraspanin molecules such as CD9, (a member of the transmembrane 4
superfamily which spans the membrane four times) have also been shown to have an
integrin association. CD9 has been shown to co-localize with ocubP^ in platelet a-granule
membranes and filopodia (Brisson et ah, 1997). Gutierrez- Lopez et ah, (2003) reported
the presence of a functionally relevant epitope on CD9 whose expression depends on
CD9's association with o^Pi.
CD98 is a 125kDa heterodimeric transmembrane glycoprotein amino acid
transporter. It has now been recently implicated as a regulator of integrin activation,
using a screening strategy based on identifying proteins that overcome dominant
suppression (Fenczik et ah, 1997). It has also been shown to associate with integrins
through the (3ia cytoplasmic tail (Zent et ah, 2000). This association modulates integrin
avidity and adhesion (Fenczik et ah, 1997; Warren et ah, 2000). Fenczik et ah, (1997),
also found that crosslinking CD98 using monoclonal antibodies stimulated (31 -dependent
adhesion. These studies indicated that CD98 is involved in the regulation of ligand
binding activity of integrins. Therefore for my thesis I wanted to explore the exciting




CD98 is a heterodimeric glycoprotein which is ubiquitously expressed on cell
surfaces and is highly conserved between species. It was discovered in 1981 by Haynes
et al., while studying monoclonal antibodies reactive with lymphocyte cell surface
differentiation antigens. It was previously known as 4F2 but was later given a cluster
designation (CD) number at the Fifth International Workshop and Conference on Human
Leukocyte Differentiation Antigens (Diaz et al., 1995). CD98 has been shown to have
many functional effects in processes such as adhesion, fusion and amino acid transport.
It is also highly upregulated following cellular activation. However no definitive role for
CD98 in cell activation has been established.
1.2.1 MOLECULAR STRUCTURE
CD98 is a disulphide linked 125 kDa heterodimeric type II transmembrane
glycoprotein. It is composed of a glycosylated heavy chain of 80 kDa and a non-
glycosylated light chain of -40 kDa (Haynes et al., 1981).
Heavy Chain
Three separate laboratories, Lumadue et al., 1987; Quackenbush et al., 1987 and
Texeira et al., 1987, have cloned the cDNA for the heavy chain of CD98. The sequence
was predicted to encode a glycosylated protein of 529 amino acids. Amino acids 83-106
encode a single transmembrane segment. The CD98 protein was found to have an
extracellular carboxyl terminus and an internal amino terminus. This orientation is
shared by other type II transmembrane proteins, eg. the transferrin receptor, the HLA-
associated invariant chain (Bertran et al., 1992) and CD69.
The primary sequence contains four potentially glycosylated asparagine residues
which are located in the carboxy-terminal half of the protein (Deves and Boyd, 2000).
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Cysl09 has been shown to participate in disulphide bond formation with the light chain
(Pfeiffer et ah, 1998; Torrents et ah, 1998) as shown in figure 1.2.1.
The murine (Parmacek et al., 1989), rat (Broer et al., 1997) and hamster (Fenczik
et al., 1997) CD98 heavy chain have been cloned and showed a high level of sequence
identity to human CD98 heavy chain (CD98HC).
Light Chains
The CD98 light chains consists of 502-535 amino acids and are predicted to be
very hydrophobic proteins with 11 or 12 putative transmembrane domains (Nakamura et
al., 1999). These light chains are linked to the CD98 heavy chain throught the
extracellular cysteine, Cysl09, which participates in disulphide bond formation (Pfeiffer
et al., 1998). So far 7 cDNA's encoding distinct chains have been identified.
LAT-1, y+LAT-l, y+LAT-2, xCT and LAT-2 have all been shown to be linked
with the CD98HC (Okamoto et al., 2002). The heterodimer composed of LAT-1 and
CD98HC is known to be responsible for sodium independent neutral amino acid
transport (L-type transport). The LAT-1-CD98HC heterodimer is found ubiquitously
and is highly expressed in proliferating tissues, in particular tumour tissues, suggesting a
role in amino acid transport (Meier et al., 2002). LAT-2-CD98HC is found only in
tissues containing epithelial barriers (Bassi et al., 1999; Pineda et al., 1999; Rossier et
al., 1999; Segawa et al., 1999; Rajan et al., 2000). LAT-2 transports large and small
neutral amino acids with a lower affinity than LAT-1 (Pineda et al., 1999; Segawa et al.,
1999). y+LAT-1 and y+LAT-2 are associated with y+ L- type transport which transfers
basic amino acids in a sodium-independent manner and neutral amino acids in a sodium
dependent manner. The xCT-CD98HC heterodimer transports cysteine/glutamate
(Okamoto et al., 2002).
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Figure 1.2.1 Proposed model of CD98.
The heterodimer is composed of a glycosylated heavy chain (yellow) and a light chain
with 12 transmembrane domains (purple). The two types of subunits are connected by a
disulphide bond. Redrawn from Mastroberadino et al.,1998; Deves and Boyd, 2000.
1.2.2 THE GENE
The CD98HC is located on the long arm of chromosome 11 and is composed of
nine exons and spans approximately 8 kb (Diaz et al., 1998). The expression of
CD98HC is partially regulated by a 5' upstream G+C rich binding sites with four
potential Spl (transcription factor) binding sites (Deves and Boyd, 2000). No studies
have been carried out on the genes encoding the light subunits. However Nakamura et
al., (1999), indicated that the CD98HC is expressed on the cell surface as a monomer on
its own, whereas the CD98LC is transported to the plasma membrane only in the
presence of the CD98HC.
1.2.3 TISSUE EXPRESSION
CD98 is ubiquitously expressed and highly conserved between species. It is
expressed at low levels on the surface of quiescent cells but is rapidly upregulated
following cellular activation. This level of expression remains elevated until the cell
cycle is complete (Azzarone et al., 1985; Suomalainen et al., 1986; Parmacek et al.,
1989). CD98 is strongly expressed on human embryonic fibroblasts but this expression
gradually diminishes from 100 to 1% on fibroblasts from normal adults (Azzarone et al.,
1985). CD98 has been found to be highly expressed on many tumour cell types (Bellone
et al., 1989; Dixon et al., 1990) as shown in figure 1.2.3. Increased CD98 expression has
also been shown to have a correlation with the development, progression and metastatic
potential of tumours (Esteban et al., 1990; Garber et al., 2001; Yoon et al., 2003).
LAT-1 message is highly expressed in the brain, spleen, and placenta and at very
low levels in epithelial cells and adult liver (Kanai et al., 1998; Prasada et al., 1999;
Nakamura et al., 1999). LAT-2 is highly expressed in the kidney and placenta and at
lower levels in liver, skeletal muscle and heart (Pineda et al., 1999). Human y+ LAT-1
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Figure 1.2.3. CD98 is highly expressed in tumour tissues.
Photographs showing various tumour tissues. Expression of CD98 is shown here by
areas of brown staining.CD98 is highly expressed in Small Cell Lung Cancer.
Pictures courtesy of N Henderson.
1.2.4 FUNCTIONS
Fusion
Membrane fusion is an important process in many cellular functions such as
exocytosis, endocytosis, organelle formation and intracellular trafficking.
Multinucleated giant cells are considered to originate from the fusion of monocyte-
macrophage lineage cells and have been induced in vitro from human blood monocytes
(Anderson, 2000). Multinucleated giant cells can be classified into two groups,
Langhans' giant cells or foreign body giant cells (FBGC's). Langhans' giant cells are
commonly seen in infective granulomatous diseases such as tuberculosis and
schistosomiasis and the granulomatous disorder sarcoidosis. FBGC's are most
commonly found in foreign body granulomas. However in addition to these two groups,
the osteoclast and HIV-1 induced CD4+ T cell derived synctia are also considered
multinucleated giant cells.
Ito et al., 1987 previously found that synctium formation in Newcastle Disease
Virus (NDV)-infected L929 cells was enhanced after addition of anti-L929 anti-serum to
culture medium. This finding suggested that there were factors present on the cell
surface of host cells capable of regulating virus-mediated cell fusion. Monoclonal
antibodies capable of enhancing cell fusion were isolated and 2 molecules gp80 and
gpl35 were immunoprecipitated. These molecules were designated fusion regulatory
proteins, FRP-1 and FRP-2 respectively. They were found to induce HIV-mediated cell
fusion. When U2ME-7 cells, a cell line transfected with the HIV gpl60 gene, were
cultured in the presence of anti-FRP-1 mAb or anti-FRP-2 mAb, formation of synctium
occurred (Ohta et al., 1994). Tabata et al., (1994), also found that antibodies raised
against FRP-1 could also enhance cell fusion induced by the measles virus. Ohgimoto et
al., (1995) then reported that eleven of fifteen N-terminal amino acids of FRP-1 were the
same as the amino acid sequence of the CD98 heavy chain. The functional properties of
FRP-1 were also very similar to those of CD98. They found that HBJ127 (heavy chain
sub-unit of CD98 mAb) induced multinucleated giant cells in U2ME-7 cells and
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treatment of monocytes with other antibodies (4F2, H227) directed against CD98
resulted in the formation of polkaryocytes. Ohgimoto et al., (1996) also found that by
modifying the FRP-1 system, the HIV-mediated cell fusion could be regulated. This was
demonstrated by FRP-1 (CD98HC) monoclonal antibodies either suppressing or
inducing multinucleated giant cell formation, indicating that FRP-1/CD98HC is a
multipotential molecule. This finding was further clarified by work carried out by
Okamoto et al., (1997).They found that anti-FRP-1 antibodies which enhanced cell
fusion in Newcastle Disease Virus infected Hela cells, delayed human parainfluenza
virus type 2 (HPIV-2) induced cell fusion. Both of these viruses belonged to the same
genus, Rubulavirus indicating that anti-FRP-1 antibodies could not only enhance/induce
but also inhibit/delay virus induced fusion, suggesting that CD98 is a multi-functional
molecule. This was further confirmed when the same authors using mutated CD98
constructs, caused dominant negative suppression of CD98HC induced fusion. The
CD98 constructs either had the cytoplasmic domain replaced with the cytoplasmic
domain of human parainfluenza virus type 2 (HPIV2) haemagglutinin-neuramidase
(HN) or the FRP-1/330 cysteine was mutated to serine. Anti-FRP-1 antibodies enhanced
NDV polkaryocyte formation in Hela cells whereas in NDV- infected cells constitutively
expressing FRP-l/HN, anti-FRP-1 antibodies had no effect on polykaryocyte formation.
These constructs proved that an intact CD98 molecule is required for viral-mediated cell
fusion. The authors also speculated that the dominant negative suppression was a
consequence of sequestering the CD98 light chain. The mutation (C330A) abolishes the
covalent bond link between the heavy and light chain and also inhibited viral induction
of fusion.
FRP-1/CD98HC is expressed selectively on monocytes but is absent on other
PBMC's and granulocytes (Tabata et al., 1994). Anti-CD98HC monoclonal antibodies
have been shown to promote (32 integrin activation stimulating monocyte cell-cell
aggregation. This subsequently activates (31 promoting cell fusion and polykaryocyte
formation. This effect however could be blocked by a (32 antibody (Ohta et al., 1994)
suggesting that integrin activation may be involved in the effect of the antibody. This
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was clarified by work carried out by Fenczik et al., (1997), on the role of CD98HC on
integrin activation.
Kudo et al., (2003) showed by manipulating CD98 expression by transfection
with the anti-sense oligonucleotide, that the rate of cell fusion is suppressed in placental
synctiotrophoblast formation. They also showed that following fusion, amino acid influx
activity through system L is inhibited by anti-sense oligonucleotides to CD98. This
indicates that there is a posssibility that amino acid transport plays a role in cell fusion
and that the CD98LC may be invoved in the induction of cell fusion through amino acid
transport.
FRP-1/CD98HC antibodies have also been found to be capable of fusing blood
monocytes giving rise to multinucleated cells which express structural and functional
properties of osteoclasts (Higuchi et al., 1998). The osteoclast is responsible for bone
resorption and membrane fusion is the first step of osteoclast formation. Higuchi et al.,
(1998,1999), found that when human blood monocytes were incubated in the presence
of anti -FRP-1/CD98HC mAb, TRAP (tartrate resistant acid phosphatase, an osteoclast
marker)-positive multinucleated giant cells appeared present. Mori et al., 2001 found
that an inhibiting CD98HC mAb (HBJ127) blocked cell fusion but also suppressed
RANKL (receptor activator of NF-kB ligand)-induced cell fusion and this indicated that
there is cross-talk between the CD98 mediated and RANKL-mediated
osteoclastogenesis. However how NF-kB pathways are involved in CD98 function is
unknown at present.
Integrins and Intracellular signalling
In addition to a possible involvement in NFkB and RANKL-induced
osteoclastogenesis, CD98 has also been shown to have a role in other intracellular
signalling pathways.
Warren et al., (1996), obtained evidence that CD98 could transduce signals that
manifested in both the tyrosine phosphorylation of a ~125kD protein and the induction
of homotypic aggregation in a Pro-T cell progenitor line. They elucidated this using a
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Jorol77 monoclonal antibody which they found in their search for cell surface markers
expressed on hematopoietic stem cells. By searching in databases such as BLASTn,
BLASTx and GAP programs they showed that Joro 177 cDNA had 77.5% nucleotide
sequence identity, 76.4% and 86.4% amino acid sequence identity and similarity to the
heavy chain of CD98.
The involvement in intracellular signalling was further confirmed by work
carried out by Fenczik et ah, (1997), on the role of CD98 in integrin activation. By
designing a new genetic cloning strategy based on changes in integrin affinity, Fenczik
et ah, (1997), identified a potential modulator of integrin activation. They used a CHO
cell line stably expressing a chimaeric integrin (a2b 0C6A (33(31) that contains the
extracellular and transmembrane domains of 0C2b|33 fused to the cytoplasmic domains of
0(6Apl. This chimaeric integrin was activated through the 0C6a(31 but had the ligand-
binding properties of 0C2b[33. In CHO cells this chimaeric integrin is constitutively active.
When isolated integrin (31 cytoplasmic domains (Tac(3l chimera) were overexpressed,
integrin signalling was suppressed however when a(3py cells were co-transfected with a
CHO-cell cDNA expression library and Tac(3l, FACs analysis produced cDNA's which
complemented (rescued) dominant suppression. 5F8 was a single cDNA , and was found
to be able to reverse Tac(3l suppression. After a BLAST database search, 5F8 was found
to be 72% identical to the heavy chain of 4F2/CD98.Having identified CD98 as a
potential modulator of integrin activation they investigated CD98's role in integrin
function. They found that the anti-CD98 monoclonal antibody 4F2 markedly enhanced
SCLC cell adhesion to both laminin and fibronectin. Fab fragments of 4F2 did not
enhance SCLC adhesion suggesting therefore that clustering of CD98 is required for
4F2-induced upregulation of (31 function.
In addition, Chandrasekaran et al., (1999), showed that the a3(3l integrin
mediated adhesion of MDA-MB435 and MDA-MB231 breast cancer cells to
thrombospondin-1. Thrombospondin (TSP-1) is an extracellular matrix glycoprotein
which has diverse effects on cell behaviour. Via the integrin a3(3l they also showed that
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adhesion to laminin and TSP-1 could be stimulated by exogenous stimuli such as the
ligation of CD98 and IGF-1.
The role CD98 plays in integrin activation was investigated further by Zent et al.,
(2000). They reported that CD98 associated with integrin P cytoplasmic domains and
that this association occurred in a specific manner. CD98 only interacted with integrin
P cytoplasmic domains which were a particular class and splice variant. In particular
CD98 associated with pi A but not plD or p7 integrin cytoplasmic domains. This group
also showed that the capacity of CD98 to overcome dominant suppression of integrin
activation correlated with its capacity to bind to integrin tails. Many groups have been
unable to crosslink the CD98HC to pi integrins however Merlin et al., (2000), showed
that CD98 could selectively co-immunoprecipitate with both LAT2 and pi integrins and
were all polarized to the basolateral domain. They concluded that by associating with
pl integrins, CD98 may influence pi integrin distribution and function. Cho et al.,
(2001), confirmed that there was an important interaction between CD98 and pi. They
revealed this by analysing their respective aggregation properties. The aggregation
produced CD98 and pi shared many properties, suggesting that the heterogeneity
between the aggregation induced by CD98 and pi reflected the presence of specific
conformational epitopes on the CD98 molecule and indicated that only some of these are
involved in inducing aggregation. However there was also differences between the
induced aggregational properties of CD98 and p 1, CD98 induced aggregation was
EDTA insensitive compared to that of pi induced aggregation therefore, suggesting that
CD98 did not require divalent cations and implied that pi plays a role in the inductive
phase of the response rather than mediating the actual cell-cell adhesion.
Warren et al., (2000), also found evidence of a functional association between
CD98 and integrins in lymphocytes. They found that uniquely for a non-integrin, CD98
co-stimulation could be blocked by an antibody to pi integrin. They previously showed
that T-cell co-stimulation mediated by integrins a4pl, a5pi, a4p7 and ocLp2 could be
partially prevented by a pl integrin specific monoclonal antibody 18D3. They found that
co-stimulation mediated by non-integrins was unaffected; however in 2000 they reported
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that CD98 was uniquely sensitive and affected by the inhibitory effects of pi blocking
antibodies.
Kolesnikova et al., (2001), demonstrated that CD98 constitutively and
specifically associated with intact (31 heterodimers. They showed that the CD98-integrin
interaction occurred in the context of low density protein-lipid microdomains,
suggesting that lipid rafts may be involved. Kolesnikova also demonstrated that the
CD98 light chain might be necessary for CD98-integrin association by using mutants of
extracellular cysteines. These cysteines were mutated to serine, C330S or C109S. C330S
retained association with (31 in NIH 3T3 cells but C109S (cysteine required for
disulphide linkage to the light chain) showed no detectable (31 association. However this
finding was in disagreement with that of Fenczik et al., (2001). By using chimeras of
CD98HC and a type II transmembrane glycoprotein CD69, they examined the
relationship between CD98HC's ability to stimulate amino acid transport and affect
integrin function. They reported that mutations of cysteines which disrupt CD98HC and
light chain association had no effect on integrin activation and did not disrupt its binding
to (31A. They also showed that the cytoplasmic domains and transmembrane domains of
CD98HC were necessary and sufficient for effects on integrin function. However if
those domains were replaced with those of CD69, while affecting integrin fucnction,
these replacements had no effect on the amino acid transport function of CD98HC. This
therefore indicated that the amino acid transport activity of CD98HC is not required for
its effects on integrin function.
By clustering (31 integrins, Rintoul et al., (2002), proposed that CD98 acts like a
"molecular facilitator", when crosslinked resulting in integrin activation and adhesion.
They showed that CD98 and (31 integrin were constiuitively colocalized in SCLC cells
regardless of integrin activation state and cell polarization. They also found that by
crosslinking CD98, PI3-kinase, its product PIP3 and its down stream effector PKB/AKT
were stimulated. This finding was in agreement with reports by Ito et al., (1992) and
Warren et al., (1996), in which they showed that tyrosine kinase activation mediated
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CD98 homotypic aggregation. PI3-kinase can be activated by receptors with intrinsic
tyrosine kinase activity.
There is increasing evidence that CD98 can regulate different types of adhesion
molecules through distinct mechanisms. Kakugawa et ah, (2003), demonstrated that
anti-CD98 antibodies could induce rapid cell aggregation in BaF3 cell lines expressing
CEA-CAM1, but not in parental BaF3 cells. A significant portion of CEA-CAM could
also be co-immunoprecipitated by anti-CD98 mAb and CEA-CAM 1 and CD98 were
also found to be colocalized at the cell adhesion sites. These results suggested that CD98
stimulation could activate the cell adhesion mediated by CEA-CAM 1. This finding
supported the idea that CD98 acts as a "molecular facilitator" in the plasma membrane.
A molecule which plays a role in integrin-dependent cell adhesion is Rap-1. Suga
et al., (2001), showed that the Ras-related GTPase known as Rap-1 can be activated by
crosslinking CD98 which stimulates LFA-1 through the PI3-kinase pathway. The
activation of LFA-1 via CD98 was completely inhibited by PI3-kinase inhibitors such as
wortmannin and Ly294002. This suggested the involvement of PI3-kinase pathway and
the involvement of "inside-out" signalling for integrin activation. They proposed that
LFA-1 activation by PI3-Kinase generates active Rap-1 GTP, both mediating
cytoskeletal cell adhesion and increasing (32 activation in forming a positive feedback
loop.
The physical association between CD98 and (31 has recently been further
confirmed by work carried out by Miyamoto et ah, (2003) on T-lymphocytes. They
showed that (31 integrin and CD98 colocalized to the same region of a T-lymphocyte and
demonstrated that (31 could be reprecipitated from CD98 complexes from T-
lymphocytes lysates.
All of these findings implicate a role for CD98 in integrin function and suggest
that CD98 may be a member of macro-molecular signalling complex. Integrin-mediated
interactions are required for many essential processes such as inflammation, cell
adhesion, migration, proliferation and differentiation. Therefore abnormal regulation of
integrin function may result in a disruption in growth control and altered cell function.
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This is confirmed by work carried out by many groups in which they have investigated
the role in which CD98 plays in cancer and tumorigenesis.
Transformation
Anchorage independence is a phenomenon which enables malignant tumour cells
to survive and grow. Oncogenes are genes or gene locus in which mutation, loss of
function or aberration in expression induces transformation. There is now increasing
evidence that CD98 has oncogenic potential. Parmacek et al., (1989); Nakamura et al.,
(1999), reported that the heavy chain of CD98 is expressed in most tissues and is present
in all cell lines and tumour cells. In addition, increased CD98 expression correlates with
the development, progression and metastatic potential of tumours (Esteban et al., 1990;
Garber et al., 2001; Yoon et al., 2003). Recently Yoon et al., (2003), examined the
alterations in CD98HC expression levels in hamster buccal cancers. They found that the
CD98HC expression level increased in correlation with the hamster buccal pouch
malignant progression.
In 1999, Hara et al., demonstrated that overexpression of CD98 induced
anchorage independent growth of NIH 3T3 cells. This was examined by testing the
ability of human CD98-transfected clones to grow in soft agar, as this is a measurement
of malignancy. This group also showed that overexpression of CD98 also caused
tumours to form in athymic mice and that the degree of malignancy of CD98-transfected
clones was proportional to the expression levels of CD98. In addition, in 2000, Hara
attempted to characterize the functional domains of CD98HC in terms of cellular
proliferation and malignancy. This was carried out by analysing the effects of truncation
of the extracellular domain. They found that expression of CD98HC with truncated
extracellular domain was sufficient to transform mammalian fibroblasts. These results
suggested that the extracellular domain of CD98HC played a regulatory role in the
process of malignant transformation.
Shishido et al., (2000) examined whether the light chain of CD98 was required
for transformation capabilities of the CD98HC. They showed in BALB 3T3 cells, that
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the ability to transfom by CD98 was lost when CI03 was replaced with a serine residue,
resulting in inability to associate with the light chain. These results suggested that the
association between exogenous CD98HC and endogenous CD98LC at the cell surface
was necessary for anchorage-independent growth induced by the transfection of
CD98HC. They also found that Cysteine 103 of the CD98HC is involved in the
disulphide linkage, which is in accordance with studies by Nakamura et ah, (1999);
Pfeiffer et ah, (1998). However the debate whether the CD98LC is required for CD98
functions other than amino acid transport goes on.
Recently Rintoul et ah, (2002), demonstrated that crosslinking CD98 can
promote anchorage independent growth in SCLC cells. These findings are producing
more and more evidence that CD98HC has oncogenic potential and plays a role in
tumourgenesis.
1.2.5 GALECTIN 3
The possible ligands for CD98 remain to be determined. One possibility is
Galectin 3. Galectin 3 is a lectin that recognises (3-galactosidase containing
carbohydrates. It is secreted from the cytoplasm of macrophages, eosinophils,
neutrophils and mast cells and then binds with appropriately glycosylated proteins either
at the cell surface or in the extracellular matrix. It then plays a role in cell signalling,
triggers superoxide production in neutrophils and potentiates IL-1 production by
monocytes (reviewed by Deves and Boyd, 2000).
Sato et al., (1992), showed that galectin 3 bound to matrix glycoproteins such as
tumour derived laminin and foetally derived fibronectin and blocked attachment and
spreading of cells to these matrices, suggesting a possible role for steric hindrance of cell
binding and modulation of integrin binding. Dong and Hughes, (1996) showed
exogenous galectin 3 bound to the surface glycoproteins, including CD98 of human
Jurkat T cell line.
However to date, no direct link between galectin 3 and CD98 and biological
function has been discovered.
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1.2.6 CALCIUM
Some evidence suggests that CD98 is involved in the regulation of intracellular
Ca2+ concentration via the Na+/Ca2+ exchanger. There is also evidence linking calcium
and galectin 3 , producing another possible link between CD98 and galectin 3. Posillico
et al., (1987), showed that incubating human parathyroid adenoma cells with the
monoclonal antibody 4F2 triggered a transient increase in intracellular Ca2+ and a
decrease in parathyroid hormone secretion. Dong and Hughes, (1996), as well as
demonstrating a possible link between CD98 and galectin 3 also showed that galectin 3
binding to cell surface glycoproteins lead to an increase in intracellular calcium.
However R.Rintoul (unpublished data) showed that stimulation with the CD98
monoclonal antibody 4F2 did not cause an increase in SCLC intracellular Ca2+
concentration.
1.2.7 TROPOMYOSIN AND OTHER CYTOSKELETAL PROTEINS
Shishido et al., (2000), reported that there may be a physical association between
CD98 and tropomyosin isoforms either directly or indirectly and that there may be a
possible functional relevance in cell-cell adhesion. This work confirmed findings by the
same group in which they found that vimentin, tropomyosin and heat shock cognate
protein 70 (hsc70), associated with FRP-1. By using monoclonal antibodies prepared
against immunoaffinity -purified FRP-1 complex and subsequently gene cloning using a
Hela lambda gtl 1 cDNA library (Suga et al., 1995).
1.2.8 NCAM (NEURAL CELL ADHESION MOLECULE)
The neural cell adhesion molecule (NCAM) is a member of the Ig superfamily. It
plays a pivotal role in neural development and synaptic plasticity (Ronn et al., 1998 and
Berezin et al., 2000). Three isoforms of NCAM are generated through alternative
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splicing, NCAM-120, NCAM-140 and NCAM-180. NCAM engages in homophilic
(NCAM-NCAM) and this has been suggested to induce neurite outgrowth (Kolkova et
ah, 2000) . New evidence has now come to light, showing that NCAM can also exert
heterophillic interactions with various molecules such as the cell adhesion molecule LI,
members of the FGFR family and signal transducing molecules such as FAK and p59fyn
(Cavallaro et ah, 2001 and Seidenfaden et ah, 2003). NCAM also plays an important
role in tumour progression. In many cancers, the expression of NCAM changes from
NCAM-120 to the transmembrane isoforms NCAM-140 and NCAM-180 (Cavallaro and
Christofori, 2001). Reduced overall levels of NCAM expression has also been shown to
correlate with increased malignancy and poor prognosis in pancreatic and colorectal
cancers (Fogar et ah, 1997). Cavallaro et ah, (2001) indicated that (31 integrin may play
a functional role in neurite outgrowth and matrix adhesion. They found that when
adherent NCAM+/+ tumour cells were treated with neutralizing antibodies against (31,
neurite outgrowth was abrogated. A relationship between CD98 and NCAM has yet to
be examined but it does seem to be a plausible concept as it could make up part of the
signalling complex formed by CD98 and the pi integrin.
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1.3. HYPOTHESIS
There is therefore abundant evidence that CD98 is an important signalling
molecule involved in cellular activation and tumorigenesis. My hypothesis is that CD98
expression leads to cellular transformation by interacting with (31 integrins to induce a
membranous signalling complex that activates intracellular signals which stimulate
mitogenesis and adhesion independent growth. This investigation therefore has
important implications for possible cancer therapy as this molecule appears to be present
in all cancers studied so far.
1. To discover the role CD98 plays in transformation.
To examine whether this transformation is dependent on PI3-Kinase
activation and serum concentration.
2. To find out whether CD98 colocalises with (31 integrin.
To find out what is the nature of CD98 interaction with integrins.
To investigate the role of lipid rafts in the CD98/Integrin interaction.
3. To examine which part of the CD98 molecule is important in these processes.
4. To investigate the effect CD98 has on the cytoskeletal organization and
microtubule network.
5. To examine whether there are any other molecules like CD98 which have
similar effects on integrins.
1.4. AIMS
To find out whether CD98 expression induces any phenotypical
changes.
To investigate whether there are any other molecules to accompany






Unless otherwise stated, all chemicals were purchased from Sigma (Dorset, UK). The
following reagents were obtained from Life Technologies (Paisley, UK): Dulbecco's
Modified Eagles Medium (DMEM); penicillin; streptomycin; dialysed foetal calf serum
(FCS); L-glutamine 30% (w/v) and non-essential amino acids.
For western blotting the following antibodies were used: anti-PKB or anti-phospho PKB
(serine 473) antibody (New England Biolabs Inc., Beverly MA), anti-FAK or anti-
phospho FAK antibody (pT397) (Biosource, Belgium), anti-ERK2 (C-14) or phospho-
ERK1/2 (ERK-PT115) Sigma, Dorset U.K), anti-PI3-Kinase p85 N-SH3 antibody
(Upstate Biotechnology, Lake Placid, USA), anti-CD98 antibody (SC-7095) (Santa Cruz
Biotechnology), anti-CD56 (NCAM) antibody (Abeam Ltd.,Cambridge, UK) and anti-
(31 integrin (141720 BD Transduction Labs). For flow cytometry protein A-purified 4F2
was used for identification of CD98 and CD98-chimeras containing the extracellular
domain of CD98. Anti-human CD69 (clone FN50 DAKO, UK) for identification of
CD69 and chimeras containing the extracellular domain of CD69. For |3l integrin the rat
clone 9EG7 was used (Pharmingen BD). For immunoprecipitation experiments the anti-
human pi integrin K20 (DAKO, UK) was used. All anti-species specific horseradish
peroxidase-conjugated antibodies were from DAKO; UK. All anti-species specific
Alexa-Fluor-conjugated antibodies were purchased from Molecular Probes (The
Netherlands).
Transformation competent Escherichia coli strain DH5a cells were purchased from Life




Full length human CD69 was kindly provided by Dr F Sanchez-Madrid (Madrid, Spain).
The CD98 HC chimeras were made by overlap polymerase chain reaction or restriction
digest and re-ligation. 98EC contains amino acids 1-81 of CD98 HC (Swiss-Prot
accession number P08195), amino acids 121-183 of CD69 (Swiss-Prot accession
number Q07108) and amino acids 105-529 of CD98 HC. 98ET contains amino acids 1-
40 of CD69 and amino acids 82-529 of CD98 HC. 98TC contains amino acids 1-104 of
CD98 HC and amino acids 62-199 of CD69. 98C contains amino acids 1-81 of CD98
HC and amino acids 41-199 ofCD69. 98T contains amino acids 1-40 of CD69, 82-104
of CD98 and 62-199 of CD69. 98E contains amino acids 1-61 of CD69 and 105-529 of
CD98. A98 deletes amino acids 2-77, which removes the entire cytoplasmic domain of
CD98 HC, maintaining the initiator methionine as well as the presumptive stop transfer
sequence Val-Arg-Thr-Arg. D5 (kindly provided by Drs D Merlin and JL Madara,
Atlanta, USA) deletes amino acids 1-86 which removes the entire cytoplasmic domain
and the five proximal amino acids of the transmembrane domain. The above cDNAs
were subcloned from pcDNAl into the BarnHI and Xho-l-digested mammalian
expression vector, pcDNA3.1 which confers neomycin resistance (Invitrogen). The
subcloned plasmids were verified by sequencing. Plasmids were purified using the
Qiagen Maxiplasmid kit.
2. 2Cell Culture
CHOKl cell line was purchased from ECACC (European Collection of Cell Cultures).
The CHOKl cell line was cultured in Dulbeccos Modified Eagles Media
(DMEM;Sigma), supplemented with 10% (v/v) foetal bovine serum (FBS-heat
inactivated at 57°C for 1 hour), 50 IU/ml penicillin, 50 IU/ml streptomycin, 5mg/ml L-
glutamine and 1% (v/v) non essential amino acids; all obtained from Life Technologies
(Paisley, UK). This will be referred to as complete media.
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When culturing stable cell lines expressing chimeras, G418 (antibiotic, Promega)
400 |ig/ml was used to maintain expression of chimeras.
Quiescent media for CHOK1 stables was supplemented with 0.1% (v/v) heat inactivated
FBS rather than 10%.
SCLC cell lines NCI-H69, NCI-H345 and NCI H510 were purchased from the American
Type Tissue Culture Collection (Rockville, Maryland, USA). All SCLC cell lines were
cultured in Rosewell Park Memorial Institute Medium 1640(RPMI 1640) containing
25mM Hepes supplemented with 10% (v/v) FBS (heat inactivated) and 50 IU/ml
penicillin, 50 IU/ml streptomycin, and 5|lg/ml L-glutamine.
Quiescent media for SCLC comprised RPMI-1640 with 25mM Hepes supplemented
with 0.25% (w/v) BSA and 50 IU/ml penicillin, 50 IU/ml streptomycin, and 5|lg/ml
L-glutamine.
All cell lines were maintained in a humidified atmosphere of 5% C02/95% air at 37°C
and were regularly screened for mycoplasma infection and were used at the lowest
possible passage number.
2.3 Transformation of Escherichia coli
Frozen aliquots of strains DH5a (Life Technologies) and Topl0/P3 (Invitrogen) were
thawed on ice and transferred to chilled eppendorfs. In the case of Topl0/P3 cells, |3—
mercaptoethanol 25mM final concentration was added to cell prior to addition of DNA.
DNA l-10ng was gently mixed with the cells and incubated for 30 mins on ice. Cells
were then heat shocked at 42°C in a thermomixer (Eppendorf, Cambridge UK) for 45-
60 seconds and returned to ice for a further 2 mins. Transformed cells were allowed to
grow for 60 mins by incubating the cells in antibiotic free SOC media @ 37°C. Cells
were then spread onto appropriate antibiotic selection plates. Plates were incubated at
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37°C overnight in an incubator. Individual colonies were picked into LB broth
containing antibiotics and grown overnight for DNA purification and restriction enzyme
digest verification.
2.4 DNA Purification
Small scale (1-10 ml) DNA purifications were performed using Wizard SV Miniprep kts
(Promega) as per manufacturers instructions. Large scale (100-500 ml) DNA
purifications were performed using Qiagen Endotoxin Free Maxi-Prep Kit
(Qiagen,Crawley UK) as per manufacturers instructions. For Low Copy plasmids the
Qiagen Mini-Prep kits were used together with their low copy number plasmid protocol.
Purified DNA was checked with diagnostic restriction digests with the appopriate
restriction enzymes (Promega) and were resolved on 1% Agarose (Seakem,
Rockland,Maine,USA.) gels containing 0.3|ig/ml ethidium bromide to enable UV
visualisation.
Quantification of purified DNA was performed using a Pharmacia Biotech Ultraspec
2000 UV spectrophotometer.
2.5 Cell Transfection
Transient transfections of CHOK1 cells was undertaken using Lipofectamine™ and the
Plus reagent (Invitrogen). Cells were seeded at an appropriate density to reach 50-70%
confluency overnight in 60/100mm tissue culture treated dishes (Corning, High
Wycombe, UK). Purified DNA was placed in 5ml BD Falcon tubes (Part No: 352034,
Oxford, UK) in a volume ranging from l-20pl. The DNA was pre-complexed with
11 OjllI of the plus reagent and gently mixed. The Plus reagent contained Plus reagent
0.25% (v/v) diluted in DMEM containing 1% (v/v) non-essential amino acids
(DMEM+AA). Following a 15 minute incubation at room temperature, the DNA was
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complexed with 110|ll of the Lipofectamine mixture and gently mixed. The
Lipofectamine reagent contained Lipofectamine 0.25% (v/v) diluted in DMEM+AA.
After a further 15 minutes incubation at room temperature, the transfection mixture was
made up to a final volume of 4 ml with pre-warmed DMEM+AA and placed onto
washed cells. Cells were cultured for 5 hrs at 37°C and fed with complete media (4ml).
Twenty four hours after transfection, media containing DNA and lipofectamine was
removed and replaced with fresh complete media.
For experiments where protein kinase activities were to be assessed, the transfection
media was replaced with quiescent media after 24 hrs.
2.5.1 Production of stable cell lines
For each plasmid DNA to be stably expressed, CHOK1 cells were transfected in 100mm
dishes using 3pg of plasmid DNA. Forty eight hours post transient transfection, CHO-
K1 complete media was supplemented with G418 at 800pg/ml (stable selection media).
Stable selection media was replaced frequently as untransfected cells began to die and
selected cells grew back to confluency. Once the 100mm plates were fully confluent,
cells were trypsinised, washed and resuspended in PBS (w/o ca and mg). The single cell
suspension was seeded into 96-well plates at a density of approximately one cell/well.
Cells were incubated at 37°C until clonal growth was observed in the wells (colour
change). Cells were trypsinised from the wells and plated out in duplicate wells (of 6-
well plates) and grown to confluency in selection media. Clones showing equivalent
wild type, mutated or truncated human CD98 expression by SDS page and western blot
analysis or by intracellular FACS staining were selected for this study.
2.6 Assessment of protein concentration
Protein concentrations were quantified using a BCA protein assay (Pierce, IF,USA). A
protein standard curve was generated using bovine serum albumin (Sigma) at a range of
0.1-0.5mg/ml diluted in 1:10 lysis buffer. Samples were diluted 1 in 10 in dH20 and
lOpl was incubated with 200fil BCA reagent (30mins, 37°C) in 96 well plates. Protein
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concentration was determined using an automated plate reader (MRX microplate reader,
Dynatech, Chantilly, VA).
2.7 SDS-PAGE and Western blotting
2.7.1 Cell lysis
Transfected cells were washed once with ice cold PBS and lysed at 4°C in an appropriate
amount of lysis buffer. Lysates were cleared by centrifugation at 13,000 rpm for 10
minutes at 4°C, assessed for protein concentration (described above) and solubilised in
4x sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer at 99°C for 5 minutes. Samples were analysed immediately or stored at -20°C for
future analysis.
Buffer
50mM Hepes (Na Salt), 0.3M NaCl, 1.5mM MgCl2, 1.2mM EDTA, 0.5% Triton X-100,
20mM p-glycerophoshate, lOOmM sodium fluoride, lOmM sodium pyrophosphate,
ImM sodium vanadate, 0.5mM dithiothreitol (DTT). One complete™ protease inhibitor
tablet (Boehringer Manheim, Lewes, UK) was added per 50 ml of lysis buffer.
2.7.2 SDS-PAGE and Western Immunoblotting
Samples were cooled and equal amounts of protein (10-lOOjlg) were resolved on SDS
polyacrylamide gels using a vertical electrophoresis tank Biorad protean 3 system
(Biorad, Hemel Hempstead, UK) and (ATTO corp., Japan). Samples were
electrophoresed at 100-150 Volts using SDS-Tris-Glycine electrophoresis buffer for 1-2
hours beside pre-stained molecular weight markers (Life Technologies, Paisley, UK).
For optimal separation, 8% gels were used for 60-120 kDa proteins, 10% for 40-70 kDa
proteins and 12% gels for 10-40 kDa proteins.
Proteins were transferred onto Hybond C nitrocellulose membranes (Amersham
Pharmacia Biotech, Amersham, UK), in a methanol based transfer buffer at 400
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milliamps for lhr using a Mini Protean II blotting tank (Biorad, UK). Equal protein
loading was confirmed by incubating blots for 5 minutes in Ponceau S (Sigma), which
allows visualisation of protein bands. Non-specific protein binding sites on the
membranes were blocked by incubation in TBS-Tween 20 containing 5% non-fat dried
milk powder overnight at 4°C. Membranes were washed in TBS-Tween 20 (3 x 30
second vigourous washes and 3 x 10 minute washes) before species appropriate
horseradish peroxidase (HRP) conjugated secondary antibody (DAKO, Ely, UK.)
(diluted in washing buffer ) was added for 1 hr.
Finally membranes were rewashed as above and immunoreactive bands were identified
using enhanced chemiluminescence, (ECL) (Amersham Pharmacia Biotech, Amersham,
UK.) as per manufacturers instructions.
Buffers
4x SDS-PAGE sample buffer
50mM Tris-HCl, 10% (v/v) glycerol, 2% (v/v) SDS, 0.1% (v/v) bromophenol blue and
10% (v/v) (3-mercaptoethanol.
Gel electrophoresis buffer
5mM Tris Base (pH 8.3 ), 25mM glycine and 0.01% (v/v) SDS.
Transfer buffer
210mM glycine, 24.7mM Tris Base and 20% methanol (v/v) methanol.
TBS-Tween 20 Wash buffer
TBS containing 0.2% (v/v) Tween 20 (Sigma).
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SDS polyacrylamide gels
Separating Gel: 0.375 M Tris Base (pH 8.8), 0.1% (v/v) SDS, 8-12 % (v/v) acrylamide
(Life Technologies, Paisley, UK.), 0.1% (v/v) ammonium persulphate and 0.08% (v/v)
TEMED.
Stacking Gel: 0.13 M Tris Base (pH 8.8), 0.15% (v/v) SDS, 4.6% (v/v) acrylamide,
0.13% (v/v) ammonium persulphate and 0.1% (v/v) TEMED.
2.8 Flow Cytometry
Aliquots of 5 xlO3cells were washed and resuspended in lOOul PBS containing lpg 4F2
(for CD98 and chimeras containing the extracellular portion of CD98) or lpg anti-CD69
antibody (for CD69 and chimeras containing the extracellular portion of CD69). Cells
were incubated for 30 minutes at room temperature followed by two washes with PBS.
Samples were then incubated with species specific appropriate FITC-conjugated
secondary antibody (1:50) (DAKO, UK.) for 30 minutes at 4°C and again washed twice
in PBS. Samples were finally resuspended in PBS and analysed by flow cytometry using
FACS Calibur™ (Becton Dickinson). Control IgG2a and IgGl antibodies for 4F2 and
CD69 respectively were also used.
2.9 Liquid growth Assay
Stably expressing CHOK1 cells were seeded into 100cm3 plate and left to grow for 10
days in a humidified atmosphere of 5% CC>2/95% air at 37°C. Plates of cells were then
removed at various time points and trypsinised and counted. Cell number was
determined using a Coulter Counter (Coulter Electronics, Luton, UK).
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2.10 Immunofluorescence
Transfected cells or stable cell lines were grown on sterile glass cover slips (22 x 22
mm, Fisher, Loughborough, UK) placed within 6-well tissue culture plates (Corning,
High Wycombe, UK), and left overnight in complete medium at 37°C. After 2 days of
growth, the media was removed and the cells were washed with PBS x 2.
2.10.1 Indirect Immunofluorescence- Formaldehyde Fixation
Cells were fixed using 2mls of 3% Paraformaldehyde solution (PFA) for 20 minutes at
room temperature. The PFA was then removed and the aldehyde groups were quenched
by incubating the cells with a solution of 50mM NH4C1/ CMF-PBS for 10 minutes at
room temperature. After further washing with TBS, non-specific binding sites were
blocked using l-2mls FSG( 0.2% Fish skin gelatin) for 30-60 minutes or overnight at
4°C.
2.10.2 Methanol (protein precipitation) Fixation
Coverslips were immersed in -20°C 100% methanol for 10 minutes. Cells were then
washed 3 x for 5 minutes in room temperature TBS. Cells were then quenched in fresh
0.1% sodium borohydride in TBS for 5 minutes. Non-specific binding sites were
blocked with 1% BSA for lhr with TBS.
2.10.3 50:50 Methanol:Acetone Fixation
Coverslips were immersed in -20°C 50:50 Methanol:Acetone for 30 seconds .Cells were
then washed 3x for 5 minutes in room temperature TBS. Non- specific binding sites
were blocked using l-2mls FSG( 0.2% Fish skin gelatin) for 30-60 minutes or overnight
at 4°C.
2.10.4 Triton Fixation : Used for cytoskeletal components.
Cells were fixed in 3% PFA for 3-5minutes at room temperature and then washed x 2
with PBS. Cells were then permeabilised with 0.1% TritonXlOO for 3 minutes. Cells
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were then washed in lx PBS + 0.05% Triton X 100 (PBSTX). Non-specific binding sites
were blocked with an incubation in FSG for lhr at room temperature.
After each fixation cells were probed with appropriate primary antibodies (Table
2.10.5) diluted in 0.2% FSG for a variety of different times either at room temperature or
at 4°C. Cells were washed with PBS/TBS/PBSTX (3x2 minute washes) before species
appropriate Alexa-Fluor-conjugated antibodies (Molecular Probes, The Netherlands)
was added, diluted in 0.2% FSG for 30 minutes on ice and in the dark. Cover slips were
removed from the tissue culture plates, washed in dFFO and allowed to dry. Coverslips
were mounted on slides using Mowiol.
All cells were visualised using a Leica TCS NT confocal microscope (Leica
Microsystems, Heidelburg GmbH) and images captured and analysed using Leica




















4F2 (anti CD98) 20pg/ml 1 hr at 4oC Alexa488-conjugated goat
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Table 4 Antibodies used in immunofluorescence studies
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2.11 Manipulation of plasma membrane cholesterol content using
Methyl-(3- cyclodextrin
Cells required for immunofluorescence were left attached to coverslips inside 6-well
plates with 2ml of quiescent media.
Cells were treated with PBS containing MpCD (Sigma) to a final concentration of 1%
and incubated for 1 hour at 37°C. Following incubation, MpCD-containing media was
removed and the cells were resuspended in 2ml quiescent media. For experiments
requiring cholesterol replenishment, 0.5mM cholesterol/ml was added to quiescent
media for 1 hour at 37°C in the form of cholesterol-MpCD inclusion complexes.
Cholesterol-MpCD inclusion complexes were produced as described by Klein et al.,
(1995). In brief, a solution of 30mg cholesterol (Sigma) in 400pl of 2:1 (v/v)
methanol/chloroform was added drop-wise to a stirred solution of lg MpCD in 11ml
PBS prewarmed in an 80°C waterbath. The solution was stirred at 80°C until a clear
solution resulted. The cholesterol-MpCD inclusion complexes were used immediately or
aliquoted and lyophilised. For convenience, 375pl (5 x 69.4gl) aliquots of the
cholesterol-MpCD inclusion complex solution were lyophilised. For use, the individual
aliquots could be resuspended in 5ml PBS to provide 5 x 1ml treatments (0.5mM
cholesterol).
Following treatment, cells were washed in PBS. Cells were then labelled with
appropriate antibodies or fixed for immunofluorescence as mentioned in section?
2.12 Anchorage-Independent Growth Assays (Colony assays)
CHOK1 cells (2x107ml were suspended in 0.3% (w/v) agarose in DMEM containing
1% FCS unless otherwise indicated. The cells were layered over a solid base of 0.5%
(w/v) agarose in DMEM in 6 well culture dishes. Cultures were incubated in a
humidified atmosphere of 5% CC>2/95% air at 37°C. After 6 days, colonies greater than
4 cells were counted using light microscope.
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A 50:50 mixture of Seakem agarose (Cambrex Bioproducts, Maine): low melting point
agarose (Sigma), was used to prepare 5% and 3% (w/v) (lOx) stock solutions of agarose
in sterile water, in autoclaved bottles. Solutions were boiled to dissolve the agarose and
stored at room temperature. On the day of the assay, stock solutions were melted and
maintained at 45°C in a water bath. The 0.5% agarose layer was prepared by diluting the
5% stock solution in warmed growth medium (i.e., DMEM + required serum
concentration); 2ml were added to each well of a 6 well plate.
Once the bottom layer had set, a single cell suspension containing 1x10 cells per ml of
growth medium (i.e., DMEM + required serum concentration + any required antibiotics)
was warmed and the melted 3% agarose stock was added to a final concentration of
0.3%. The cell and agarose suspension was mixed gently by pipetting to resuspend the
cells uniformly, then 2ml per well was added to the hardened 0.5% agar base layer and
left to set. Plates were covered with tinfoil, to prevent drying-out, and incubated at 37°C
in a humidified 10% CO2 environment. On day 6, the number of colonies from five
random fields was counted for each replicate.
Percentage cloning efficiency was calculated as follows:
(((Mean / 5*) x 160f) /2000s) x 100.
Mean Total colonies counted for each sample divided by the number of replicates (in
this case, n=3).
Number of fields viewed per well.
(Well area/ view area). Multiplying by this figure allows an approximation of the
total number of colonies per well to be made.
§ Number of cells seeded
For colony assays using SCLC cells, cells were washed and resuspended in quiescent
media before being disaggregated using a cell strainer into a single cell suspension, lx
103 cells /ml were added onto the top of the 0.5% (w/v) agarose layer in a 24 well plate.
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A 0.3% (w/v) agarose layer was then layered on to the top of the cells. After 3 weeks
SCLC colonies were stained using 5mg/ml MTT and then scanned in order to make
comparisons between treatments.
2.13 PI3-Kinase Activity Assay
Cultures of stably expressing CHOK1 cells were washed and resuspended in quiescent
media and incubated at 37°C for 24 hours. The following day cells were washed with
PBS and then treated with either :
- lOOnM Wortmannin for 20 minutes at 37°C
-20|ig/ml 4F2 for 10 minutes at 37°C
-10% FCS for 10 minutes at 37°C
The media was removed with an aspirator and the plates were washed with cold PBS.
The plates were then transferred to an ice bath. 1ml of ice cold lysis buffer was added to
the plates. The plates were then scraped and the cells were put into cold 2 ml
eppendorfs.
Ice cold Lysis Buffer:
50mM HEPES (pH 7.4), 150mM NaCl, 10% (v/v) glycerol, 1% (v/v) Triton X-100,
1.5mM MgC12, ImM EGTA, lOOmM sodium fluoride, lOmM sodium pyrophosphate,
ImM sodium orthovanadate, 0.5mM dithiothreitol and 1 protease inhibitor tablet to
50ml buffer.
The cells were then vortexed for 15 minutes at 4°C and then clarified by centrifugation
at 13,000 rpm for 10 minutes at 4°C. Protein concentration was equilibriated by
performing a BCA protein assay. For each assay point lflg of p85-SH3 PI3-Kinase
antibody was added and incubated overnight at 4°C.
30|ll of goat-anti-mouse IgG agarose beads in lysis buffer were added for an additional 2
hours. The beads were then pelleted and washed twice in lysis buffer, once with a high
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salt buffer containing lOOmM TrisHCl and 500mM LiCl (pH 7.6) and twice with a
solution containing 200mM HEPES, 40mM MgC12 and 600mM NaCl (pH 7.4).
PI3-Kinase assays were performed using phosphatidylinositol as a substrate in a final
volume of 200|il containing : 50mM HEPES (pH7.4), lOmM MgC12, 150mM NaCl,
[y^P] ATP (5uCi, 500 Ci/mmol) 50uM ATP and 0.5mg/ml sonicated
phosphatidylinositol: phosphatidylserine (3:1 w/v).
Reactions were carried out for 10 minutes at 37°C and terminated by addition of
chloroform:methanol: 0.1M HC1 (40:80:1 v/v/v; 750|ll), and phase partition was
achieved by the addition of chloroform (250|il) and 0.1M HC1 (250|il). After
centrifugation, the lower phase was washed twice with synthetic upper phase
(methanol: 1M HC1: chloroform, 48:47:3 v/v/v), dried and lipids were separated using
thin layer chromatography (TLC).
The TLC running solution consisted of methanol:chloroform:ammonia solutiomwater, in
the proportions 100/70/15/25 (v/v/v/v). 3' phosphorylated lipids were identified by
autoradiography using Kodak "X-OMAT" Film and radioactivity was quantified by
liquid scintillation counting using Flo-Scint IV.
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c) Ins(l,3,4,5) P4 standards
d) [32P] Ins(l,3,4,5)P4 label
e) Wash buffer
f) Assay buffer
a) Cultures of 2 x 5ml of GAP IP4 in LB Broth with ampicillin and kanomycin (1:1000)
were grown overnight at 37°C. The overnight culture (2.5ml) was then added to 500mls
of LB Broth with ampicillin and kanomycin, and incubated for 2 hrs at 37°C with
mixing. IPTG (0.5mM) was then added and the culture was incubated for a further 5 hrs
at 37°C. The culture was then centrifuged at 4000rpm, the supernatant discarded and the.
pellet resuspended in 9mls of cold E.Coli lysis buffer.
E.Coli lysis buffer:
53mM Na2HP04, 3mM NaH2P04,4mM NaCl, 1 mM EDTA, 1 mM EGTA,
ImM p-mercatoethanol
Lysozyme(2mg/ml) was then added and kept on ice for 30 minutes. This was then
sonicated on ice for 5 x 30 second bursts. 2% v/v Triton X-100 was then added and kept
on ice for 30 minutes. This solution was then centrifuged for 30 minutes and the
supernatant collected and incubated with prepared glutathione agarose beads for 2hrs
(0.2g of glutathione agarose was swelled with 12.5mls of H20 for 2hrs, then washed 4 x
with the E.Coli lysis buffer). This mixture was then washed 2x with 10 mis of cold lysis
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buffer and 2 x with high salt buffer, then resuspended in 20mls of high salt buffer and
glycerol. This solution was then mixed, aliquoted and kept at -20°C.
ft T
b) 2 x 10 cells were seeded into 10cm tissue culture plates and then when cells were at
~ 60-70% confluency were resuspended in quiescent media overnight at 37°C.
Stage 1
The cells were then treated with agonists or antagonists if needed, medium was aspirated
and then washed with PBS. The cells were the fixed with 1ml of 10% TCA for 10
minutes on ice, scraped off and collected in eppendorfs. The cell lystes were centrifuged
at 13,000rpm for 2 minutes and the pellets were then washed with 5% TCA/lmM
EDTA. Lipids were extracted using 750jll1 of (40:80:1 v/v/v) CHCkVMeOH/conc HC1
and incubated on ice for 20 minutes. The phases were then split by the addition of 250jil
of CHCI3 and 450(ll of 0.1M HC1. The lower phase, obtained after a minute
centrifugation at 13,000 rpm was transferred to a screw cap tube and the upper phase
was re-extracted once with 450pl of the synthetic lower phase. The lower phases were
pooled and dried down.
Stage 2
Alkaline hydrolysis of dried lipids was carried out by vortexing in 50(ll of 1M KOH and
incubated at 100°C for 30 minutes. Neutralisation was then carried out by adding 50jll of
1M Acetic acid and the fatty acids removed by 2 extractions with 0.5mls of water
saturated butanol/petroleum ether/ethyl acetate (20:4:1 v/v/v). The resulting water
soluble fractions were dried down in a speedivac for 3 hours and resuspended in 110|il
of dilute acetic acid to a final pH of 5.0.
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c) The Ins(l,3,4,5)Pj standards containing 0.5M KOH/acetic acid were prepared at
the following concentrations: 8 x 10"6 M, 24 x 10"7 M, 8 x 10"7 M, 24 x 10~8 M, 8 x 10"8
M, 24 x 10~9 M, 8 x 10~9M, 24 x 10"'°M, 8x 10~10M, 24 x 10"" M, 8 x 10"nM.
d) O.OOljiCi [32P]Ins(l,3,4,5)P4 label was used per assay point.
e) Wash buffer:
25mM Sodium acetate, 25mM KH2PO4, ImM EDTA, 5mM NaHC03, pH5 with acetic
acid
f) Assay buffer:
0.1M Sodium acetate, 0.1M KH2PO4, 4mM EDTA, pH5 with acetic acid
Stage 3
The standards were prepared as follows:
10|il of standard
40jll1 H20
50|il 1M Kac pH5
The samples were made up to a final volume of 400ul and comprised of:
lOOpd of sample or standard
100|ll of assay buffer
lOOpl [32P]Ins(l,3,4,5)P4 (0.001 uCi in ofH20)
lOOfa.1 GAPIP4BP
On addition of the binding protein the samples were vortexed and incubated on ice for
30 minutes, with occasional vortexing. Filtration of bound [ l2P]Ins(l,3,4,5)P4from
unbound was achieved by filtration through GF/C filters (Whatman;Maidstone,UK). The
samples were filtered onto pre-wetted filters and immediately rinsed x 2 with 1 Omls of
ice cold wash buffer. The filters were then allowed to air-dry and transferred to
69
scintillation vials containing 3 mis of "Floscint V" (Packard Biosciences;Groningen,
Netherlands) and the radioactivity counted in a liquid scintillation counter.
2.15 Immunoprecipitation
Confluent cultures of CHOK1 cells from 100 mm3 plates were quiesced overnight in
0.1% FBS media and washed in PBS. SCLC cells were quiesced overnight, centrifuged
at 1000 rpm for 4 minutes then the resulting pellet was washed with PBS. All cells were
lysed at 4°C in lysis buffer comprising 20 mM Flepes pFl 7.4, 1% CHAPS, 150 mM
NaCl, 2 mM MgCl2, 1 mM MnCl2, 0.5 mM CaCl2 and protease inhibitors (EDTA-free
protease inhibitor cocktail, Roche, Germany) or the MAPK lysis buffer as mentioned in
2.7.1 and clarified by centrifugation at 13,000 x g for 10 min at 4°C. The lysate (lmg/ml
protein) was incubated with 2 |ig immunoprecipitating antibody overnight at 4°C.
Immune complexes were captured using 15 p.1 Protein-G agarose and washed x3 with
lysis buffer. Following elution with Nu-PAGE buffer associated proteins were resolved
on 4-12% gradient gels. The proteins were transferred to nitrocellulose membranes,
blocked using 3% (w/v) albumin in TBS-Tween (20 mM Tris-HCL (pH 7.4), 150 mM
NaCl, and 0.02% (v/v) Tween 20) for one hour at room temperature and then incubated
with primary antibody overnight at 4°C. Species appropriate horseradish peroxidase-
conjugated antibodies (DAKO, UK) were used for secondary labeling. Immunoreactive
bands were identified using enhanced chemiluminescence (Amersham, UK) according
to the manufacturer's instructions.
2.16 Cell adhesion assay
SCLC cells were quiesced for 2 hours at 37°C in RPMI containing 0.25% BSA. During
this time a 96 well plate was coated with various ligands. Negative controls were left
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empty and positive controls were coated with 100j!g/ml poly-L-lysine. lOOjil of ligand
was added to each well and incubated for an hour at 37°C.The plate was then washed
with PBS and each well was blocked using 2% BSA for lhour at 37°C, to prevent non
specific binding. Quiesced SCLC cells were then pelleted and counted. lOOpl of cells
were then added at lx 105 per well and then incubated at 37°C. After an hour the cells
are removed from the wells, washed x 2, using 100[ll of PBS and then fixed for 20 mins
using 100|ll 3% PFA (Paraformaldehyde). The fixative was then removed and left to air
dry overnight. Once dry, methylene blue was added to the wells and left for 30 minutes
at room temperature. After several washes in water, the plate was left to dry again. After
drying lOOpl of 0.1M HC1 was added to the wells and once the colour in the wells
became uniform, the absorbance is then measured at 630nm.
The percentage of adhesion is then calculated compared to the controls. It is calculated
as shown below:-
adhesion = Ligand - negative control X 100%
Positive control - negative control
2.17 Production ofNCAM Fusion Protein (NCAM-FC)
CHOK1 cells at -50-60% confluency were transfected as mentioned in section 2.5 with
the NCAM-FC plasmid. The chimaeric protein was allowed to accumulate in the
medium for 6 days. The medium was then collected and spun down to remove any cell
debris and purified with protein A sepharose. Protein A sepharose beads were washed x
2 in PBS and then added to the supernatant and incubate overnight at 4°C on a roller.
The mixture was then centrifuged at 1000 rpm for 4 minutes and the supernatant
removed, the pellet washed and then transferred with 1ml of PBS to an eppendorf. This
was then centrifuged at 13,000rpm for 1 minute and the supernatant removed. To elute
the protein lOOmM Glycine HC1 (pH 2.7) was added and left on ice for 5 minutes, spun
down again at 13,000rpm and then the resulting supernatant was then collected and
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added to lMTris HC1 (pH 9) to neutralise the glycine. Ten fractions were collected. In
order to determine the location of the protein, fractions were run on an SDS-PAGE gel
and the gel was stained with Comassie blue. The fractions containing the protein were




THE CLONING AND CONSTRUCTION OF CD98 AND
CHIMERIC STABLE CELL LINES.
3.0 INTRODUCTION
The aim of this present study was to investigate the structure/function
relationship between CD98, integrin association, intracellular signalling and
transfonnation. In 2000, Fenczik et al., indicated that the cytoplasmic and
transmembrane domains of the CD98HC are important for integrin function and the
extracellular domain was required for amino acid transport. In order to elucidate which
regions in the CD98 molecule are functionally important, chimeras of CD98 were
obtained from Csilla Fenczik (Scripps). These chimeras varied in domains ofCD98 and
anothermolecule CD69.
CD69 is another type II transmembrane heterodimeric glycoprotein with a C-
type lectin binding domain which acted as a control against CD98 (Natarajan et al.,
2000). CD69 is a molecule with a wide cellular distribution and when crosslinked
intracellular signals are induced. This induction of signals suggests a role for the CD69
receptor in the biology of hematopoietic cells. Similar to the molecule CD98, it has been
reported that CD69 may be involved in the pathogenesis of diseases such as rheumatoid
arthritis, chronic inflammatory liver diseases, mild asthma and AIDS (Marzio et al.,
1999). As originally seen with CD98, CD69 once expressed acts as a co-stimulatory
molecule for T cell activation and proliferation (Ziegler et al., 1994).
The chimeras of CD98 and CD69 were made by overlap polymerase chain
reaction or restriction digest and re-ligation. All of these constructs were originally
cloned into pcDNAl vectors and are described in detail in MATERIALS AND
METHODS and shown in Figure 3. These chimeras were then subcloned into pcDNA
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3.1 which contains a G418 selection marker and stable cell lines ofeach were produced.
All of this work was carried out in collaboration with Neil Henderson, another PhD
student in my laboratory.
Tlie chimeras vary in domains of CD98 and CD69 and are described briefly down
below:
1. 4F2TM:- consisted of the extracellular domain ofCD69 and the transmembrane
and cytoplasmic domains ofCD98.
2. 4F269:- consisted of the extracellular and transmembrane domain ofCD69 and
the cytoplasmic domain ofCD98.
3. 69CYTO:- consisted of the extracellular and transmembrane domain of CD98
and the cytoplasmic domain ofCD69.
4. 69TM:- consisted of the extracellular domain of the extracellular domain of
CD98, the transmembrane domain of CD69 and the cytoplasmic domain of
CD98.
5. A98:- consisted of the extracellular and transmembrane domains of CD98, but
had the cytoplasmic domain deleted.
6. D5:- consisted of the extracellular domain of CD98 and a truncated CD98
transmembrane domain ofCD98.
Two extra chimeras (98EX and 98TM), containing the significant regions in tire CD98
molecule were designed and constructed by Neil Henderson in order to critically assess
how important the transmembrane and extracellular regions ofCD98 were in the
structure/function relationships examined in this study.
7. 98TM:- consisted of the extracellular domain of CD69, the transmembrane
domain ofCD98 and the cytoplasmic domain ofCD69.
8. 98 EX:- consisted of the extracellular domain of CD98 and the transmembrane
and cytoplasmic domains ofCD69.
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3.1 Transformation of chimeras.
Initially, chimera DNA was transformed into TOP10/P3 E.coli in order to
produce DNA for CHOK1 cell transfection. Transformation was carried out as described
in MATERIALS AND METHODS section 2.3. In brief, lpl of each plasmid was
incubated with 50pl of competent TOPI 0/P3 cells on ice for 30 minutes. The cells were
then heat shocked for 60 seconds at 42°C and 450pl SOC media was added. The cells
were then shaken in a thermomixer for 1 hour at 37°C and then centrifuged at 4000 rpm
for 4 minutes. The pellet was then resuspended and spread onto selective agar plates and
left overnight at 37°C. Single colonies were transferred to LB broth containing the
antibiotics ampicillin and grown overnight at 37°C.
Minipreps and maxipreps (Qiagen) were then carried out to purify the DNA, as
described in MATERIALS AND METHODS, Section 2.4. The purified DNA was then
verified for content with diagnostic restriction digests as shown in figure 3.1.1. The
digests show 69TM and 69CYTO digested with both Bam HI and Xho 1 or just with
Bam HI restriction enzymes and confirm that the cloning of the two cDNA's, 69TM and
69Cyto had been achieved. Figures 3.1.2 and 3.1.3 show restriction maps of vectors




Figure 3.1.1 Verification of DNA content of 69TM and 69CYTO.
Verification of DNA content was carried out using restriction digests. The digests were
then run on a 1% agarose gel containing ethidium bromide allowing visualisation using
UV light. This figure shows 69TM and 69 CYTO fragments obtained from digests with








Having verified the DNA content, CHOK1 cells were transfected with the
chimeric DNA using lipofectamine plus, described in MATERIALS AND METHODS,
Section 2.5. The transfection efficency of each chimera was analysed using flow
cytometry or expression was checked by western blotting. An example of this step is
shown in figure 3.2.1. In figure 3.2.1, panel A, the western blot shows successful
transfection of 69TM and 69CYTO and panel B shows the results from FACS analysis
carried out on another chimera 4F269. The FACS analysis shows a variably enhanced
signal of FITC/PE binding which indicates that a good transfection efficiency of 4F269
was achieved.
It became evident after several different experiments that in order to
study events such as transformation and integrin association, stable cell lines of each
chimera were required. Chimeras were subcloned into pcDNA 3.1 and stable cell lines
were produces under neomycin selective pressure Single cell clones were isolated,
propagated and screened by FACS analysis and western blotting.
80
B)
Figure 3.2.1 Analyses of transfection efficiency and expression of chimeras.
A) CHOK1 cells were transiently transfected with either of the two chimeras, 69TM or
69CYTO which are HA tagged. As a control CD98 was also transfected alone into cells.
The cells were lysed after 24hrs and run on an SDS-PAGE gel, transferred to
nitrocellulose membrane and probed for HA. This blot shows successful transfection of
the HA-tagged chimeras. The arrow indicates the positive control CD98HC.
B) Transient transfection of CHOK1 cells with 4F2-69 cDNA. The black shading
represents FITC/PE binding in transfected cells; representing expressed protein on the
surface.
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pcDNAl (5)_Lg) with the chimera insert and 2\ig of pcDNA 3.1 were digested
using Bam Hi and Xno 1 restriction enzymes for 2-3 hours at 37°C, heat inactivated at
80°C for 15 minutes and then left to cool down. The inserts and the vectors were then
run on a 1 % agarose gel containing ethidium bromide. The bands were visualized using
UV liglit and tlic bands containin^ tlic inserts and the vectors were removed. Ttie DNA
was then purified using a Qiagen gene extraction kit, eluted and quantified using a
spectrophotometer.
Ligation was then performed using the calculation below:
np Insert = amount ofvector (1 Oflnot x insert size fkht x 3 (ratio!o V / xx x. x
vvwt JUiV
The ligation mixture was incubated at room temperature for 2-3 hours Transformation
of the ligation mix was performed as described in section 3.1 but this time it was carried
out using DH5 alpha competent cells. After incubation overnight at 37°C mini-preps
were carried out and the samples were run on gels and visualized using TJV light. The
mini-preps carried out are shown in figure 3.3.1 and 3.3.2. Maxi-preps were carried out
on the colonies selected and diagnostic restriction digests were performed. Digest gels
are shown in figure 3 3 3 Having confirmed an appropriately sized insert following




Figure 3.3.1. 4F2TM and 4F269 subcloned from pcDNA 1 to pcDNA 3.1.
A) Mini-prep showing insert in 2 colonies in subclone 4F2TM. Insert size ~ 800 base
pairs. Colony 9 was selected for maxi prep. B) Mini-prep showing insert in 9 colonies in






Figure 3.3.2. 69CYTO and 69TM subcloned from pcDNA 1 to pcDNA 3.1.
A) Mini-prep showing insert in 5 colonies in subclone 69CYTO. Insert size 1543 base
pairs. Colony 7 was selected for maxi prep. B) Mini-prep showing insert in all 10






Figure 3.3.3 Maxi-preps of subclones
Maxi-preps were carried out on the subclones and the DNA was then digested using
Bam HI and Xho 1 restriction enzymes and the samples run on 1% agarose gels. The
correct size inserts were present in all the subclones.
3d PrnHiirtinn nf ctaKIp ppllc pvnvpccinn thp PHQS rhimprQC« ' *- » ^ v» v« vy» vv>»«u yuuit*^ •-' *-*•
The plasmids verified by sequencing were transfected into subconfluent CHOK1
cells. Plasmid DNA(3pg) was transfected into these cells using lipofectamine plus in
ooriiw iroo -»>-» i o fXr* ^ VjAiiro oe rlooonKorl in ATCDT AT Q A\TT\ A^CTUr^T^C 'JPPflfir.OVlUltL JJ.WW 1LLVUXU iVl -/ 11CUJ.O, UO UVOVilUVU 111 iVjLt L 1 JL/1VJU U_/»J t U.'lty iVlUlliVU/Uj kJVVllV/11
2.5 For the subsequent 48 hours serum was added and transfeetants selected in media
with 1.2 mg/ml G418. Single clones selected from each construct weremaintained in 1.2
mg/m! G418 and expanded. Clones were then screened by western blot analysis or by
FACS analysis. The western blots were either probed with an anti-CD69 antibody or an
anti-CD98 antibody depending on the extracellular domain expressed. The chimeras
which required probing with the CD69 antibody were run on a non-reduced gel as the
anti-CD69 antibody only recognizes the native protein. The resulting blots are shown in
figure 3.4.1. For the FACS analysis, aliquots of cells were washed and resuspended in
PBS containing either the 4F2 antibody (for CD98 and chimeras containing the
extracellular portion of CD98) or anti-CD69 antibody (for CD69 and the chimeras
containing the extracellular portion of CD69). Cells were incubated for 30 minutes at
room temperature, washed and then incubated with species specific FTTC conjugated
secondary antibodies for 30 minutes at 4°C in the dark. After washing, the samples were
finally suspended in PBS and analysed by flow cytometeiy. The resulting FAC'S
tvnolvcio -io cVirvwn ir» ^ A 0 T Vip» 17 or>H tVi£* wpofprn M/\ttir»or r»rvnfirm#*r1 thati UikX XU uxxv *fxx xxx xx^ xxx v • I . 4mt. xxxv x X x \—- »—' uxxvx uxv 1ivvwxxx vxvxxxxx^ wxxxuxxxvu. Ul&mv u1v
CHOK1 stable cell lines were expressing each chimera at comparable levels. The clones
showing equivalent wild type, mutated or truncated human CD98 expression by the




Figure 4.1.1a FACS analysis of CD69 or CD98 expression in stable CHOK1 clones.
CHOK1 cells were stably transfected with either CD69 or CD98. Expression of the
constructs was verified by FACS analysis. Two clones stably expressing different cell
surface levels of CD98 were selected by flow cytometry. CHOK1 cells stably expressing
CD69, were used as a negative control. Cells were incubated with 4F2 antibody (for
CD98) or an anti-CD69 antibody for 30 minutes at room temperature and then incubated
with the appropriate FITC conjugated secondary antibody for 30 minutes at 4°C.
Samples were analysed using a FACS Calibur™ (Becton Dickinson). Isotype controls
IgG2a and IgGl were used respectively to ensure there was no non- specific binding.
Graphs are representative of three independent experiments.
New CD98 stables fees .001
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Figure 3.4.2 FACS analysis of the chimeric stable cell lines
Stably expressing CHOK1 cells were incubated with either anti-CD98 antibody or anti-
CD69 antibody for 30 minutes at room temperature, washed and incubated with a
corresponding species specific secondary FITC antibody for another 30 minutes at 4°C.
The samples were analysed by FACS. These figures show that the cells were expressing
each chimera at comparable levels.
CHAPTER 4
THE ONCOGENIC PROPERTIES OF CD98
4.0 INTRODUCTION
The survival and growth of a malignant tumour is a consequence of a
phenomenon called "anchorage independence" (Stoker at al., 1968; Paul et al., 1978).
This ability enables tumour cells to proliferate in the absence of adhesion to the
extracellular matrix (ECM) proteins (Schwartz, 1997), and reflects the tendency of
tumour cells to survive and grow in inappropriate locations in vivo, metastasise and
invade. Incorrect localization is the characteristic that distinguishes malignant from
benign tumours (Robbins et al., 1984).
Oncogenes are points on normal growth regulatory pathways that are
constitutively activated by mutation or expression, (Schwartz, 1997). There is now
increasing evidence that CD98 has oncogenic potential. The heavy chain of CD98 is
expressed in most tissues and appears to be present in all tumour cells (Parmacek et al.,
1989; Nakamura et al., 1999). NIH3T3 cells transfected with human CD98 were found
to be capable of anchorage independent growth and CD98 transfected clones gave rise to
tumours in athymic mice (Hara et al., 1999). Rintoul et al., (2002), have shown that
cross-linking CD98 promoted anchorage independence. The ability of cancer cells to
form colonies in semi-solid agarose is a fundamental feature of the transformed
phenotype and anchorage independence. Colony formation shows good correlation with
tumorigenesis and invasion (Carney et al., 1980). Full oncogenic transformation is
believed to require both anchorage and serum independent growth, (Schwartz, 1997),
facilitating signalling by integrin and growth factors.
The development of serum and anchorage dependence by CD98 was investigated
using stably expressing CHOK1 cells suspended in semi-solid agarose medium.
The linkage between CD98 and integrins has been demonstrated in terms of cell
membrane fusion. Ohgimoto et al, (1995) have shown via the comparison of amino-acid
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sequence data that CD98HC and FRP-1 are the same molecule. Antibodies raised
against FRP-1 enhanced cell fusion, induced by viruses such as HIV and Newcastle
disease virus (Tabata et ah, 1994). Okamoto et al., (1997) demonstrated that an anti
CD98HC antibody (HBJ127) was able to inhibit fusion by the human parainfluenza
type-2 virus, but also enhanced fusion induced by certain other viruses. This lead to the
conclusion that the heavy chain of CD98 was "multifunctional".
An important feature of various oncogenes is their ability to activate signalling
pathways downstream of integrins and integrin-activated tyrosine kinases.
Phosphoinositol 3-OH kinase (PI3-Kinase) has been identified to have a critical role in
compensating the cell survival and growth signals normally provided by the cell-matrix
interaction (Wei et al., 2001). CD98 activity in haematopoietic cells could be inhibited
by tyrosine kinase inhibitors suggesting that tyrosine kinase activation is involved in
CD98 signalling (Warren et al., 1996). Rintoul et al, (2002), showed that when CD98
was cross-linked in SCLC cells using the monoclonal antibody 4F2, PI3-kinase
activation was stimulated. PI3-kinase has also been shown to promote anchorage-
independent growth acting through PKB (Moore et al., 1998).
PI3-Kinase activation and transformation was investigated using the CD98/CD69
chimeras in order to determine which part of the CD98 molecule is essential for these
processes.
In cell anchorage-dependent survival and growth, the importance of the
integrin/tyrosine kinase signalling pathway has been demonstrated by introducing
constitutive active form of Focal adhesion kinase (FAK) into anchorage dependent cells
and rendering them anchorage independent (Frisch et al., 1996). FAK is a tyrosine
kinase that is rapidly activated following integrin-mediated attachment to the ECM and
is thought to play an essential role in integrin signalling (Clark and Brugge, 1995;
Schwartz et al., 1995).
Phosphorylation of FAK was investigated in terms of phenotypic changes and to
find out which part of the CD98 molecule is crucial for the formation of focal adhesion
complexes.
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The importance of the cytoskeletal organization in transformed cells appears to
be an issue which gives rise to conflicting views on this subject. Loss of anchorage
independence and growth control is a common feature of cancer cells as mentioned
above. Boyd et ah, (1995) suggested that cytoskeletal components may play a role in the
uncoupling cell shape and growth control. However, it has been extensively documented
that an intact actin cytoskeleton is essential for signal transduction and integrin
dependent focal adhesion (Bershadsky et al., 1996). In order to determine which
hypothesis rings true for CD98, the actin cytoskeleton and another component of the
cytoskeleton, the microtubular system were examined using CHOK1 cells stably
transfected with either CD98 or CD69 and immunofluorescence staining.
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4.1 Expression of CD98 induces anchorage independence and serum
independent growth.
4.1.1Clonal growth is dependent on level ofCD98 expression.
CD98 is highly expressed on the surface of most tumour cells irrespective of
tissue origin (Bellone et al., 1989; Dixon et al., 1990). The ability of cancer cells to
proliferate in the absence of adhesion to extracellular matrix proteins is termed
anchorage independent growth (Stoker et al., 1968, Paul et al., 1978 and Schwartz.,
1997). Anchorage independence reflects the tendency of tumour cells to metastasise and
grow in inappropriate locations in vivo. This property is the basis of the agar suspension
technique used to clone transformed cells (Sanders and Burford, 1964, Stoker et al.,
1968). The ability of cancer cells to form colonies in a semi solid agarose medium is a
fundamental feature of the transformed phenotype.
Two clones stably expressing different cell surface levels of CD98 were selected
by flow cytometry as shown in figure 4.1.1a. CHOK1 cells stably expressing CD69,
another type II transmembrane protein was used as a negative control. Cells were
incubated with 4F2 antibody (for CD98) or an anti-CD69 antibody for 30 minutes at
room temperature and then incubated with the appropriate FITC conjugated secondary
antibody for 30 minutes at 4°C. Samples were then analysed using a FACS Calibur™
(Becton Dickinson). Isotype controls IgG2a and IgGl were used respectively to ensure
there was no non- specific binding.
In order to investigate the role CD98 plays in cancer, the effect of over-
expressing human CD98 heavy chain in CHOK1 cells on anchorage-independent growth
in soft agar was examined as described in MATERIALS AND METHODS. Colonies of
4 or more cells were counted and cloning efficiency was calculated as described in
MATERIALS AND METHODS. Figure 4.1.1b. shows representative pictures of
colonies seen after 4 days in 1% FCS. They show the difference between cells
overexpressing CD69 and CD98 and the difference a higher level of surface expression
has on the size of colonies. Figure 4.1.1c shows low power pictures of the colonies
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produced by overexpression of CD69, CD98 and CD98+ in CHOK1 cells and confirms
the above observations. Figure 4.1.Id shows a time course of cloning efficiency,
between CHOK1 cells expressing CD98 and CD69. The CHOK1 cells overexpressing
CD98 showed cloning efficiencies higher than those seen in CHOK1 cells
overexpressing CD69 regardless of the number of days suspended in 0.3 % agarose,
(day 2, 27.20 ±6.217 and 2.208 ± 1.597 respectively compared to day 4, 40.37 ± 3.573
and 2.0 ± 1.2 and day 6, 20.92 ± 4.698 and 0.68 ± 0.68). When these cells were left to
grow for 10 days in culture, CHOK1 cells overexpressing CD98 showed a higher
saturation density compared to CHOK1 cells overexpressing CD69 (Figure 4.l.le). The
cloning efficiency of CD98 expressing cells in 1% FCS was significantly higher than the
control CD69 stably transfected CHOK1 cells (figure 4.1.If). The level of CD98
expression also affected the cloning efficiency as clonal growth was greater in the clone
with the highest level of CD98 surface cell expression. For all subsequent experiments
the high expressing CD98 clone was used unless otherwise indicated.
These findings indicate that the CD98 heavy chain promotes anchorage




Figure 4.1.1b Colonies visible after 4 days.
CD98 or CD69 were stably transfected into CHOK1 cells which were then suspended in
0.3% agarose over a layer of 0.5% agarose in DMEM containing 1 %FCS, as described
in MATERIALS AND METHODS. (A) CD69 stables, (B) CD98 stables and (C)




Figure 4.2.3. Amino acids 82-26 of CD98 are critical for PDKinase
activity and anchorage independent growth.
CHOK1 cells stably transfected with D5 were analysed to determine whether these cells
could promote PDKinase activity and transformation.
A) Expression of D5 was determined by flow cytometric analysis as described in
MATERIALS AND METHODS using the monoclonal antibody 4F2.
B) The effect of stable D5 expression on PI3-kinase activity and anchorage independent
growth was compared with 98TM and CD69 using the method described in
MATERIALS AND METHODS.*=P<0.05 (ANOVA). These graphs represent the mean
± S.E.M. of four independent experiments.
CD69 CD98 CD98+
Figure 4.1.1c CD98 increase clonal growth in CHOK1 cells.
CD98 or CD69 was stably transfected into CHOK1 cells and then suspended in 0.3%
agarose over a layer of 0.5% agarose in DMEM containing 1% FCS, described in
MATERIALS AND METHODS. After 4 days, colonies of cells were stained using











Figure 4.1.Id Time course of clonal growth of CHOK1 cells overexpressing CD98
and CD69.
CD98 or CD69 was stably transfected into CHOK1 cells and then suspended in 0.3%
agarose over a layer of 0.5% in DMEM containing 1% FCS, described in MATERIALS
AND METHODS. By counting the number of 4 cell colonies present on days 2, 4 and 6
the cloning efficiency was then calculated as described in MATERIALS AND
METHODS. Results represent the mean ± SEM of four independent experiments.
* = P <0.05
CH0K1 cells overexpressing CD98 or CD69 were left to grow for 10 days in complete
media. On days 2, 4, 6 8 and 10, the cells were harvested and counted using a Coulter
counter (Coulter Electronics, Luton, UK.)
150 n
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Figure 4.1.If CD98 increases clonal growth in CHOK1 cells.
CD98 or CD69 was stably transfected into CHOK1 cells and then suspended in 0.3%
agarose over a layer of 0.5% agarose in DMEM containing 1% FCS, as described in
MATERIALS AND METHODS. On day 4 cloning efficiency was established by
counting the number of colonies with four cells or more and carrying out the calculation
for cloning efficiency, described in MATERIALS AND METHODS. Results represent
the mean ± SEM of four independent experiments. * *= clonal growth is significantly
different in CHOK1 cells overexpressing CD98 compared to CD69 and CD98+, (P=<
0.01).
4.1.2 Overexpresssion of the CD98 heavy chain results in serum independent
clonal growth.
Oncogenes commonly by-pass the requirements for serum independence as well
as anchorage independence and this phenomenon was examined, (figure 4.1.2). CHOK1
cells stably expressing the CD98HC were suspended in 0.3% agarose over 0.5% agarose
in DMEM containing either 1% or 0% FCS. After 6 days, colonies greater than 4 cells
were counted using light microscopy. We found that even in serum free conditions
CD98 heavy chain could still support anchorage independent growth.
The above results show that over-expression of CD98 results in serum
independent and anchorage independent clonal growth.
4.1.3 CD98 stimulated anchorage independent growth is PI3-kinase dependent.
Moore et al., (1998) found that PI3-kinase acting through PKB could promote
anchorage independent growth and having determined that the CD98HC could promote
clonal growth, I decided to examine the effect of PI3-kinase inhibition on CD98
stimulated anchorage independent growth. Colony assays were carried out in the
presence of the PI3-Kinase inhibitor LY294002. By inhibiting PI3-Kinase activation
using LY294002, there was a marked concentration dependent inhibition of colony
formation in semi-solid agarose medium of CHOK1 cells stably over expressing CD98
in 1% FCS. (IC50 = 2.1JIM, Figure 4.1.3).
The above results show that over-expression of CD98 promotes anchorage
independent growth which is sensitive to the PI3-kinase inhibitor FY294002.
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Figure 4.1.2. CD98 stimulated clonal growth is serum independent.
CHOKlcells stably transfected with CD98 (filled bars) or CD69 (open bars) were
suspended in 0.3% agarose over a layer of 0.5% agarose in DMEM containing FCS as
indicated as described in MATERIALS AND METHODS. After 6 days colonies greater
than 4 cells were counted using a light microscope. Results are expressed as % cloning
efficiency and are the mean ± SEM of 3 independent experiments.* = P<0.05 (student t-
test). CD98 transfected cells cloning efficiency is significantly different to that of CD69
transfected cells.
[LY294002] |dM
Figure 4.1.3 Effect of LY294002 on CD98 stimulated clonal growth.
The clonal growth of CHOK1 cells after 4 days expressing CD98 in semi-solid 0.3%
agarose medium containing 1% FCS was determined at different concentrations of
LY294002 as indicated. Results are expressed as % cloning efficiency and are the mean
± SEM of 3 independent experiments.
4.1.4 The CD98 heavy chain stimulates PI3-kinase activation.
PI3-kinase plays a key role in integrin activation, cellular activation and
transformation (Carpenter and Cantley, 1996). Rintoul et al., (2002) found that by cross-
linking CD98 using the monoclonal antibody 4F2, PI3-kinase and its product PI (3,4,5)
P3 was stimulated in SCLC cells. In order to examine this interaction further, the effect
of over-expressing CD98 in CHOK1 cells on PI3-kinase activity was investigated.CD98
or CD69 stably expressing CHOK1 cells were lysed and PI3-kinase was
immunoprecipitated using a p85a monoclonal antibody, (figure 4.1.4(B)). Activity was
measured using an in vitro kinase assay and lipids were resolved using thin layer
chromatography as described in MATERIALS AND METHODS. Expression of CD98
significantly increased PI3-kinase activity by 2-2.5 fold compared to CD69 and wild
type CHOK1 cells (figure 4.1.4 (A)). CD98 expression also increased phosphorylation


















Figure 4.1.4 CD98 activates PI3-Kinase.
(A) Quiesced CH0K1 cells stably expressing CD69 or CD98 (low and high (+)
expressing cells) were lysed, protein equilibrated and PI3-kinase activity was measured
from p85a immunoprecipitates using an in vitro kinase assay as described in
MATERIALS AND METHODS. Radiolabeled PI3P was resolved by thin layer
chromatography, visualised by autoradiography and 32p PI3P scraped from the plate and
quantified by liquid scintillation counting. Results are expressed as cpm and represent
the mean ±SEM of four independent experiments. (B) Aliquots of lysate were run on
SDS-PAGE and western blotted with p85a, to ensure equal immunoprecipitation. (C) An
autoradiograph showing the 3-phosphorylated product [PI(3)P]. Lysates were western
blotted with anti-PKB antibody (D) or (E) anti-pS473PKB.
4.2 Investigating structure/function relationship with CD98/CD69
chimeras
4.2.1 The transmembrane domain (amino acids 82-104) of CD98 heavy chain is
necessary and sufficient for P13-kinase activation and the elevation of
intracellularPI (3, 4, 5)P3 formation.
The CD98/CD69 chimeras, kindly donated by C.Fenzik (as described in chapter
1) were used to investigate the structure/function relationship of CD98 and PI3-kinase
activation. CHOK1 cells stably expressing CD98/CD69 chimeras were quiesced in
serum free medium for twelve hours prior to lysis and PI3-kinase activity was measured
by an in vitro kinase assay as described in MATERIALS AND METHODS. PI(3,4,5)P3
production was also measured using a radioisotope dilution assay as described
previously (van der Kaay et al., 1999). This assay is based on radioligand displacement
of radiolabeled Ins(l,3,4,5)P4 from binding sites present in platelets that display high
affinity and specificity for Ins(l,3,4,5)P4. Following a Folch extraction of cellular
phospholipids, Ins(l,3,4,5)P4, the polar head group of Ptdlns (3,4,5)P3, is released by
alkaline cleavage and its mass can be measured by radioligand displacement using a
calibration curve obtained using unlabelled Ins(l,3,4,5)P4 standards. Figure 4.2.1a.
shows again that expression of CD98 increases PI3Kinase activity by 2-2.5 fold
compared to wild type CHOK1 cells and CHOK1 cells overexpressing CD69. It also
shows that the transmembrane domain of CD98 is sufficient and necessary to activate
PI3-kinase. Figure 4.2.1b demonstrates that again the transmembrane domain of CD98 is
sufficient to promote PI(3,4,5)P3 production. This became apparent because the chimera
98TM (which has the transmembrane domain of CD98 and the extracellular and
cytoplasmic domains of CD69) and the truncated mutant A4F2 (which has the
cytoplasmic domain amino acid 2-77 deleted) were both able to stimulate PI3-kinase
activation and PI(3,4,5)P3 production. These chimeras, 4F2TM, A 4F2 and 98TM also
showed a 2-2.5 fold increase in PI3Kinase activity and PIP3 production compared to
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wild type CHOK1 cells and CHOK1 cells overexpressing CD69. However the chimera
69TM in which the transmembrane domain of CD98 is substituted with the
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Figure 4.2.1a The transmembrane domain of CD98 heavy chain (amino acids 82-
104) is necessary and sufficient for PI3K activation.
Quiesced CHOK1 cells stably expressing CD69, CD98 or CD98 chimeras were lysed,
and PI3-kinase activity was measured from p85a immunoprecipitates using an in vitro
kinase assay as described in MATERIALS AND METHODS. (A) Aliquots of lysate
were run on SDS-PAGE and western blotted with p85a, to ensure equal
immunoprecipitation. Radiolabelled PIP3 was resolved by thin layer chromatography,
visualised by autoradiography and 32p PIP3 scraped from the plate and quantified by
liquid scintillation counting.(B) An autoradiograph showing the 3-phosphorylated
product PIP3.(C) Results are expressed as % activity of control untransfected cells and
represent the mean ± SEM of four independent experiments. The first bar represents
wild type CH0K1 cells. Wild type CHOK1 cells were also treated with lOOnm
wortmannin or 10% FCS for 10 mins at 37°C, as negative and positive controls
respectively, bars two and three. ** = PI3-Kinase activity is significantly different to
wild type CHOK1 cells (P=< 0.01 ANOVA).
CD69 CD98 98EX 4F2TM 4F269 A4F2 98TM 69TM
Figure 4.2.1b The transmembrane domain (amino acids 82-104) of CD98 heavy
chain is sufficient and necessary for intracellular PI(3,4,5)P3 production.
The effect of chimeras on intracellular PI(3,4,5)P3 levels. PI(3,4,5)P3 levels were
measured in quiesced CHOK1 cells stably expressing CD69, CD98 or CD98 chimeras.
The level of PI (3, 4, 5) P3 was quantified by an isotope dilution assay as described in
MATERIALS AND METHODS. Results are expressed as pmol/mg protein and
represent the mean± SEM of four independent experiments. * = PIP3 production is
significantly different to CHOK1 cells overexpressing CD69. (P=< 0.05 ANOVA).
4.2.2 The transmembrane domain (amino acids 82-104 ) of the CD98 heavy
chain is necessary and sufficientfor colony formation.
The structure/function relationship of CD98 in the phenomenon of anchorage
independence was examined using the CD98/CD69 chimeras. CHOK1 cells stably
transfected with the CD98/CD69 chimeras were suspended in 0.3% agarose layered over
a layer of 0.5% agarose in 1% FCS and were counted after 6 days using a light
microscope as described in MATERIALS AND METHODS. All the chimera clones
containing the transmembrane domain of CD98 showed cloning efficiencies comparable
with CHOK1 cells over-expressing wild type CD98 whereas the chimeras containing the
transmembrane domain of CD69 had cloning efficiencies which were not significantly
different from untransfected CHOK1 cells or the CD69 stables, (figure 4.2.2). The
chimeras A 4F2 (mutant with the cytoplasmic domain deleted) and 98TM (containing
the CD98 transmembrane domain and the extracellular and cytoplasmic domains of
CD69) both markedly enhanced colony formation when stably expressed in CHOK1
cells (30.2 ± 6.2 and 33.2 ± 3.4 respectively compared to control 2.2 ± 1.7, mean of four
independent experiment done in triplicate mean ± S.E.M.). However the opposite
equivalent chimera 69TM (in which the transmembrane domain within CD98 is replaced
with the transmembrane domain of CD69) did not enhance colony formation (9.6 ± 6.2 n
= 4 in triplicate mean ± S.E.M.).The difference between CD98 clones and wild type
CHOK1 cells and CD69, 69TM and 98EX clones is significant as measured by one way
ANOVA with a P value ranging from <0.05-0.001.
Therefore the transmembrane domain of the CD98 heavy chain is sufficient and
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Figure 4.2.2 The transmembrane domain (amino acids 82-104) of CD98 heavy
chain is necessary and sufficient to promote anchorage independent growth.
CHOK1 cells stably expressing CD69, CD98 or CD98 chimeras were grown in colonies
for 6 days in 0.3% agarose over a layer of 0.5% agarose in 1% FCS culture medium as
described in MATERIALS AND METHODS. Colonies greater than 4 cells were
counted by light microscopy. Results are expressed as % cloning efficiency and are the
mean± SEM of four independent experiments.* = Cloning efficiency is significantly
different from wild type CHOK1 cells (-). (P= < 0.05 ANOVA).
4.2.3 Amino acids 82-86 of CD98 are critical for PI3-Kinase activation and
anchorage independent growth.
The above finding was then examined further using the CD98 truncation mutant
D5. The D5 mutant lacks amino acids 1-86 but is well expressed in CHO cells, as
detected by flow cytometry. While the chimera 98TM (which has the extracellular and
cytoplasmic domains of CD69 and the transmembrane domain of CD98) and the A4F2
mutant (which lacks the putative cytoplasmic tail (amino acids 2-77)), were able to
stimulate PI3-Kinase activation and promote anchorage independent growth in semi¬
solid agarose medium (Figure 4.2.1a/b and 4.2.2), the D5 mutant in contrast failed to
stimulate PI3-kinase activity when stably expressed in CHO K1 cells and did not support
anchorage independent growth (Figure 4.2.3).
The above results suggest that the five amino acids 82-86 at the putative cytoplasmic
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Figure 4.3.1 CD98 has no effect on the cytoskeleton of CHOK1 cells.
CHOK1 cells stably transfected with the CD98 or CD69 were fixed and incubated with
rodamine phalloidin and CD98 or CD69 antibodies and secondary alexa fluor antibodies
as described in MATERIALS and METHODS. White bars, 28.6 |im. Confocal
microscopy was performed using a TCS NT Confocal microscope system, (Leica).
(A) Disruption of the cytoskeleton by cytochalasin D treatment. CD98 expressing cells
treated with 2pM cytochalaisin D for 30mins labelled with (4F2-green) and rhodamine
phalloidin (red). B) Effect of CD98 on the cytoskeleton. CD98 cells labelled with (4F2-
green) and the cytoskeleton (red). (C) Effect of CD69 on the cytoskeleton. CD69
expressing cells labelled with (FN50-green) and rhodamine phalloidin (red).
4.3 CD98 has no effect on the architecture of the cell.
There appears to be conflicting views on the importance of cytoskeletal
organization in neoplastic transformed cells. A common change in transformed cells is
the loss of anchorage dependence to the ECM or shape dependent controls on growth,
(Benecke et al.,(l978). It has been hypothesised that cytoskeletal components may play
a role in the uncoupling of cell shape and growth control (Boyd et al.,1995). However
more recently it has been extensively documented that an intact actin cytoskeleton is
essential for integrin dependent focal adhesion assembly and signal transduction
(Bershadsky et al.,1996). Oncogenes appear to have the ability to bypass the need for
anchorage independence and growth factors but can still activate integrin-dependent
signalling. Therefore these hypothesises were examined in terms of whether over-
expressing CD98 disrupted the actin cytoskeleton.
4.3.1 CD98 has no effect on the cytoskeleton ofCHOK1 cells.
Quiesced CHOK1 cells stably transfected with CD98 or CD69 were incubated
with a drug, which directly binds to actin, (rhodamine phalloidin) and the antibodies
CD98 (4F2) or CD69 (FN50-FITC), described in MATERIAFS AND METHODS and
analysed by confocal microscopy (Figure 4.3.1) The actin cytoskeleton of CD98
expressing cells was chemically disrupted using 2pg/ml of Cytochalasin D for 30
minutes and visualised by rhodamine phallodin. Cytochalasin D treatment resulted in the
disruption of the filamentous appearance of actin within the cell with no radial
microfilaments observed. This was then used as a control to compare the actin
cytoskeleton of both CD98 and CD69 stably expressing CHOK1 cells. CD69 and CD98
expressing cells displayed a well organised actin assembly, with no obvious differences
between the two cells types. Equally the microfilaments appeared to still be intact and
thus there was no apparent disruption of the cytoskeleton.
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In many cell types the actin cytoskeleton functions together with other
cytoskeletal components, especially the microtubular system to induce signal
transduction pathways and the assembly of focal adhesions. Bershadsky et al., (1996)
found that in serum starved Swiss 3T3 cells; the microtubular system was well
developed and had the typical radial organization but poorly organized actin bundles.
However when the microtubular system was chemically disrupted using nocodazole, the
assembly of focal adhesion and actin microfilament bundles was induced. These
observations lead to the examination of whether the CD98 stables (which have an intact
actin cytoskeleton) have a disrupted microtubule network.
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Figure 4. 3. 2 .CD98 has no effect on the microtubule network.
CHOK1 cells were stably transfected with CD98 or CD69 or the chimeras and wild type
CHOK1 cells were labelled with a tubulin or rodamine phalloidin. White bars 28.3p.m.
Confocal microscopy was performed using a TCS NT Confocal microscope system,
(Leica).
(A) Wild type CHOK1 cells were treated with lOpM nocodazole for 30 minutes and
then incubated with tubulin antibody (green).
(B) Wild type CHOK1 cells were incubated with tubulin antibody (green).
(C) CD98, (D) CD69, (E) 98TM stables and (F) wild type CHOK1 cells were incubated
with antibodies against tubulin (green) and rhodamine phalloidin.
4.3.2 CD98 has no effect on the microtubular system ofCHOK1 cells.
CH0K1 cells stably transfected with either CD98 or CD69 the CD98/CD69
chimeras and the wild type CHO K1 cells were fixed and labelled with rhodamine
phalloidin and/or tubulin antibody described in MATERIALS AND METHODS and
visualised by confocal microscopy. The microtubule network of wild type CHOK1 cells
was disrupted using the microtubule disrupting drug, Nocodazole (10|lM) for 30 mins.
and then incubated with the tubulin antibody. This caused the characteristic tubulin
paracrystals as shown in Figure 4.3.2 (A). This again was used as a control in
comparison with CHOK1 cells stably expressing CD98, CD69 and the chimera 98TM
(has the transmembrane domain of CD98 and the extracellular and cytoplasmic domain
of CD69). There was no significant difference between the CD98, CD69, 98TM stables
and the wild type CHOK1 cells and again the microtubule network of these cells was
intact.
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Figure 4. 3. 2 .CD98 has no effect on the microtubule network.
CHOK1 cells were stably transfected with CD98 or CD69 or the chimeras and wild type
CHOK1 cells were labelled with a tubulin or rodamine phalloidin. White bars 28.3|im.
Confocal microscopy was performed using a TCS NT Confocal microscope system,
(Leica).
(A) Wild type CHOK1 cells were treated with 10|iM nocodazole for 30 minutes and
then incubated with tubulin antibody (green).
(B) Wild type CHOK1 cells were incubated with tubulin antibody (green).
(C) CD98, (D) CD69, (E) 98TM stables and (F) wild type CHOK1 cells were incubated
with antibodies against tubulin (green) and rhodamine phalloidin.
4.3.3 The transmembrane domain of the CD98 heavy chain is sufficient to
induce phenotypic changes.
One of the earliest events in integrin mediated signal transduction is an increase
in tyrosine phosphorylation of multiple cytoskeletal proteins and the enzymatic
activation of the focal adhesion kinase (FAK) (Meng and Lowell, 1998). Therefore the
effect of expressing CD98 in CHOK1 cells on the localisation of focal adhesion
complexes was examined using confocal microscopy. CHOK1 cells stably expressing
CD98 or CD69 or the chimera 98TM were incubated with rhodamine phalloidin and a P-
FAK (Tyrosine 397) antibody as described in MATERIALS AND METHODS. There
was a striking difference between CD98 stables and CD69 in terms of P-FAK
localisation and the size of the focal adhesions (Figure 4.3.3). The CD98 heavy chain
promoted larger and more extensive focal adhesion complexes in comparison to CD69.
The transmembrane domain of CD98 also appeared to be sufficient to promote the
changes seen with CD98 as the chimera 98TM also showed the same phenotype.
The above results have shown that CD98 transmembrane domain is sufficient to
promote the formation of extensive focal adhesion complexes but does not appear to
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Figure 4.3.3 The transmembrane domain of CD98 is sufficient to induce phenotypic
changes such as the promotion of large and extensive focal adhesion complexes
CHOK1 cells stably transfected with the CD98 or CD69 or 98TM were incubated with
rodamine phalloidin and P-Fak antibody, described in MATERIALS and METHODS.
White bars, 28.6 |im. Confocal microscopy was performed using a TCS NT Confocal
microscope system, (Leica).
(A) CD69, (B) CD98 and (C) 98TM expressing cells labelled with P-Fak, (green) and
the cytoskeleton (red).
4.4 DISCUSSION
There is now increasing evidence that CD98 has oncogenic potential. Most
tissues, cell lines and tumours appear to express the heavy chain of CD98 (Parmacek et
al., 1989; Nakamura et al., 1999). Hara et al., (1999), found that NIH3T3 cells
transfected with human CD98 were capable of anchorage independent growth and CD98
transfected clones also gave rise to tumours in athymic mice. Rintoul et al., (2002) has
also shown that cross-linking CD98 using the monoclonal antibody 4F2 promoted
transformation in SCLC cells. In this study, the structure/function relationship between
CD98, intracellular signalling and transformation was examined.
A fundamental feature of anchorage independence is the ability of cells to grow
in semi-solid agarose medium. The agar suspension technique uses these properties to
clone transformed cells (Sanders and Burford., 1964; Stoker et al., 1968). Anchorage
independence reflects the tendency of tumour cells to survive and grow in inappropriate
locations in vivo, metastasise and invade. This correlates with tumorigenicity and the
invasiveness of the tumour (Carney et al., 1980).
Oncogenes are points on normal growth regulatory pathways that are
constitutively activated by over expression or mutation. We found that CD98 transfected
CHOK1 cells were capable of both anchorage and serum independent growth. Full
oncogenic transformation is believed to require both anchorage and serum independent
growth. This finding suggests that CD98 mediates oncogenic transformation.
The ability to activate signalling pathways downstream of integrins and integrin
activated tyrosine kinases is an important property of oncogenes. Two major cell
survival and growth signalling pathways downstream of tyrosine kinase are the PI3-
Kinase-AKT pathway and the MAPK pathway (Wei et al., 2001). It has been shown
previously that tyrosine kinase activation mediates CD98-induced homotypic
aggregation of haematopoietic cells (Warren et al., 1996).
PI3-Kinase catalyzes the phosphorylation of inositol lipids resulting in the
formation of 3-phosphorylated phoshoinositides (3-PPI's): [PI(3)P], [PI(3,4)P2], which
generates [PI(3,4,5)P3], AKT possesses a PIP2/PIP3 binding PH domain, which requires
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PI3K stimulation for activation (King et al., 1997). Once activated AKT, can inhibit
apoptosis by a number of actions, including the phoshorylation and inactivation of the
pro-apoptotic Bel 2 homolog; Bad, caspase 9 (apoptosis initiating enzyme) and the
forkhead family transcription factor FKHR1 (mediates transcription of pro-apototic gene
products) (Madge et al., 2000). A number of oncogenes and tumour suppressor genes
that function upstream of AKT have been found to influence cancer progression by
regulating AKT (Datta et al., 2001). Oncogenes which increase PI3-Kinase, eg. Ras and
Bcr/Abl have been shown to promote oncogenesis. Khwaja et al., (1997) showed that
oncogenic ras conferred cells with anchorage independence by activating the PI3-Kinase
and AKT pathway. In 1998, Moore et al., found that PI3-Kinase acting through PKB
promoted anchorage independence. By cross-linking CD98 in SCLC cells, Rintoul et al.,
(2002) showed that PI3-Kinase activation was promoted. In addition to the level of
CD98 cell surface expression we found that stimulation of PI3-Kinase activity also
affected anchorage independent growth. The level of CD98 cell surface expression
affecting anchorage independence may be a consequence of its regulation throughout the
cell cycle. CD98 is rapidly up regulated early in transition from GO to G1 phase, it then
remains at elevated levels until the cell cycle is complete (Azzarone et al., 1985;
Suomalainen,1986; Parmacek et al.,1989). Moore et al., (1998) have shown that PI3-
Kinase inhibition by LY294002 inhibits SCLC growth, which caused a cell cycle arrest
at G1 and a decreased number of cells entering mitosis. Over-expression of CD98 heavy
chain stimulated PI3-Kinase activity and CD98 induced anchorage independence was
sensitive to PI3-Kinase inhibitors LY294002 and wortmannin (results not shown). This
suggests that PI3-Kinase activation is central to the ability of CD98 to regulate cellular
activation, progression through G1 phase of the cell cycle and the promotion of
anchorage independence.
The results of this study support the hypothesis that there is a threshold level of
expression for CD98 mediated transformation as endogenous CD98 does not result in a
malignant phenotype. This suggests that constitutively high levels of CD98 expression
as found on tumour cells results in PI3-Kinase activation and the promotion of
tumorigenesis.
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The association of CD98 and (31 integrin which is investigated in the next
chapter has been shown to occur in the context of low density membranes. Kolesnikova
et al., (2001) found that CD98 was localized to the "light" membrane fractions, typically
containing caveolae and membrane rafts. These fractions are thought to be enriched with
active signalling complexes. However less than 5% of total (31 integrins were found in
these "light" membrane fractions. It was proposed that the CD98 heavy chain may
interact with the amino acid transport light chain and regulate integrins. By mutating the
extracellular cysteines in the CD98 heavy chain this interaction was examined. The
C109S mutant which disrupts the disulphide linkage to the CD98 light chain showed no
association with (31 integrins and lost its ability to transform cells. However Fenczik et
al., (2001) found that mutation of the cysteines C109S and C330S disrupted the covalent
association with the light chain but did not impair interactions or effects on integrins.
Even though this covalent association is lost, Pfeiffer et al., (1998) have reported that the
C109S mutant still supports the surface expression of the light chain. This therefore
indicates that a non-covalent interaction may still be present. The effects of the
CD98/CD69 chimeras, especially those which lacked the extracellular domain were
examined in order to determine the possibility of a non-covalent interaction between the
light and heavy chain of CD98.
Chimeras, in which the transmembrane domain of CD98 heavy chain was
replaced with that of CD69, lost the capacity to stimulate PI3-Kinase and promote
anchorage independence. However these chimeras had no significant effect on the amino
transport function of CD98 (W.Wong data unpublished). When the extracellular domain
of CD98 was exchanged with that of CD69, transformation and activation of PI3-Kinase
were not affected. These findings indicated that the covalent association of CD98 heavy
chain with the light chain is not required for the functional regulation of integrins. These
results have also shown that the transmembrane domain of the CD98 heavy chain is both
necessary and sufficient for activating PI3-Kinase, elevating intracellular PIP3 levels and
the induction of anchorage independent growth. In addition the transmembrane domain
of the CD98 heavy chain was sufficient to promote extensive focal adhesion complexes
and to induce these phenotypic changes. In particular by analysing specifically the
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chimera 98TM and the mutants A 4F2 and D5, the amino acids 82-86 appeared to be
critical for these processes.
There are many conflicting views on the subject of cytoskeletal changes in terms
of oncogenic potential. As mentioned earlier, a common change in cancer cells is a loss
of anchorage dependence and growth control. Boyd et al., (1995) suggested that
cytoskeletal components may play a role in the uncoupling of cell shape and growth
control. However an intact actin cytoskeleton has also been proposed as an essential part
of signal transduction and integrin dependent focal adhesion (Bershadsky et al., 1996). A
model used to study integrin activation and function; the homotypic aggregation assay
(Bernarczyk et al., 1993) has shown that an active metabolic process and intact
cytoskeleton are required for homotypic aggregation (Bednarczyk and Mclntyre, 1990).
However cytoskeletal changes are required for interactions mediated by specific
integrins and signalling proteins (Miyamoto et al., 2003). This observation may explain
our findings that in CHOK1 cells over-expressing CD98, the actin cytoskeleton
appeared to be intact and that other cytoskeletal components such as microtubules are
also unaffected.
The data presented here confirms that the CD98 heavy chain is an oncogene
which promotes anchorage and serum independent growth when over expressed in
CHOK1 cells. This oncogenic activity is dependent on PI3-Kinase activation and the
level of CD98 cell surface. The transmembrane domain, particularly the amino acids 82-
86 are essential for activation of PI3-Kinase, elevation of intracellular PIP3 levels,
phenotypic changes and anchorage independence. In addition to this, in agreement with
Miyamoto et al., (2003), we have found that CD98 heavy chain over-expression has no
effect on the actin cytoskeleton and the microtubule network despite being able to
promote transformation and PI3-Kinase activity.
This work has been accepted for publication in the Journal of Biological
Chemistry and is in press.
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CHAPTER 5
INTERACTION OF CD98 WITH (31 INTEGRIN
5.0 INTRODUCTION
A requirement for growth and survival of cells is adhesion to extracelllular
matrix proteins (ECM). This was first described by Stoker et al, (1968) who found that
normal cells were blocked in the G1 phase of the cell cycle when cultured in suspension.
They termed this phenomenon "anchorage dependence".
Integrins are a large family of heterodimeric cell surface adhesion receptors
which bind ECM proteins and cell surface ligands (Fernadez et al., 1998). These
adhesive properties can be regulated by altering their active state through conformational
changes or receptor clustering. Integrin signalling can be controlled bi-directionally,
"inside out signalling" or "outside in signalling". The former is initated by interaction of
specific intracellular proteins with the cytoplasmic tail of the integrin promoting a
structural change within the integrin. "Outside in signalling" occurs when integrins
cluster at distinct sites, known as focal contacts providing a link between the ECM and
the actin cytoskeleton, regulating ligand binding. This ability to bind to various proteins
allows integrins to play a major role in inflammation, cell adhesion, migration,
proliferation and cell differentiation.
Central to integrin function are the integrin p subunit cytoplasmic domains.
Chimeric receptors containing p cytoplasmic domains connected to extracellular
reporters such as the IL-2 receptor extracellular domain (Tac) or the CD4 extracellular
domain can activate specific signalling events such as the phoshorylation of the tyrosine
FAK •
kinase ppl25 (Akiyama et al., 1994; Lukashev et al., 1994). These domains have also
been shown to function as dominant negative mutants, by inhibiting endogenous integrin
function by interacting with cytoplasmic components which are crucial for processes
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such as cell spreading and cell migration (LaFlamme et al., 1994). Therefore these
cytoplasmic domains may mediate integrin function by binding to specific cytoskeletal
and signalling proteins which would normally activate endogenous integrins. These
include Cytohesin-1, a guanine nucleotide exchange protein which induced ocLp2
dependent binding to ICAM-1 when overexpressed (Kolanus et al., 1996), ILK which
was found to bind to (31 cytoplasmic domains but could also interact with (32 and (33
cytoplasmic domains (Hannigan et al., 1996) and signalling proteins such as IAP, a
thrombospondin-1 receptor which has been implicated in the modulation of integrin
function in (32 mediated neutrophil migration (Gao et al., 1996, Cooper et al.,1995).
Proteins which interact directly with integrin cytoplasmic domains are potentially
excellent candidates for regulators of activation (Hughes and Pfaff., 1998). Recently
CD98 has been implicated as a regulator of integrin activation. Fenczik et al.,(1997),
carried out a genetic cloning strategy based on changes in integrin affinity to identify
potential modulators of integrin activation. When isolated integrin (31 cytoplasmic
domains were overexpressed, integrin signalling was suppressed. Using a CHO-cell
cDNA expression library and Tac(3l (overexpression of isolated cytoplasmic (31
domains) reversal of this dominant suppression was examined. A single cDNA, 5F8 was
found to have the ability to reverse Tac(3l suppression. Sequencing and using a BLAST
database showed that the amino acid sequence of 5F8 was 72% identical to the heavy
chain of CD98, 4F2. CD98 was found to rescue the suppression of integrin activation
caused by Tac(3l. It was also shown that CD98 was involved in the regulation of SCLC
adhesion. When CD98 was crosslinked using the monoclonal antibody 4F2, the adhesion
of the SCLC cell line H345 to laminin and fibronectin was markedly enhanced.
Chandrasekaran et al., (1999) showed that the adhesive and chemotactic activities of
thrombospondin-1; an extracellular matrix glycoprotein, could be mediated by CD98.
Ligation of CD98, increased OC3P1 mediated adhesion of breast carcinoma cells to
thrombospondin and to laminin, indicating a role for CD98 in pi dependent cell
adhesion.
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There have been many papers which indicate that CD98 may be involved in
integrin function. Anti-CD98 monoclonal antibodies have been demonstrated to activate
(32 integrins, stimulating monocyte cell-cell aggregation. The subsequent activation
of (31 integrin leads to cell fusion and the formation of polykaryon, (multinucleated
giant cells) (Tabata et al., 1994). This phenotype is seen in many chronic inflammatory
diseases such as tuberculosis and sarcoidosis. The link between CD98 and cell fusion
has also been investigated, Ohgimoto et al., (1995), demonstrated that FRP-1 (Fusion
Regulatory Protein) was an indentical molecule to 4F2/CD98. This molecule was found
to induce integrin dependent FHV gp 160 mediated cell-fusion and to promote cell fusion
induced by the Newcastle disease virus (Ito et al., 1992).
Zent et al., (2000) reported that CD98 associated with integrin (3 cytoplasmic
domains with a unique integrin class and splice variant specificity. They found that
CD98 interacted with (3iA but not (3id or (37 leukocyte specific cytoplasmic domains.
Merlin et al., (2001) found that CD98 selectively immunoprecipitated with LAT-2 and
(31 and were all found to be polarized to the same (basolateral) domain. This association
between CD98 and (31 has been further demonstrated by Kolesnikova et al., (2001).
They showed CD98 constitutively and specifically associated with a variety of (31
heterodimers. Rintoul et al., (2002) has also shown that CD98 constitutively associated
with (31 regardless of activation state in SCLC.
The aim of this part of the study was to investigate this interaction further and
determine which part of the CD98 molecule was important for this association using the
CD98/CD69 chimeras discussed in chapter 3.
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5.1 Optimisation of immunofluorescence conditions :
5.1.1 The 9EG7, rat monoclonal antibody gave optimal staining of the J31
integrin.
In order to examine the expression of (31 integrin on CHOK1 cells stably
transfected with either CD98 or CD69 or the chimeras, a number of (31 integrin
antibodies were tested using the secondary antibodies, alexa fluor 568. Eight different
antibodies were tested, 9EG7, 12G10, N-20, TS216, K20, MCA1949, Chemicon (3land
BD (31, however the three most effective are shown in Figure 5.1.1. In comparison to
TS216, K20 and the other five antibodies tested, 9EG7 stained the membrane
exclusively. This staining was in a punctate fashion which had been previously
described by Rintoul et al., (2002), when they investigated (31 colocalisation in SCLC
using K20, and TS216.
Therefore 9EG7 was the (31 antibody used throughout this investigation as this
was the most specific to (31 integrins in hamster cells.
5.1.2 Localisation of (51 integrin within the cell membrane.
The 9EG7 rat monoclonal antibody recognises an epitope up-regulated in
response to Mn2+ (Lenter et al., 1993). (31 integrin function is inhibited by Ca2+ because
it prevents a conformation favourable to ligand binding. However, Mn2+ enhances (31
function inducing the same active conformation that is formed by adding ligand or
removing Ca2+, (Bazzoni et al., 1995). It has been demonstrated in previous studies that
0C5(3i mediated cell adhesion can be enhanced by Mn2+ (Bazzoni et al., 1995), and this
stabilises the (31 conformation recognised by the 9EG7 antibody (Lenter et al., 1993,
Mould et al., 1998). This suggests that the integrins are in an active conformation which
promotes cell attachment, when they bind 9EG7 (Mastrangelo et al., 1999). 9EG7 is
therefore a useful antibody to study regulation of (31 integrins, as it identifies activated
(31.
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Ng et al (1999) found that in untreated MCF-7 cells activated (31 integrin was
found predominantly in a perinuclear/pericentriolar compartment where pi recycles.
However when the cells were treated with a PKC activator, the P1 integrin redistributed
to the plasma membrane. Equally a dramatic redistribution of activated pi to the plasma
membrane was observed after a short incubation at 20°C. They hypothesised that pi is
being constantly recycled to the cell surface, a process which is abolished at low
temperatures. Using the technique described in MATERIALS AND METHODS,
CHOK1 cells stably transfected with CD98, were fixed using 3% PFA for 20 minutes
and then incubated with 9EG7, post fixation), (Figure 5.1.2 (A)). This localised pi
within the perinuclear region of the cell. However when cells were incubated with 9EG7
at 4°C before fixation with 3% PFA for 20 mins, pi localised within the plasma
membrane, (pre-fixation), (Figure 5.1.2. (B)).
These findings corroborate with those of Ng et al., (1999) and imply that there is
constant trafficking of integrin to the cell surface and that pi is being continuously
recycled.
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Figure 5.1.1 Binding of (31 integrin antibodies to CHOK1 cells stably transfected
with CD98.
Stable CHOK1 cells were incubated with various antibodies against (31 integrin, as
described in MATERIALS and METHODS.White bars 38jam Confocal microscopy was
performed with a TCS NT Confocal microscope (Leica). Localisation of [31 integrin
using (A) TS216 (red), (B) K20 ( red) and (C) 9EG7 (red) and corresponding secondary
antibody alexa fluor 568 in a single confocal plane. The nucleus was visualised using
TOPRO 3 (blue). TS216 and K20 gave perinuclear staining whereas the 9EG7 antibody
specifically stained the plasma membrane. The images shown here are representative
views of 3 independent experiments.
9EG7 Topro 3 Merged
(A) Prefixing
(B) Post fixing
Figure 5.1.2 Optimising fixation conditions in CHOK1 ceils stably transfected with
CD98.
Stable CHOK1 cells were incubated with antibodies against (31 integrin (9EG7), (A) pre
(labelling with 9EG7 was performed at 4°C before fixing with 3% PFA and then the
cells were incubated with the secondary alexa fluor 568) or (B) post fixation, (labelling
with 9EG7and then the secondary alexa fluor 568 after fixation with 3% PFA). Images
were taken using a TCS NT Confocal microscope (Leica). Localisation of (31 integrin
using 9EG7 (red) in a single confocal plane. Nuclear staining was visualised using
TOPR03 (blue). Staining with 9EG7 post fixation gave perinuclear staining whereas
labelling pre fixation appeared to give clear (31 labelling around the plasma membrane.
White bars, 11,7pm. The images shown here are representative views of 3 independent
experiments.
5.1.3 Optimisation offixation conditions.
Stable CH0K1 cells were incubated with 9EG7 at 4°C and then fixed using three
different fixation techniques, described in MATERIALS AND METHODS, (Figure
5.1.3). Methanol fixation works by precipitating proteins. With this fixation there is no
need to permeabilise the cells or quench the fixative. However lipids and soluble
proteins will be extracted from the cell and the morphology of the cell is significantly
changed with the cell becoming thin. Compared to fixation with 100% methanol and
fixation using 50:50, MethanokAcetone, fixation with 3% PFA gave the optimal images.
(Figure 5.1.3 (C)), 3% PFA gave very clean and clear labelling of the cells and allowed
permeabilization of the cell membrane while retaining the overall architecture of the
cells.
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9EG7 Topro 3 Merged
Figure 5.1.3 Comparison of fixation methods in CHOK1 cells stably iransfected
with CD98.
Stable CHO K1 cells were incubated with 9EG7 at 4HC and then fixed. The cells were
then incubated with a secondary antibody alexa fluor 568. Localisation of (31 integrin
using 9EG7 (red) in cells fixed with:- (A) 100% methanol at -20 °C for 10 minutes, (B)
50:50, methanohacetone at -20°C for 30 seconds or (C) 3% PFA. Nuclear staining was
visualised using TOPR03 (blue). White bars 23.6pm. Images were taken using a TCS
NT confocal microscope (Leica). Both fixation with 100% methanol and 50:50
methanohacetone gave unspecific staining and was located in the perinuclear region.
However fixation with PFA gave clean and clear staining in a punctuate fashion around
the plasma membrane. Shown here are representative images from 3 independent
experiments.
5.2 Colocalisation of CD98 and B1 integrins
5.2.1 CD98 colocalises with pi integrins.
Rintoul et al (2001) showed that (31 and CD98 were constitutively associated in
SCLC cells using immunofluorescence.Thus this interaction was further examined to
determine which part of the CD98 molecule was important for this association.
The relationship between (31 integrins and CD98 was examined in CHOK1 cells
stably transfected with CD98 or CD69 or the CD98 chimeras detailed in Chapter 2 by
dual label confocal immunofluorescence. In the CD98 stably expressing cells, CD98
(detected by 4F2) and the (31 integrin (detected by 9EG7) were colocalised in the plasma
membrane. However, no colocalisation was seen between CD69 (detected by FN50-
FITC) and (31 in the CD69 stables. The chimeras 4F2TM which has the extracellular
domain of CD98 replaced with that of CD69 and 4F269 which has the extracellular and
transmembrane domain replaced with those of CD69 were examined. Colocalisation was
seen in cells expressing 4F2TM but not in cells expressing 4F269, (Figure 5.2.1a).
69TM a chimera which has its transmembrane domain replaced with CD69 did not show
colocalisation between (31 and CD98 whereas 69cyto which has its cytoplasmic domain
replaced with that of CD69, did show colocalisation, (Figure 5.2.1b). The 98TM chimera
which has the extracellular and cytoplasmic domain of CD69 and the transmembrane of
CD98 and cells expressing the chimera 98EX which has the transmembrane and
cytoplasmic domain of CD69 and the extracellular domain of CD98 showed
colocalisation of CD98 and (31,(Figure 5.2.1c). The truncation mutant A4F2 which only
has the extracellular domain and transmembrane domain of CD98 also showed
colocalisation, (Figure 5.2.Id). The isotype controls, IgGi and IgG2A antibodies for
CD98 /CD69 and (31, respectively, showed no evidence of non-specific binding.
These findings indicate that the transmembrane domain of CD98 is necessary
and sufficient for colocalisation with (31 integrins. However the finding that cells






Figure 5.2.1a (31 integrin and CD98 are colocalised in CHOK1 cells stably
transfected with CD98 and the CD98/CD69 chimera 4F2TM.
Stable CHOK1 cells were incubated with 9EG7 and 4F2 or FN50 as described in
MATERIALS and METHODS. White bars, 5pm. Localisation of either CD98 or CD69,
is shown in the upper panels using either 4F2 or FN50 respectively). (31 localisation is
shown in the middle panel using 9EG7. In the merged panel, areas of colocalisation of
(31 and CD98 appear yellow. All images shown are of a single confocal plane. Both
CHOK1 cells stably expressing CD98 and the chimera 4F2TM showed colocalisation
between (31 and CD98 whereas the cells stably expressing CD69 and the chimera 4F269
did not. Confocal microscopy was performed using a TCS NT Confocal microscope
system, (Leica). Images were analyzed using Bitplane Imaris 4 software. Images shown
are representative of 5 independent experiments.
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Figure 5.2.1b (31 integrin and CD98 are colocalised in CHOK1 cells stably
transfected with the CD98/CD69 chimera, 69cyto.
Stable CHO K1 cells were incubated with 9EG7 and 4F2 (CD98) or FN50 (CD69) as
described in MATERIALS AND METHODS. White bars 5um. Localisation of either
CD98 or CD69 is shown in the upper panels using either 4F2 or FN50 respectively. (31
localisation is shown in the middle panel using 9EG7. In the merged panel, areas of
colocalisation of (31 and CD98 appear yellow. All images shown are of a single confocal
plane. CHOK1 cells stably transfected with the chimera 69cyto showed colocalisation
of (31 and CD98 similar to that seen with CD98 stably expressing cells. The cells stably
expressing the chimera 69TM did not show colocalisation. Confocal microscopy was
performed using a TCS NT Confocal microscope system, (Leica). Images were analyzed







Figure 5.2.1c (31 integrin and CD98 are colocalised in CHOK1 cells stably
transfected with the CD98/CD69 chimeras, 98TM and 98EX.
Stable CHOK1 cells were incubated with 9EG7 and 4F2 (CD98) or FN50 (CD69) as
described in MATERIALS AND METHODS. White bars 5pm. Localisation of either
CD98 or CD69 is shown in the upper panels using either 4F2 or FN50 respectively. (31
localisation is shown in the middle panel using 9EG7. In the merged panel, areas of
colocalisation of (31 and CD98 appear yellow. All images shown are of a single confocal
plane. CHOK1 cells stably expressing the chimeras 98TM and 98EX showed
colocalisation of (31 and CD98, similar to that seen in cells expressing the whole CD98
heavy chain. Confocal microscopy was performed using a TCS NT Confocal
microscope system, (Leica). Images were analyzed using Bitplane Imaris 4 software.




Figure 5.2.1d (31 integrin and CD98 are colocalised in CHOK1 cells stably
transfected with the CD98 truncation mutant, A 4F2.
Stable CHOK1 cells were incubated with 9EG7 and 4F2 (CD98) or FN50 (CD69) as
described in MATERIALS AND METHODS. White bars 5um. Localisation of either
CD98 or CD69 is shown in the upper panels using either 4F2 or FN50 respectively. (31
localisation is shown in the middle panel using 9EG7. In the merged panel, areas of
colocalisation of (31 and CD98 appear yellow. All images shown are of a single confocal
plane. CHOK1 cells stably expressing the mutant, A 4F2 showed colocalisation of (31
and CD98, especially at the ends of the filopodia. Confocal microscopy was performed
using a TCS NT Confocal microscope system, (Leica). Images were analyzed using
Bitplane Imaris 4 software. Images shown are representative of 5 independent
experiments.
CD98 CD69 A 4F2
5.2.2 Confocal analysis
To quantify these findings, confocal images were analyzed using Bitplane Imaris
4 software. This software examines the voxels (3D cubes) within these images, which
overlap and the programme forms a colocalisation channel. This provides data which
can be expressed quantitatively, (figure 5.2.2). The histogram represents the total
amount of colocalisation between CD98 and |3l in each stable from 3 independent
experiments. CHOK1 cells stably transfected with CD98, A 4F2, 98TM, 4F2TM and
69cyto, (61.2 ± 8.5, 79 ± 1.0, 69.8 ± 5.5, 62.7 ± 5.0 and 46.5 ± 0.5 respectively), showed
significantly higher percentages of (31 colocalisation compared to the stables of the
negative control, CD69,(26.3 ± 11.20). 98EX gave variable results (44.5 ± 22.5) but
40% of (31 integrins colocalised in cells expressing 98EX.
This again confirms the importance of the transmembrane domain of CD98 in
colocalisation with (31 and indicates a possible role for the extracellular domain of
CD98.
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Figure 5.2.2 Colocalisation of pi with either CD98,CD69 or various chimeras.
Confocal images were analysed using Bitplane Imaris 4 software and the % of
colocalisation of CD98 with pi was calculated. The results are expressed as %
colocalisation and are the mean ± SEM of 5 independent experiments.
CD69 colocalisation is minimal compared to CD98. The stables which had the
transmembrane domain of CD98 also had significantly higher percentages of
colocalisation compared to CD69 and 4F269. The cells expressing the chimera 98EX
also colocalised with approximately 40% of the pi integrins.*=: significant compared to
CD69 transfected cells (P<0.05, ANOVA).
5.2.3 Amino acids 82-86 ofCD98 are criticalfor integrin association.
To further examine the interaction of CD98 with pi integrins, the CD98
truncation mutant D5 was used. The D5 mutant lacks amino acids 1-86, but is well
expressed in CHOK1 cellls, as shown by flow cytometry, (figure 4.3.4). Dual label
immunofluorescence was carried out using CHOK1 cells stably transfected with the
chimera D5,(figure 5.2.3). While 98TM (which has the extracellular and cytoplasmic
domain of CD69 and the transmembrane domain of CD98) and A4F2 (truncation mutant
which lacks the putative cytoplasmic tail (amino acids2-77)), were able to colocalise
with pi integrins, the D5 mutant was unable to colocalise. This was confirmed using the
Bitplane Imaris 4 software (as above). Figure 5.2.3 (D), represents the total amount of
colocalisation between CD98 and pi in each stable. CHOK1 cells stably transfected
with CD98 showed significantly higher percentages of pi colocalisation compared to the
stables of my negative control, CD69 and the truncation mutant D5.
These results suggest that the five amino acids 82-86 at the cytoplasmic
taiil/transmembrane domain interface are required for integrin association and are in
agreement with work done by Cal et al., (2005). They have also showed that when these
five N-terminal amino acids (WALLL) are deleted no increase in adhesion or migration
is seen in IMCD cells compared to the wild type controls. When CD98 is truncated
before the tryptophan residue of the WALLL sequence but retains the first five amino
acids (WVRTR) of the cytoplasmic tail, these cells adhere and migrate on to collagen to
a similar degree as the CD98 expressing cells. Their results indicate that the WALLL
sequence is required for increased cell adhesion and migration and is therefore required
for CD98-pl interactions.
The transmembrane domain and juxtamembrane portion of the cytoplasmic tail
of CD98 has been shown to be 100% identical in all known mammalian CD98 orthologs
highly conserved in other CD98 homologs (Cal et al., 2005). These findings suggest that
these domains play a critical role in mediating specific cellular functions.
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5.2.4 Iso-surface rendering ofCD98, CD69 and 98TM stables.
Colocalisation images were analysed using Bitplane Imaris 4 software, and 3D
images were made of various chimeras (figure 5.2.4). This programme takes into
account information about the whole cell. The localisation of pi was on the basolateral
surface as seen by Cook et al, (2002) who found that pi colcoalised with CD9 (a
member of the TM4SF and tetraspanin) in punctuate patches across the lower cell
surface, and filopodia. The location of CD98 and CD69 was more generalised across the
whole of the cells. In the CHOK1 cells stably transfected with CD69 the pi staining
appeared to form a separate layer from that of CD69, whereas in the CD98 stables the
CD98 and pi layers appeared to localise together. The colocalisation channel formed
using the Biplane Imaris 4 software confirmed these observations. This channel
(yellow), (Fig 5.2.4(C)), showed areas within the cell where colocalisation of
CD98/CD69 and pi was present. While the stables of CD69 had very little
colocalisation, both CD98 and the 98TM stables had significantly more CD98 and pi
colocalising. These 3D images also showed that CD98 stable CHOK1 cells were quite
flattened and elongated and the stables of 98TM showed the same phenotype. However
the CD69 stables had a more rounded morphology.




Figure 5.2.3. The chimera D5 shows no colocalisation between pi and CD98.
CHOK1 cells stably transfected with the chimera D5 were incubated with antibodies
against pi integrin and CD98 as described in MATERIALS and METHODS. White
bars, 5 |im. Images were taken using a TCS NT confocal microscope, (Leica.
(A)Localisation of CD98, (4F2-green), (B) pi integrin (9EG7-red) and ( C) merged
images. (D) Total colocalisation of CD98 and pi in D5 stably expressing cells compared





Figure 5.2.4 Iso-surface rendering of CD98, CD69 and 98TM.
Colocalisation images were analysed using Bitplane Imaris 4 software, and 3D images
were made of various chimeras. Images (A) and (B) indicate localisation of either CD98
(4F2) or CD69 (FN50) as green and (31 integrin, (9EG7) as red. (C) The yellow is the
colocalisation channel formed using the Imaris software.
5.3 Improving image quality by deconvolution.
Opinions vary on the value of colocalisation and whether it is an accurate
measure of physical association between two molecules. This antipathy towards
colocalisation is mainly due to the limitations of confocal microscopy in terms of lateral
spatial resolution. This is the resolution in the direction of the optical axis, called z, and
related to the depth of field which depends on the numerical aperture of the objective
lens.
When an image is generated using confocal microscopy the image is convolved,
(Figure 5.3.0). This is where every point of the object is replaced by an appropriately
blurred point and the final image is the sum of these blurred points. The point spread
function (PSF) describes the spreading or blurring of a point source of light under
specific optical conditions. Deconvolution is an improved method for confocal imaging
as it effectively reverses the convolution process. This process uses the PSF, a
mathematical algorithm, which removes the blur and haze from an image.
Deconvolution therefore improves the resolution of the image especially along the z
axis.
To confirm that the colocalisation seen with the CD98 stables was real and not a
consequence of poor resolution, scans were taken of both CD98 and CD69 and these
images were then loaded in to Huygens, a deconvolution software package.
Figure 5.3.1 (A) and (C) demonstrate the poor resolution along the z axis which
is obtained through confocal microscopy. The resolution was greatly improved when the
images of CD98 and CD69 were deconvolved, (B) and (D). The blur had virtually
disappeared and the image quality was improved along both the x-z axis and y-z axis.
This improved resolution was again then visible when x-y slices were analysed
before and after the deconvolution process, (Figure 5.3.2). This process further
confirmed that the colocalisation between (31 and CFIOKI CD98 stables was real.
Deconvolved images were analysed by the Bitplane Imaris 4 software, as before, (Figure
5.3.3). There was a 2 fold increase in (31 colocalisation in CHOK1 cells stably
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expressing CD98, compared to cells expressing CD69, (mean ± SEM, 51.50 ± 2.723 and
26.00 ± 1.080, respectively).
These experiments demonstrated the value of deconvolution in colocalisation

















Deconvolution figure adapted from Linda Wilson
Figure 5.3.0 The process of deconvolution
CD98 CD69
Figure 5.3.1 Deconvolution improves the resolution of the x-z axis and y-z axis.
Images of CD98 and CD69 expressing cells were taken using a TCS NT Confocal
microscope system, (Leica) and then deconvolved using Huygens software. (A) and (B)
are images of a slice taken at the x-z axis. (C) and (D) are images of a slice taken at the
y-z axis.(A) and (C) show the original confocal images and (B) and (D) show images
after deconvolution.
Figure 5.3.2 Deconvolution confirms colocalisation of CD98 with pi.
Cells were labelled with 9EG7 and 4F2 or FN50 as described in MATERIAFS and
METHODS. Confocal microscopy was performed using a TCS NT confocal microscope
system, (Leica). Images were deconvolved using Huygens. (A) is an image of CHOK1
cells stably transfected with CD98 or CD69 before deconvolution. (B) shows the same
images deconvolved. Areas of colocalisation appear yellow. These images are
representative of 3 independent experiments.
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Figure 5.3.3 Colocalisation of (31 with CD98 or CD69 after deconvolution.
Colocalisation data was analysed after deconvolution using Bitplane Imaris 4
software.The graph represents the percentage of (31 colocalised with either CD98 or
CD69 within the whole cell. These results are the mean ± SEM of 3 independent
experiments. Over 50% of (31 colocalises with CD98 stably expressing CHO K1 cells
after deconvolution compared to the 25% colocalisation seen with CHO K1 cells stably
expressing CD69.*= significance = P<0.05 (ANOVA).
5.4 Immunoprecipitation of CD98 and (31 integrin
5.4.1 The transmembrane domain ofCD98 is sufficent to co-immunoprecipitate
with pi.
Zent et al., (2000), showed that CD98 interacted with integrin (3 cytoplasmic
domains which had unique class and splice variant specificity. They found that CD98
associated with (31A but not the muscle specific splice variant (3ID or the leukocyte
specific (37 cytoplasmic domain. CD98 was also found to selectively immunoprecipitate
with both LAT-2 and (31 integrin and was found to polarize to the same domain, (Merlin
et al., 2001). Rintoul et al., (2002) also confirmed these results. I was therefore
interested in whether this association occurs in CHOK1 cells stably transfected with
CD98 and which part of the CD98 molecule was important for this process.
Protein lysates were made from CHOK1 cells stably transfected with either
CD98 or CD69, or the chimeras as described in MATERIALS AND METHODS. CD98,
CD69 or (31 were immunoprecipitated from these lysates, using either (2|lg) 4F2, FN50
or K20 antibodies respectively. Washed immunoprecipitates were resolved by SDS-
PAGE and subsequent western blots were then probed for either CD98, CD69 or pi.
The top panel in Figure 5.4.1 (A) shows that pi was immunoprecipitated uniformly from
all cells. The lower panel shows that CD98 co-immunoprecipitates with pi. A band
corresponding to CD98 was observed at 80kDa in the CD98 expressing cells and in the
high expressing CD98 cells (CD98+) and a truncated form 72 kDa, was seen in A4F2
cells. However in the 69TM expressing cells, which have its transmembrane domain
replaced with CD69, CD98 immunoreactivity was not detected.
When the lysates were immunoprecipitated by CD98 or CD69, (figure 5.4.1(B)),
pi was detected in CD98, CD98+, A 4F2, and 98TM expressing cells. However in the
CD69 cells and the cells expressing the CD69 transmembrane domain, such as 4F269
















Figure 5.4.1 Association of pi integrin with CD98.
Cell lysates from CHOK1 cells stably transfected with CD98/CD69 and the chimeras
were subjected to immunoprecipitation with antibodies against (A) pi or (B) 4F2 or
CD69. Immunoprecipitates were resolved by SDS-PAGE and probed with antibodies
against (A) CD98 and (B) pi. * Delta 4F2 is a truncated CD98 mutant.
5.4.2 CD98 association with [51 integrin in SCLC cells.
Figure 5.4.2a confirms that an association between (31 and CD98 exists
regardless of cell type. Immunoprecipitation was carried out on the SCLC cell line
F[69.[3l integrin was immunoprecipitated using 2|ig K20 and CD98 was
immunoprecipitated using 2(lg 4F2. Immunoprecipitations were resolved by SDS-PAGE
and probed with antibodies against CD98 (goat polyclonal antibody SC-7095) and pi
(mouse monoclonal antibody anti-pi). In both panels (A) and (B), pi and CD98 co-
immunoprecipitated with each other.
Dual label immunofluorescence was carried on SCLC cells, (Figure 5.4.2b).
SCLC cells were incubated with antibodies against pi (9EG7) and CD98 (SC-7094). In
all three cell lines H345, H69 and H510's, CD98 and pi localised together and this
could be seen in the merged panels where areas of colocalisation appeared yellow. Panel
(A) shows that the colocalisation seen between CD98 and pi was specific as no
colocalisation was seen when cells were incubated with CD71, the transferrin receptor
and CD98.
These experiments further confirmed my findings from the colocalisation studies
that CD98 associates with pi integrin and that the transmembrane domain of CD98 is









Figure 5.4.2a Association of pi integrin with CD98 in the SCLC cell line H69.
SCLC cell line H69 cell lysates were subjected to immunoprecipitation with antibodies
against pi (K20) or CD98 (4F2). Immunoprecipitations were resolved by SDS-PAGE
and probed with antibodies against (A) CD98 or (B) pi. This immunoprecipitation





Figure 5.4.2b CD98 colocalises with pi integrin in the SCLC cell lines H345, H69
and H510's.
SCLC cells were incubated with antibodies against pi and CD98 as described in
MATERIALS and METHODS. Confocal microscopy was performed using a TCS NT
Confocal microscope system (Leica). (A) Localisation of the transferring receptor CD71
and CD98. (B) Localisation of pi (9EG7) and CD98 (sc7094) in the three SCLC cell
lines. Areas of colocalisation can be seen in the merged panels and appear yellow.
Images are of a single confocal plane and are representative of three independent
experiments. CD98 and pi colocalise in all 3 SCLC cell lines. The negative control
CD71 does not localise with CD98.
5.5 DISCUSSION
CD98 has recently been implicated as a regulator of integrin activation (Fencik et
al., 1997). A genetic screen based on the physiological phenotype of integrin activation
identified the Type II transmembrane glycoprotein CD98. CD98 could rescue integrins
from Tac(3l- mediated integrin suppression. This indicated that CD98 played an
important role in modulating integrin affinity.
Zent et al., (2000) found that CD98 associated with Pi a cytoplasmic domains
using model protein mimics of dimerized integrin cytoplasmic tails. The specificity of
this interaction was confirmed by lack of binding to mimics containing cytoplasmic
domains from am, or several other subunits indicating that CD98 interacted differentially
with the pi tail in a class and splice variant specific manner. This finding also correlated
with CD98's ability to complement dominant suppression. In this investigation CD98
was added to the pi tails in the presence of other cellular proteins so it remains possible
that an intermediary protein is required for this interaction. A number of groups have
been unable to crosslink the CD98 heavy chain to pi integrins, implying that the
interaction between CD98 heavy chain and pi may not be direct (Kolesnikova et al.,
2001). However the functional relevance of the P1/CD98 complex is becoming more
evident. Cho et al., (2001) revealed that there is a close link between CD98 function and
Pi by analyzing their respective aggregation properties. They found that although the
aggregation produced by antibodies to both proteins shared many properties, there were
also significant differences between the two pathways. EDTA inhibited pi-mediated
aggregation whereas CD98 induced aggregation is EDTA insensitve and therefore does
not require divalent cations. They suggested that CD29 (Pi) plays a role in the inductive
phase of the response rather than mediating the actual cell-cell adhesion. Warren et al.,
(2000) have also shown evidence of a functional association between CD98 and
integrins in lymphocytes. Kolesnikova, et al., (2001), demonstrated that CD98
constitutively and specifically associates with pi intact heterodimers.
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A further investigation into these findings and those of of Rintoul et al., (2002),
who demonstrated that CD98 and (31 colocalised and co-immunoprecipiatated in SCLC
cells irrespective of activation state, could elucidate the physical association between
these two molecules.
Using adherent CHOK1 cells stably transfected with either CD98, CD69 or the
various CD98/CD69 chimeras, the association between CD98 and (31 was investigated
by dual label immunofluorescence and co-immunoprecipitation.
In order to carry out immunofluorescence, however, the staining techniques
needed to be optimized. The main problem was in the form of the (31 antibody and its
effectiveness in binding to hamster (31 integrin (CHO cells). After trying eight different
(31 antibodies, 9EG7 a rat anti-mouse monoclonal antibody was identified as the
antibody which gave optimal staining. 9EG7 appeared to label in a punctuate fashion
and was located mainly on the basal surface of the cells. This localization of (31 has
previously been described by Cook et al., (2002). They found that CD9 a tetraspanin
(TM4SF) colocalised with (31 integrins. They revealed that their integrin heterodimer
a5(3i of interest was located in punctuate patches across the basal surface and along
filipodia. This filipodia staining of (31 was seen when the chimeras were studied for
colocalisation, an example of this can be seen when 98TM was analysed.
Rintoul et al., (2002) described the association between CD98 and (31 occurred
irrespective of the activation state of the integrin. Activating (31, using a (31 stimulating
antibody TS216, had no effect on colocalisation and no effect was seen when a (31
blocking antibody was used.
Interestingly when cells were incubated with 9EG7 at room temperature as
described in MATERIALS AND METHODS, the (31 was located within the perinuclear
region and not the plasma membrane as expected. However when the cells were
incubated with 9EG7 at 4°C overnight, the (31 was localized within the plasma
membrane.
Very little is known about the life cycle of (31. However ECM-interacting
integrins such as a6p4, (31, anb(33 and av(33 have been found by immunofluorescence to
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reside in an intracellular vesicular compartment which at present has not been
characterized (Miranti et al., 1998). Ng et al,(1999) previously described the constant
recycling of pi. They found that in breast carcinoma cells activated pi integrin was
located predominantly in the perinuclear/pericentriolar compartments distributed
throughout the cytoplasm. Treatment with the PKC activator TPA caused redistribution
of pi to the plasma membrane and a distinct perinuclear compartment. Incubating the
cells at a lower temperature such as 20°C for 30 mins also lead to a dramatic
redistribution of activated pi to the plasma membrane. They hypothesized that this
dramatic redistribution of activated pi to the plasma membrane at 20°C implied that
"there is continuous traffic of integrin to the cell surface, which is at least partially
resistant to low temperature as well as a temperature -sensitive internalization process.
This finding appears to correlate with my observation that when the CHO cells
were incubated with 9EG7 (an activating antibody) at 4°C, the pi was located in the
plasma membrane. This may be due to the effect of low temperatures on the process
which traffics integrins.
In addition, I found that fixation techniques also altered the location of pi.
100% methanol and the mix of 50:50, methanol:acetone, caused excessive
permeabilization and made the cells very leaky which effected the architecture of the
cells. However using 3% PFA, allowed free access of the antigen but retained the
subcellular architecture of the cells.
Having optimized the staining techniques, colocalisation between CD98 and pi
was investigated. Using the chimeras, the component of the CD98 molecule which is
necessary for colocalisation was determined. As shown by many groups, Zent et
al.,(2000), Merlin et al., (2001) and Rintoul et al., (2002), CD98 and pi physically
associate. My findings corroborate these observations. Using the CHOK1 cells stably
transfected with CD98, CD69 or the chimeras, I have shown colocalisation between
CD98 and pi in the CD98 stables and not in the negative control CD69 stables. The
most striking find was that the colocalisation of CD98 and pi appeared to be dependent
on the presence of the transmembrane domain of CD98. This observation supports my
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findings from the previous chapter in which the transmembrane domain of the CD98
heavy chain played an important role in signaling and transformation. The chimera,
4F269 which had the transmembrane domain of CD98 missing and replaced with that of
CD69 did not show colocalisation with [31.
Deconvolution, an improved method of colocalisation analysis confirmed that
the colocalisation seen between CD98 and [31 existed and was not a consequence of non¬
specific labeling or poor resolution of the z- axis.
The physical association between CD98 and [31 was further confirmed by co-
immunoprecipitation experiments in both SCLC and CHOK1 cells stably expressing
CD98. This result confirms the findings by Merlin et al., (2001) who showed that CD98
selectively co-immunoprecipitates with both LAT-2 and the (31 integrin in epithelial cell
lines. The transmembrane domain of CD98 was also found to be necessary and
sufficient for this association. Co-immunoprecipitation of CD98 or (31 was not seen in
the chimera 4F269 which had the transmembrane domain of CD98 omitted. The
immunoprecipitation experiments carried out on CHOK1 cells stably transfected with
CD98, CD69 and the CD98/CD69 chimeras are very difficult to interpret. The cells were
lysed and washed with a low stringency detergent. This detergent causes perforations to
the cell membrane, breaking up the membrane into small pieces, but not completely
solubilising it. Due to the less stringent nature of the detergent, the molecules may
therefore be in the same place but may not necessarily be binding to each other. The
other discrepancy in these results is a consequence of the chimeras having different
extracellular domains and therefore being immunoprecipitated using different
antibodies. 4F2 is a very good immunoprecipitating antibody compared to the anti-CD69
antibody. In this respect the immunofluorescence results are more viable than the
immunoprecipitation results. It appears that the extracellular domain of CD98 which is
much bigger in molecular weight to that of CD69 may play a role in the colocalisation
of CD98 and [31. The 98EX chimera which has the transmembrane and cytoplasmic
domain of CD69 and the extracellular domain of CD98 colocalised with approximately
40% of [31 integrins and co-immunoprecipitated with (31 (results not shown). However
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this chimera was very difficult to use, and despite double checking that this chimera was
expressing the correct amino acid sequence; using sequence analysis, it still produced
variable results in these experiments. It is therefore difficult to determine what role the
extracellular domain of CD98 plays in integrin regulation without further experiments.
Conversely it also appears that the transmembrane domain of CD98 is sufficient for
colocalisation regardless of whether it consists of a CD98 or CD69 extracellular domain.
The chimera 69TM failed to co-immunoprecipitated with (31 and showed minimal
colocalisation.
The D5 mutant, which lacks the amino acids 1-86, did not show colocalisation
with the (31 integrin. The amino acids 82-86 of CD98 were found to be critical for PI3-
Kinase activation and anchorage independent growth in my last chapter. These results
indicate that these amino acids 82-86 are also important for integrin association.
However the mutant D5, also has the complete extracellular domain of CD98, but does
not show colocalisation with (31. This may be a consequence of these four amino acids
being absent. With these amino acids missing, it may cause a conformational change in
the CD98 heavy chain which is unfavourable for integrin association and signalling.
FACS data shows that both 98EX and D5 are expressed on the cell surface. This could
therefore imply that the absence of 82-86 amino acids changes the way CD98 orientates
in the membrane, preventing the association of (31 and CD98. This hypothesis may also
explain why 69TM did not colocalise. 69TM consists of the extracellular and
cytoplasmic domain of CD98 but has the transmembrane domain of CD69. This
transmembrane domain of CD69 may also cause a conformational change to the CD98
extracellular domain due to a possible difference in the amino acids sequence in the
transmembrane domain compared to that of CD98. This dependency on the
transmembrane domain for integrin regulation has also been described by Fencik et al.,
(2001). They found using the same chimeras which were kindly donated to us, that the
cytoplasmic and transmembrane domains of CD98 were required for interactions with
integrin cytoplasmic domains, specifically its ability to complement dominant
suppression. They hypothesized that the CD98 transmembrane domain may influence
the conformation of the cytoplasmic domain to promote binding to integrin cytoplasmic
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domains. However this present study has investigated the full length (31 molecule rather
than just the cytoplasmic tails and the results seem to indicate that the (31 molecule may
bind to either the extracellular domain of CD98 or that the transmembrane domain may
induce a change in the conformation of the extracellular domain promoting CD98 and
(31 association.
The biochemical mechanisms by which CD98 and integrins functionally interact
are still unclear. There is evidence that intermediary proteins may be involved in the
association of CD98 and (31. Zent, et ah, (2000) found that CD98 associated with (31A
cytoplasmic domains but this experiment was carried out in the presence of other
cellular proteins such as talin and filamin. Kolesnikova, et ah,(2001) found that GPI-
linked proteins such as CD109, TM4SF proteins such as CD81 and CD 147 which are
found in substantial levels in the light membrane fraction, did not co-immunoprecipitate
with CD98. This lead to their hypothesis, that the association of CD98 with integrins has
another level of specificity beyond simply co-localizing in light membrane fractions.
This implies that the interaction between CD98 heavy chain and (31 may be direct.
The heavy chain of CD98 contains two extracellular cysteines. Kolesnikova, et
ah, (2001), mutated these cysteines to serine. The C330S mutant retained association
with endogenous murine (31 in NIH 3T3 cells, but the C109S mutant showed no
detectable (31 association. The association of the CD98 heavy chain with the CD98 light
chain was maintained for the C330S but lost with the C109S mutant. The mutation of
cysteine 109 disrupted the disulphide linkage to the light chain. These results suggested
that the CD98 light chain may be necessary for the CD98-integrin association. Mutation
of these cysteines however, which was found to disrupt the CD98 heavy chain, light
chain association and reduce amino acid transport, did not disrupt its in vitro binding to
(3ia integrins and its effects on integrin activation, (Fenczik, et al., 2001). These results
indicate that the covalent association of the CD98 heavy chain with a light chain is not
required for its interaction with integrins.
These results seem to confirm an association between CD98 and (31 exists.
Immunoprecipitation is the most widely used immunochemical technique to study
161
protein interactions. It also enables the detection of rare proteins which would otherwise
be difficult to detect, as proteins can be concentrated up to 10,000 fold.
Immunofluorescence however allows visualization of small molecules, and interactions
between molecules can be seen in both fixed and live cells. However in order to
investigate the interaction between CD98 and (31 more thoroughly, Fluorescence
Reasonance Energy Transfer (FRET) could be used. FRET detects the proximity of
o
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fluorescently labeled molecules over distances > 100 A. It can be used to map protein-
protein interactions in vivo. It can also be used in a confocal capacity to analyze
colocalisation (Kenworthy, 2001).
Many groups have indicated a functional association between CD98 and (31.
CD98 has been shown to play an important role in many cellular processes such as
adhesion, fusion, migration and metastasis in which integrin regulation is important in
modulating these processes. It then seems plausible that a physical association between
CD98 and (31 exists.
The data presented here looking at the whole (31 integrin molecule rather than the
cytoplasmic tails indicates that this physical association between CD98 and (31 exists
and that as reported the extracellular domain and the amino acids 82-86 of the
transmembrane domain of the CD98 molecule are important for this interaction.
This work has been published in the Journal of Biological Chemistry, 2004.
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CHAPTER 6
CD98 AND ITS RELATIONSHIP WITH NCAM
6.0 INTRODUCTION
Many papers have reported that CD98 associates with a variety of different
molecules. Rintoul et al., (2002), showed that CD98 and (31 colocalised in SCLC and I
have now shown that (31 and CD98 physically associate using co-immunoprecipitation
experiments. Suga et al., (2001) reported that CD98 stimulation by anti-CD98
monoclonal antibodies induced the activation of (32-integrin (LFA) via the PI3-Kinase
pathway, activating Rap-1. Kakugwa et al., (2003), showed that CD98 co-
immunoprecipitated with CEA-CAM and stimulated CEA-CAM-1 mediated cell
adhesion. These findings suggest that CD98 acts as a "molecular facilitator" (Rintoul et
al., 2002), in the plasma membrane by regulating different types of adhesion molecules.
Having looked at the diverse effects of CD98 it seemed plausible to investigate whether
there are any other molecules like CD98 which have similar effects on integrins.
NCAM, Neural cell adhesion molecule is a membrane associated glycoprotein of
the Ig superfamily. It plays an important role in neural development and neural
regeneration. Three isoforms of NCAM are generated through alternative splicing; 2
transmembrane isoforms NCAM-140 and NCAM-180 and a 120kDa
glycosylphosphatidylinositol-linked (GPI) isoform, (Figure 6). LI is another member of
the Ig superfamily which plays a similar role in developmental processes as NCAM. It is
a 200 kDa glycoprotein which is highly expressed on neuronal cells. Both NCAM and
LI have been shown to engage in homophillic binding (cell-cell) interactions. However
more recently, they have been shown to also exert heterophillic cis and trans binding
interactions with molecules of different classes, such as the cell adhesion molecule,
members of the FGFR family and extracellular components (Seidenfaden et al., 2003).
NCAM has been shown to play an important role in the progression to tumour
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malignancy. For example, in various cancer types, the expression of NCAM shifts from
the adult 120 kDa isoform to the embryonic 140 and 180 kDa isoforms, together with a
general downregulation of expression (Cavallaro and Christofori, 2001; Christofori,
2003). Perl et al., (1999), reported that abrogation of NCAM expression in pancreatic (3
cell tumours results in a dramatic increase in the incidence of metastases. NCAM-
deficient tumour cells were shown to have an impaired cell-substrate adhesion, whilst
cell-cell adhesion was not affected by lack of NCAM, (Cavallaro et al., 2001). This
indicates a possible role for CAMS and specifically NCAM in modulating cellular
functions, critical for tumour progression (Christofori, 2003).
Reports of mechanisms involving direct Ll-integrin ligation and the induction of
transient integrin signaling and endocytosis. have recently been documented
(Mechtersheimer et al., 2001; Thelen et al.,2002 ). Silletti et al., (2004), have shown that
LI promotes the expression and utilization of integrin OC5P3 and speculated that this
discovery has broad mechanistic ramifications for the participation of LI in a variety of
normal and pathological processes, such as neurite extension ,extravasation, myelination,
and metastasis. Cavallaro et al., (2001), showed that NCAM binds to and stimulates
FGFR4 stimulated tyrosine kinase activation of pancreatic tumour cells. They
hypothesised that modulation of tumour cell-matrix adhesion by NCAM, affects integrin
regulation. This may occur by NCAM inducing the formation of a signalling complex;
activating signal transduction pathways, similar to the induction of integrin signalling by
LI.
These hypotheses lead to the investigation of whether CD98 and NCAM are
similar molecules in the terms of modulating integrin signalling and whether CD98 and
(31 could form a signalling complex.
164
hOW 120 140 fOWIBO 11
rnmunoghobulini region m hforwiotiin HI ■ PSA attachment Site
Figure 6 Structure of neural cell adhesion molecule (NCAM) and LI.
The extracellular part of all NCAM isoforms consists of 5 immunoglobulin-like and 2
fibronectin type Ill-like domains, whereas that of LI contains 6 immunoglobulin-like
and 5 fibronectin type Ill-like domains. The 120 kDa NCAM isoform is linked to the
membrane through a phospholipid anchor and thus can be easily released into the
extracellular milieu. The 140 kDa NCAM, 180 kDa NCAM, and LI, in contrast, are
anchored to the cell membrane and have specific intracellular domains, through which
they can interact with the cytoskeleton or components of the postsynaptic density. Blue
dots demarcate the attachment sites for polysialic acid (PSA) polymers on NCAM
(Welzl and Stork, 2003).
6.1 CD98 and its relationship with NCAM.
6.1.1. Expression ofNCAM isoforms in SCLC cell lines.
From the evidence gathered thus far, it is becoming evident that CD98 is an
important molecule in regulating integrin signalling. It now seems plausible that CD98
may be part of signalling complex with pi which modulates various signals. Fencik et
al., (1997) found that antibody mediated crosslinking of CD98 stimulated pi integrin-
dependent cell adhesion. Suga et al., (2001) demonstrated that CD98 stimulation by anti-
CD98 mAbs induced activation of p2-integrins (LFA-1) via PB-Kinase and Rap-1
activation. Kakugawa et al., (2003), reported that CD98 stimulation could activate CEA-
CAM-1 mediated cell adhesion via protein kinase C8 (PKC8) activation. These results
indicate that CD98 can regulate different types of adhesion molecules. Therefore this
hypothesis was tested and it was determined whether there were any other molecules
like CD98, which could have similar effects on integrin activation. NCAM, Neural Cell
Adhesion Molecule, is a membrane associated glycoprotein of the Ig superfamily and
plays an important role in neural development and neural regeneration. It is encoded by
a single gene, but a number ofdifferent isoforms are generated through alternative RNA
splicing, eg. NCAM-120, NCAM-140 and NCAM-180. NCAM engages in homophillic
(NCAM-NCAM) and heterophillic binding (NCAM-ECM etc) (Ditlevsen et al., 2003).
Homophillic binding ofNCAM has been shown to lead to the activation of a number of
intracellular signalling pathways. An example of this is induction of neurite outgrowth
through patlrways activating FGFR, PKC and MAPK (reviewed by Berezin et al., 2000).
Cavallaro et al., (2001), hypothesised thatNCAM assembles a FGFR signalling complex
leading to pi integrin mediated neurite outgrowth and matrix adhesion. These findings
lead to my hypothesis that CD98 associates with NCAM, pi and FGFR forming a
complex which can modulate signalling.
SCLC, small cell lung cancer, is a highly malignant tumour, comprising of cells
which have endocrine characteristics and in culture grow as floating spheroid
aggregates. However NSCLC, non-small cell lung cancer, cells grow as adherent
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monolayers (Pettinghill et al., 1980). The reason for the molecular differences between
SCLC and NSCLC has not yet been established. However one potential candidate tor
these changes in adhesive properties of these cells is NCAM.
To confirm that endogenous NCAM was present in SCLC cells, quiesced cells
were lvsed as described in MATERIALS ANDMETHODS and then run on SDS-PAGE
and western blotting was carried out using a mouse monoclonal antibody raised against
human NCAM. The blots were then probed with a secondary mouse HRP and visualized
using enhanced chemiluminescence (Figure 6.1.1). From three independent experiments
it was found that NCAM appears to exist in different isoforms depending on the SCLC
cell line. H345 only showed NCAM-180 whereas H69 showed both NCAM-180 and
NCAM-140. Interestingly in many cancers, the expression ofNCAM changes tfom the
isoform NCAM-120 that is linked to GPI (glycophosphatidylinositol) to the







Figure 6.1.1 Western blot of NCAM expression in two SCLC cell lines H345 and
H69.
Quiesced SCLC cells were lysed and their protein concentration was determined as
described in MATERIALS AND METHODS. Aliquots of lysate were then run on SDS-
PAGE and western blotted with an anti-NCAM antibody. The blots were then visualized
using enhanced chemiluminescence. This blot confirmed that endogenous NCAM was
present in SCLC cells. NCAM appeared to exist in different isoforms depending on the
SCLC cell line.
6.1.2. NCAM colocalises with CD98.
Having established that endogenous NCAM exists in different isoforms in
different SCLC cell lines and that there is a high level of expression ofCD98 in SCLC,
an investigation into whether these two molecules associated with each other was carried
out. This was investigated using dual label immunofluorescence.
SCLC cells were adhered to coverslips using poly-L-lysine and left to grow and
adhere overnight to the matrix at 37°C. Cells from both H69 and H345 cell lines were
incubated with antibodies against NCAM and CD98 and then the corresponding
secondary alexa fluors as described in MATERIALS AND METHODS. Images were
visualized using confocal microscopy (Figure 6.1.2a). Images are representative of four
independent experiments. Labelling of NCAM and CD98 (sc7094), appeared to be
present around the cell membrane. When these images were merged, colocalisation of
both these molecules was visible as the cell membranes were yellow in colour. This
phenomenon occurred in both cell lines H69 and H345. This colocalisation was
confirmed by analysis with Bitplane Imaris 4 software and tire % of total colocalisation
was calculated.65% colocalisation was seen between CD98 and NCAM as shown in
figure 6.1.5b and 6.1.5c.
In order to confirm this colocalisation seen was real and not a consequence of
non-specific binding, adhered SCLC cells were incubated with negative control
antibodies, Ig2a (isotype control) and the secondary alexa red 568 (goat-anti-mouse,
Figure 6.1.2b). No specific labelling was seen in the top panels, with either of these
controls. However to confirm this further, the membrane bound transferrin receptor
CD71 was tested in colocalisation studies with NCAM (Figure 6.1.2b). When images of
CD71 labelling and NCAM labelling were merged, no colocalisation was seen, the
labelling ofeach molecule appeared to be quite separate. Colocalisation analysis assured
that this finding was correct as only 14 % ofNCAM colocalised with CD71 as shown in
figure 6.1.5c.




Figure 6.1.2a NCAM and CD98 colocalise in the SCLC cell lines H345 and H69.
SCLC cells were incubated with atibodies against NCAM and CD98 as described in
MATERIALS AND METHODS. White bars, 4.4|J.m and 8.8pm respectively. Confocal
microscopy was performed using a TCS NT Confocal microscope system (Leica).
Localisation of NCAM (green) and CD98 (sc7094, red) are shown in the top and bottom
panels. Areas of colocalisation can be seen in the merged panels and appear yellow.
Images are of a single confocal plane and are representative of 3 independent
experiments. CD98 and NCAM colocalise in both H345 and H69 SCLC cell lines.
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Figure 6.1.2b CD71 does not colocalise with CD98 in the SCLC cell line H69.
SCLC cells were incubated with antibodies as described in MATERIALS AND
METHODS. Confocal microscopy was perfomed using a TCS NT Confocal microscope
(Leica). (A) Testing negative control antibodies, isotype control IgG2a antibody and
secondary alexa red antibody. White bars, 8.8p.m. (B) Localisation of CD71 and NCAM.
White bar, 3pm. No evidence of non specific binding was seen when cells were
incubated with the negative control antibodies. The transferrin receptor CD71 does not
colocalise with NCAM.
6.1.3. NCAM colocalises with pi integrins.
p 1 spectrin is a ubiquitous scaffolding protein with a functional unit made up of
an a and p heterodimer. Leshchyn'ska et al., (2003), showed thatNCAM-180,140 and
120 colocalised with pi spectrin. Cavallaro et al., (2001), found when adherent
NCAMY tumour cells were treated with neutralizing antibodies against pi, neurite
outgrowth was abrogated. They also found that expression of the different NCAM
isofonns by transient transfection in NCAM V tumour cells, restored neurite outgrowth
and cell adhesion, which in turn was repressed by antibodies against pi. This evidence
indicated a possible role for P1 integrin in NCAM signalling.
Having established that CD98 and pi physically associate, (Chapter 5) and
NCAM and CD98 colocalise, an investigation was carried out to see if p 1 and NCAM
associate with each other, thereby forming a complex with CD98.
SCLC cells were adhered to eoverslips, incubated with antibodies against NCAM
and pi integrin and then their corresponding secondary antibodies. Confocal microscopy
was performed and colocalisation between the two molecules was examined (figure
6.1.3). Labelling of NCAM was found around the cell membrane and as described
earlier in Chapter 5, the pi was found around the cell membrane, but in a punctuate
fashion. When these images were merged, partial colocalisation was observed around
the membrane. This colocalisation was confirmed by using Bitplane hnaris 4
colocalisation software, 46% ofNCAM colocalised with pi, as shown in figure 6.1.5c.
Images are representative of 2 independent experiments.
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Figure 6.1.3 NCAM partially colocalises with (31 integrin.
SCLC cells were incubated with atibodies against NCAM and (31 as described in
MATERIALS AND METHODS. White bar 5fim . Confocal microscopy was performed
using a TCS NT Confocal microscope system (Leica). Localisation of NCAM (green)
and (31 (9EG7, red) are shown in the 1st and 2 nd panels. When these two images are
merged, areas of colocalisation appear yellow. Images are of a single confocal plane and
are representative of 2 independent experiments.
6.1.4. Co-immunoprecipitation ofCD98, NCAM and pi integrin.
NCAM has been shown to associate with (31 spectrin, FGFR and PKC. Beggs et
al., (1997), found that NCAM-140 coimmunoprecipitated with pi 25Clk and p59fyn These
findings suggest that by forming a molecular complex, tyrosine kinases are activated
initiating a signalling cascade. In order to confirm the association between CD98 and
NCAM further and to look at the physical association ofNCAM and p 1 in greater detail,
co-immunoprecipitation experiments were performed.
Immunoprecipitation was carried out on tire SCLC cell line H69. Protein lysates
were made from the SCLC cells and pi, CD98, NCAM or CD71 were
immunoprecipitated using either, K20, 4F2, anti-NCAM and anti-CD71 (2pg)
respectively. These immunoprecipitates were washed and resolved by SDS-PAGE and
probed with antibodies against CD98, pi or NCAM. The blots shown below are
representative of four independent experiments.
Figure 6.1.4 shows in the top panel that NCAM and pi associates with CD98
with corresponding bands at ~85 kDa. The middle panel shows that NCAM and CD98
associate with P1 again with bands corresponding to p 1 at 130 kDa. The bottom panel
confirms these observations as CD98, and pi co-immimoprecipitate with NCAM
showing corresponding bands at mainly 140 kDa but also at 180 kDa. However tire
negative control, CD71 showed no immunoreactivity with NCAM or CD98. This
colocalisation and association was then confirmed by analysis using the Bitplane Imaris
4 software, 66% of CD98 and 46% of pi colocalised with NCAM whereas the
colocalisation seen between CD71 and NCAM was minimal at 14% as shown in Figure
6.1.5.
These experiments confirmed my colocalisation studies that CD98 and NCAM
physically associate with each other. NCAM and pi appear to be located in the same
place on the membrane as partial colocalisation was seen between the twomolecules and
also physically associate together as shown in the co-immunoprecipitation experiments.
This experiment was also carried using the SCLC cell line H345 and tire same results
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Figure 6.1.4a) Association of CD98 with |31 and NCAM and association of NCAM
with pi.
SCLC cell line H69 cell lysates were subjected to immunoprecipitation with antibodies
against pi (K20), CD98 (4F2), NCAM (anti-NCAM) and CD71 (anti-CD71).
Immunoprecipitations were resolved by SDS-PAGE and probed with antibodies against
(A) CD98, (B) pi and (C) NCAM. CD98 co-immunoprecipitated with both pi and
NCAM. NCAM co-immunoprecipitated with CD98 and (31. (31 co-immunoprecipitated
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Figure 6.1.4b). Colocalisation of NCAM with various molecules.
Confocal images were analysed using Bitplane Imaris 4 software and the % of
colocalisation of NCAM with CD98, pi and CD71 was calculated. The results are
expressed as % of colocalisation, (n=l).
The colocalisation seen between NCAM and CD71 was minimal at -14% compared to



















Having established that CD98 and NCAM colocalise and associate together, its
functional relevance was investigated. Moolenar et al., (1990) and Kibbelaar et al.,
(1989) recently demonstrated that a dominant surface antigen of SCLC cells is NCAM.
NCAM may potentially be important in the early metastasis characteristic of SCLC
cells. A potential candidate for the changes seen in NSCLC cells in terms of their
adhesive properties is NCAM. Kibbelaar et al., (1989) found that 20% ofpatients with
NSCLC whose tumours were positive for NCAM had a significantly shorter survival
than did NSCLC patients with tumours negative forNCAM immunoreactivity.
Anchorage independence was measured using a colony assay based on fire
property of tumour cells to metastasise and grow in inappropriate locations in vivo. This
technique is discussed in more detail in section 4.1.1. To investigate whether the
expression ofNCAM enhanced anchorage independence, colony assays were carried out
using H69 SCLC cells.
NCAM-Fc, a NCAM fusion protein (kindly donated to us by Melitta Schachner,
(Zentrum fur Molekulare Neurobiologie, Universitat Hamburg, Germany) was used to
stimulate the endogenous NCAM present within the SCLC cells. Beggs et al.,(1997)
found that clustering ofNCAM-140 at the neuronal cell surface either by antibodies or
by treatment with a soluble NCAM fusion protein (NCAM-Fc) caused transient
phosphorylation of both p59fyn and pl25FAk. Schmid et al., (1999) demonstrated that
when NCAM-140 expressing B35 neuroblastoma cell were treated with NCAM Fc, the
stimulation ofphosphorylation ofMAPK's increased four-fold.
NCAM-Fc was transfected into CHOK1 cells and the secreted fusion protein was
collected and then purifed from the medium by protein A-Sepharose chromatography as
described in MATERIALS AND METHODS Section 2.17. SCLC cells were suspended
in 0.3% agarose containing 2pg/ml of a NCAM-Fc. This suspension was layered on top
of the 0.5% agarose in 1% FCS and the number of colonies was counted after 14 days
using a light microscope as described in MATERIALS AND METHODS. The results,
shown in figure 6.1.6, suggest that NCAM enhanced clonal growth of SCLC cells. After
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7 days the cloning efficiency of NCAM stimulated cells was approximately 15%
compared to the 10% shown by control SCLC cells. However this difference is further
increased after 14 days where NCAM stimulated cells show a cloning efficiency of
approximately 60% compared to the 40% shown by control cells. Cells stimulated with
4F2 showed an increased cloning efficiency compared to control cells but did not further
increase growth in cells stimulated with either 1 or 2 pg/ml NCAM-Fc. As well as
increased cloning efficiency there was also a noticeable increase in size of the colonies




































Figure 6.1.5. NCAM may cause an increase in clonal growth after 14 days
compared to untreated H69 SCLC cells.
The clonal growth of H69 SCLC cells treated either with 1 or 2|ig/ml NCAM-Fc or 10
pg/ml 4F2 in semi-solid 0.3% agarose medium containing 1% FCS was determined after
7 and 14 days as described in MATERIALS AND METHODS. When cells were treated
with both 4F2 and NCAM-Fc there was no obvious difference in their cloning
capabilities. Results are expressed as % cloning efficiency and are the mean of 2
independent experiments
6.1.6. SCLC cell adhesion to laminin is enhanced by either 4F2 orNCAM.
To investigate the effect of NCAM oil integrin function cell attachment assays
were carried out. 96 well tissue culture plates were coated with lOgg/ml laminin, or
100pg/ml poly-L-lysine as positive controls as described in MATERIALS AND
METHODS, section 2.16. After blocking, 1x10"' H69 SCLC cells were plated in the
presence or absence of lOpg/ml 4F2, 2pg/ml NCAM-Fc or both and left at 37°C to
incubate for lhr. After washing and fixation with 3% PFA, methylene blue was added to
the wells and the colour is developed by adding 0.1M HC1. 'Hie graph in figure 6.1.7 is
the mean of 2 independent experiments and shows the percentage ofadhesion to laminin
etc, compared to poly-L-lysine (100%). Adhesion to laminin was enhanced in the
presence of 4F2 or NCAM. There was approximately a 40% increase in adhesion to
laminin when stimulated with 4F2 and approximately a 25% increase when stimulated
with NCAM. Stimulation with both NCAM-Fc and 4F2 had no significant effect on
adhesion to laminin. When the cells were plated onto NCAM-Fc, no adhesion occurred,
(data not shown). These results suggest a possible role for NCAM in anchorage
independent growth and cellular adhesion events but more experiments need to be
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Figure 6.1.6. The effect of 4F2 and NCAM on the adhesion of the SCLC cell line
H69 to the ECM.
A 96 well tissue culture plate was coated with lOmg/ml laminin for lhour at 37°C,
blocked with 2% BSA for lhr. The cells were then plated in the presence of 2|ig/ml
NCAM-Fc or 10|lg/ml 4F2 or both and incubated at 37°C for lhr. Cell adhesion was
then determined by staining the wells with methylene blue and elution with 0.1M HC1.
The attachment of H69 cells to wells coated with Poly-L-lysine was defined as 100 %
adhesion. The results show that in the presence of 4F2 or NCAM, adhesion to laminin is
enhanced. In the presence of both, there was no difference between adhesion with
NCAM or 4F2 alone. The results shown are the mean and SEM of 3 independent
experiments.
6.2 DISCUSSION
A physical association between CD98 and (31 has been previously demonstrated
(Chapter 5). This association appeared to be important in regulating signalling through
integrins. As well as a link with (31, Kakugwa et al, (2003) reported that CD98
stimulation could activate CEA-CAM-1 mediated cell adhesion via protein kinase C 8
(PKC8) activation. This study indicated that CD98 could regulate different types of
adhesion molecules therefore it was decided to investigate this theory and find out
whetlier there were any similar molecules to CD98 in terms of integrin regulation. In
1997, Beggs et al, showed that the neural cell adhesion molecule (NCAM) interacted
with both pl25fak and p59fyl1 non-receptor tyrosine kinases. The involvement of these
two molecules in NCAM function suggested a convergence of NCAM and integrin
dependent adhesion pathways. Therefore having studied the literature further, NCAM
appeared to be an interesting molecule to investigate.
NCAM, the neural cell adhesion molecule is a member of the immunoglobulin
(Ig) superfamily. It plays a pivotal role in the promotion of neural development and
neural regeneration. NCAM exhibits a high structural diversity and a complex
expression pattern. This is due to alternative splicing, developmental regulation and post
translational processing. Three isotbrms ofNCAM are fomied by alternative splicing of
a single gene, these are the transmembrane forms, NCAM-140 and NCAM-180 and tire
glycosylphosphatidylinositol-linked (GPI) isoform, NCAM -120.
In order to investigate NCAM and its potential role in integrin signalling, the
SCLC cell lines (Small cell lung cancer), H345, H69 and H510 were used. SCLC
accounts for 20-25% ofhuman cancers (Guo et al., 2000). Small cell lung carcinoma is a
highly malignant tumour comprising cells with endocrine characteristics (Scheidegger et
al., 1994). These endocrine characteristics include the production ofdopa decarboxylase
and neuron-specific enolase, secretion of various neuropeptides and the expression of
neuronal surface markers such as the neural cell adhesion molecule and HNK-1 (Guo et
al., 2000). SCLC cells generally grow as floating spheroid aggregates and are typically
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anchorage independent (Doyle et al., 1990). The aggregates form through the process of
cell-cell adhesion, whieh is mediated by E-eadherin and NCAM (Guo et al., 2000).
Unlike the majority ofother tumour cells, the expression ofNCAM is upregulated rather
than downregulated during tumour progression in SCLC (Cavallaro and Christofori,
2004). This makes the SCLC cell lines interesting tools to investigateNCAM expression
and function.
Whilst confirming that endogenous NCAM was present in the SCLC cell lines
obtained, it was discovered that the NCAM isoform expressed differed in terms of the
SCLC cell line. H345 only expressed NCAM-180 whereas H69 expressed both
transmembrane isofonns NCAM-140 and NCAM-180. This may be explained by the
finding that in various tumour types, NCAM expression shifts from the adult GPI-linked
120 kDa isoform to the embryonic 140-180 kDa transmembrane isofonns (Cavallaro and
Christofori, 2001; Christofori, 2003). This isofbrm switch and its significance is as yet
unknown however it may be based on differential polysialyation of the various NCAM
isofoims (Muhlenhott et al., 1996). Moolenaar et al., (1992) discovered that the SCLC
cell line H69 cells expressed tire two major isofonns ofNCAM, 140 kDa and 180 kDa.
They found no evidence for the 120 kDa isotonn as no mRNA containing exon 15 was
present, encoding the glycosyl-phosphatidylinositol-linked (GPI-linked) NCAM
isofoim.
NCAM has been shown to associate with a variety of different molecules. Beggs
et al., (1997), showed that two non-receptor tyrosine kinases, p59fyn and pi 25 interact
with the 140kDa isoform ofNCAM. When cell surface NCAM 140 was ligated using
antibodies or stimulated with NCAM-Fc (NCAM fusion protein consisting of the entire
NCAM extracellular domain fused to the Fc region ofhuman IgG ), there was a transient
increase in the tyrosine phosphorylation ofboth pl25fak and p59fyn. They suggested that
activation of these non receptor tyrosine kinases is a proximal event in the NCAM signal
transduction pathway.
Adaptor proteins such as FRS2 and She and the downstream effector PLCy were
found to associate with NCAM as well as FGFR-4. These associations suggest a role for
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the cell adhesion molecule NCAM in mediating many different cellular functions via
various signalling pathways.
To investigate whether the molecules CD98 and NCAM colocalise, dual label
immunofluorescence studies were carried out. Using the SCLC cell line H69 which
highly expresses CD98 and NCAM, I have demonstrated that these molecules colocalise
within the membrane. This finding was further confirmed by investigating another
molecule CD71. CD71, the transferrin receptor which is expressed on SCLC cells was
used as a negative control. No colocalisation between NCAM and CD71 was seen
indicating that the colocalisation between CD98 and NCAM was not a consequence of
non-specific binding or close proximity in tire membrane but suggests these molecules
may interact. To examine this further,membranes were solubilised and a molecular
association was examined by immunoprecipitation. These experiments confirmed that
CD98 was associated with NCAM and was immunoprecipitated with NCAM by
NCAM-specific antibodies which recognised both 140 kDa and 180 kDa isoforms. This
suggested that the physical association observed between NCAM and CD98 was a real
event and not just a consequence of the molecules being in the same place on the
membrane. This result was confirmed again using CD71, which did not
immunoprecipitate with NCAM. The reverse experiment where 4F2 was used to
precipitate CD98 from the cell membrane showed in addition that 4F2 pulled down
immunoreactive bands forNCAM 140 and 180 in H69 cells.
The suggested link between NCAM and integrin signalling prompted an
investigation into a possible association between NCAM and pi integrin. This was again
carried out using confocal microscopy and co-immunoprecipitation experiments. Partial
colocalisation between NCAM and pi was seen and this was confirmed by the co-
immunoprecipitation ofboth CD98 and p 1. The association betweenNCAM and p 1 has
been investigated by Cavallaro et al, in 2001. They found that neutralizing antibodies to
pi integrin repressed neurite outgrowth and matrix adhesion. They also showed that
expression of the different NCAM-isoforms by transient transtection inNCAM"'" tumour
cells restored neurite outgrowth and cell adhesion, which in turn could be repressed by
antibodies against pi integrin. These findings suggested that pi integrin is directly
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activated by NCAM-mediated signalling. However this group was unable to show co-
immunoprecipitation between pi and NCAM in NOAM"' tumour cells. Although
uncertain, the association betweenNCAM and CD98 and the link between CD98 and P1
nevertheless suggest that P1 may be involved in NCAM-mediated signalling and may be
part ofan NCAM-signalling complex.
Having proposed the idea of a signalling complex, consisting of NCAM and
CD98, it seemed sensible to investigate whether this association had any functional
relevance. NCAM plays a major role in neural development and neural regeneration but
also appears to have a potential role in die early metastatic characteristics of tumours, hi
chapter 4, I demonstrated that overexpression of CD98 induced anchorage
independence, a key feature of tumorigenesis, and stimulated PD-Kinase activation and
its downstream elfector AKT, an important property of oncogenes. In 2003, Ditlevsen et
al., showed that activation of PI3-Kinase was necessary for NCAM-mediated neurite
outgrowth and survival. They suggested that this may be a consequence ofeither FGFR-
mediated NCAM activation, induced by recruitment ofmultiple docking proteins such
as Gabl generating binding sites for the SH2-domain of the p85 subunit of PI3-Kinase,
(Ong et al., 2001) or the involvement of FAK where the p85 subunit binds to the
phosphoiylated FAK (phosphorylated upon binding to the NCAM-fyn complex, (Beggs
et al., 1997)), activating PI3-Kinase, (Chen et al., 1996). Studies with human tumour
biopsies and mouse tumour models have also revealed that NCAM plays an important
role in the progression to tumour malignancy, (Cavallaro and Christofori, 2004).
Therefore NCAM and CD98 appear to share many functional properties. Adhesion and
colony assays were perfonned to investigate whether the expression and activation of
both these molecules has any effect on these functional processes.
The results from both the colony assay and adhesion assays suggest that NCAM
may play a role in anchorage independence and cell adhesion. NCAM activation by
NCAM-Fc increased colony formation and adhesion to laminin. A similar though more
pronounced effect was shown by crosslinking CD98. Co-activation of NCAM in
addition to CD98 activation did not produce any additive effects on adhesion or colony
formation, however further dose ranging studies are required to more fully answer this
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question. Polysialylation of NCAM is very important in understanding the functional
effects of NCAM. A unique structural feature ofNCAM is the presence of polysialic
acid, a developmentally regulated carbohydrate composed of a linear homopolymer of
a (2,8>linked sialic acid residues (Finne et al., 1983).This carbohydrate is added to
specific N-glycan attachment sites in the fifth immunoglobulinlike domain of NCAM
(Muhlenhoffet al., 1998). Polysialylation (PSA) ofNCAM is a unique post translational
modification that appears during vertebrate development to cany out a variety of
biological functions, (Rutishauser and Landmesser, 1996). It is thought to facilitate cell
migration, axon pathfinding and synaptogenesis, (Fujimoto et al., 2001). PSA-NCAM
appears to increase metastatic potential and has been correlated with tumour progression
and poor prognosis, (Seidenfaden et al., 2003). Polysialylation ofNCAM has therefore
been suggested as a possible mechanism which contributes to the lack ofcell adhesion in
human lung cancers and neuroblastomas. The polysialylation ofNCAM therefore may
explain my results which showed that NCAM enhanced cloning efficiency. The
upregulation of NCAM expression seen in SCLC is also accompanied by NCAM
polysialylation (Bruses and Rutishauser, 2001). Tire results from the adhesion assays
showed a minor increase in adhesion to laminin after stimulation with NCAM-Fc.
However more confusing was the lack of cell adhesion when plated on NCAM Fc. The
lack of effect of NCAM-Fc could simply be a consequence of the concentration of
NCAM-Fc used to coat the plates being insufficient to cause any effect. It could also be
due to the NCAM-Fc being washed offduring the process of the assay. Another possible
explanation for the lack of effect ofNCAM-Fc could be due to the endogenous NCAM
in SCLC cells being bound to other NCAM molecules on neighbouring cells, so
therefore may not be available to be stimulated byNCAM-Fc.
Unfortunately due to time and resource constraints I was unable to research these
functions further to obtain a greater understanding in NCAM function. However if I had
had the time, I would have carried out both the colony and adhesion assays again but
using suboptimal level of both 4F2 and NCAM-Fc. I would also remove the PSA from
the SCLC cells by treating the cells with endoneuraminidase, as carried out by
Scheidegger et al., (1994) in which the effects ofPSA were investigated in tenns of its
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role in tumour cell growth and differentiation. This study showed that expression of
PSA affects NCAM-dependent signalling involved in tumourigenesis. Removal of this
carbohydrate may therefore be useful in obtaining a more conclusive answer. PI3 -kinase
assays in the presence of both NCAM and CD98 would be useful experiments to
elucidate whether PI3-Kinase activation is involved in NCAM-mediated signalling in
SCLC as well as colony assays using cells stimulated with NCAM-Fc and 4F2 in the
presence or absence of a PDkinase inhibitor. Another interesting assay to cany out
would be a proliferation assay, Pardoe et al., suggested a role for FGFR's in inducing
increased proliferation in SCLC, therefore CD98 and NCAM may also be involved in
this process. If it was possible I would have transiently transfected CHO K1 cells with
NCAM and CD98 and investigated whether the Ras-MAPK pathway was activated via
SDS-PAGE analysis, as the Ras pathway has been suggested as a method of signal
transduction for modulation of expression of genes required for neuronal growth and
survival, (Sehmid et al., 1999).
This chapter has therefore demonstrated an association between CD98 and
NCAM and NCAM and (31,. The associations between these molecules may form a
signalling complex and crosstalk between the integrin and growth factors may modulate





Figure 6.2. Schematic representation of proposed NCAM/CD98/ FGFR/N-
cadherin signalling complex.
An signalling complex consisting ofNCAM, N-cadherin, FGFR and CD98 forms,
mediating the signal transduction pathways. The crosstalk between the growth factor
receptor and integrins modulate the signals produced, influencing the surrounding
cellular environment leading to transformation. The dashed lines represent the as of yet
poorly understood signalling pathways linking the NCAM complex to integrins. This
diagram is adapted from Cavallaro and Christofori, 2004.
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CHAPTER 7
FINAL CONCLUSIONS AND FUTURE DIRECTIONS
Adhesion to the extracellular matrix is a pivotal requirement for survival of
normal cells. This relationship between the cell and the extracellular matrix is regulated
by components of the ECM or cell surface ligands and governed by members of a family
of cell-surface adhesion receptors known as integrins. In addition to their roles as
adhesion receptors, integrins also play a role in signalling. Much is known about the
extracellular interactions between integrins and their ligands however, significantly less
is known about the biochemical pathways that the integrins regulate and the cellular
functions which are thereby controlled (Clark and Brugge, 1995).
CD98 is a 125 kDa heterodimeric transmembrane glycoprotein amino acid
transporter. Recent studies have indicated that CD98 is also a regulator of integrin
activation (Fenczik et al., 1997; Zent et al., 2000: Warren et al., 2000). These studies
suggested that CD98 is involved in the regulation of ligand binding activity of integrins.
There is also increasing evidence that CD98 has oncogenic potential. Most tissues and
tumour cells have been shown to have a high expression of the CD98 heavy chain
(Parmacek et ah, 1989; Nakamura et ah,1999) and increased CD98 expression has been
shown to correlate with the development, progression and metastatic potential of
tumours (Esteban et ah, 1990; Garber et ah, 2001; Yoon et ah, 2003). The central aim of
my thesis was to investigate the diverse effects of CD98 and to elucidate which part of
the CD98 molecule was important for these processes. This was carried out using a
series of CD98 chimeras.
Endogenous levels of CD98 do not result in a malignant phenotype.
However the results of this study suggest that constitutively high levels of CD98
expression result in both anchorage and serum independent growth. This oncogenic
activity is dependent on PI3-Kinase activation. This finding is in agreement with Moore
et ah, 1998, in which they found that PI3 kinase acting through AKT promoted
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anchorage independence. Rintoul et al., (2002), also showed that when CD98 was
crosslinked PI3-Kinase activation was stimulated. The study of CD98 chimeric
constructs suggest that the transmembrane domain is required for the mediation of
oncogenic transformation. In addition the transmembrane domain of the CD98 heavy
chain was sufficient to promote extensive focal adhesion complexes and to induce these
phenotypic changes. The chimeras which had the transmembrane domain of CD98
heavy chain replaced with that of CD69 lost the capacity to stimulate PI3-Kinase and
promote anchorage independence. Studies have shown that the mutation of extracellular
cysteines C109S and C330S of CD98HC disrupt the covalent association with the light
chain but do not impair interactions or effects on integrins (Fenczik et al., 2001). The
extracellular domain of CD98 when exchanged with that of CD69 however did not
appear to affect these processes. This implies that the covalent association of the CD98
heavy chain with the light chain is not required for the functional regulation of integrins.
More specifically, studies with the chimeras, 98TM and the mutants A 4F2 and D5,
suggested that the amino acids 82-86 were critical for these processes. In addition to this
I found that CD98 heavy chain over-expression had no effect on the actin cytoskeleton
and the microtubule network despite being able to promote transformation and PI3-
Kinase activity.
Rintoul et al., (2002), demonstrated that CD98 and (31 colocalised and co-
immunoprecipitated in SCLC cells. CHOK1 cells stably transfected with CD98, CD69
or the chimeras, showed colocalisation between CD98 and (31 in the CD98 stables but
not in the negative control CD69 stables. The colocalisation of CD98 and (31 appeared to
be dependent on the presence of the transmembrane domain of CD98. The chimera,
4F269 which had the transmembrane domain of CD98 missing and replaced with that of
CD69 did not show colocalisation with (31. Deconvolution and surface rendering
confirmed these results. Co-immunoprecipitation experiments corroborated these results
indicating that the amino acids 82-86 of CD98 were also important for integrin
association as well as PI3-Kinase activation and anchorage independent growth.
However there were some exceptions. The chimera 69TM co-immunoprecipitated with
(31 but did not show colocalisation. This finding was further confused by the truncation
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mutant D5. The D5 mutant, which lacked the amino acids 1-86, but did have an intact
extracellular domain of CD98, did not show colocalisation with the (31 integrin. This
may be a consequence of these four amino acids being absent. These results implied that
the pi molecule may bind to either the extracellular domain of CD98 or that the
transmembrane domain may induce a change in the conformation of the extracellular
domain promoting CD98 and pi association.
Kakugwa et al, (2003) reported that CD98 stimulation could activate CEA-
CAM-1 mediated cell adhesion via protein kinase C8 (PKC8) activation. This study
suggested that CD98 may regulate different types of adhesion molecules. NCAM
appeared to be a potential candidate. I found that the NCAM isoform expressed differed
in terms of the SCLC cell line. H345 only expressed NCAM 180 whereas H69 expressed
both transmembrane isoforms NCAM-140 and NCAM-180. This may be explained by
the isoform switch seen in various tumour types (Cavallaro and Christofori, 2001;
Christofori, 2003). A possible link between CD98 and NCAM, NCAM and pi and was
demonstrated using colocalisation and co-immunoprecipitation studies. Cavallaro et al.,
(2001), suggested that NCAM modulates neurite outgrowth and matrix adhesion by
assembling a signalling complex consisting of FGFR-4 and various other signalling
molecules such as N-cadherin, PLCy and cortactin. Unfortunately the investigation into
the functional relevance of an association between CD98 and NCAM was not completed
due to time and resource constraints. The results which were obtained suggest a role for
NCAM in similar functional processes as CD98, such as anchorage independence and
adhesion. However the post-translational modification polysialylation ofNCAM appears
to be very important in understanding the functions of NCAM.
It is important to be aware that these studies have been carried out in CHOK1
cells which overexpress the CD98 molecule. Crosslinking CD98 using the monoclonal
antibody 4F2 also clusters the CD98 molecules together causing overexpression of
CD98. This overexpression of protein may therefore affect normal cellular events. To
combat this problem, methods such as siRNA and dominant negative protein expression
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could be used and compared against control cells. This would help further confirm the
results obtained in this investigation.
Overall the results obtained in this thesis have demonstrated that the heavy chain
of CD98 is an oncogene which promotes transformation when overexpressed in CHOK1
cells. This oncogenic activity is dependent on PI3-Kinase activation and the level of
CD98 cell surface expression. Using the CD98 chimeras, it has been established that the
transmembrane domain of CD98, specifically the amino acid residues 82-86, is
necessary and sufficient for integrin association, PI3-kinase activation, anchorage
independence and the induction of phenotypical changes such as extensive focal
adhesion formation.
Evidence has shown that CD98 plays an important role in inflammation and viral
diseases in addition to the role it plays in cancer via its effects on cellular activation and
integrin regulation. Abnormalities in the function and regulation of ECM interactions
have recently been implicated in the etiology of various inflammatory disorders such as
inflammatory bowel disease. Kucharzik et al., (2005) found in Caco2- BBE monolayers
and colonic tissues that the expression of CD98 was upregulated by the proinflammatory
cytokine INFy. This study found evidence that the activation of CD98 aggravates
intestinal inflammation. All this mounting evidence suggests that CD98 is an important
molecule to study not only as a mediator of transformation but also as a potential therapy
target for many inflammatory diseases.
As approximately 90% of all cancer deaths arise from metastasis (Cavallaro and
Christofori, 2004), understanding the molecular mechanisms involved in tumour
progression, invasion and metastasis, may provide unique targets for cancer therapy.
Recent advances in research have indicated that changes in cell adhesion play critical
roles in tumour progression. The association between CD98 and the cell adhesion
molecule NCAM, as well as the possible link between (31 and FGFR-2, may provide a
method of modulating the signals produced from the crosstalk between integrins and
growth factors, by forming a signaling complex. This complex may therefore influence
the signals being produced leading to the process of oncogenic transformation.
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The work in this thesis has provided the groundwork for this important area of
study and has identified key targets for further research.
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